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Prelamin A is one of two protein products of the LMNA gene and undergoes proteolytic 
processing to become mature lamin A, a crucial protein for nuclear envelope structure and 
function. Evidence suggests that when this process is hindered, resulting in accumulation of 
prelamin A, premature ageing disorders and cardiovascular complications occur. Moreover, 
mutations to LMNA are known to lead to dilated cardiomyopathy (DCM), with some of these 
mutations possibly resulting in accumulation of prelamin A, thus potentially implicating 
prelamin A in DCM pathogenesis.  
 To explore whether prelamin A has a role in DCM and heart disease, I used targeted 
transgenesis to the Rosa26 locus of the mouse genome of an uncleavable prelamin A construct 
(L647R-LMNA). Cardiac selective expression was achieved via MLC2v promoter linked cre-
recombinase mediated cassette exchange to yield mice which expressed prelamin A exclusively 
in cardiomyocytes—PLA Tg mice. They were compared to mice harbouring but not expressing 
the transgene, referred to as Wildtype  (Wt). 
 Compared to Wt, PLA Tg mice failed to thrive and succumbed at 5-6 weeks of age 
from a phenotype indicative of DCM and heart failure as defined by echocardiographic analysis 
of cardiac function, i.e. ejection fractions were dramatically reduced in PLA Tg (19.56%) 
compared to Wt (60.6%). Additional characterisation identified myocardial disarray and 
inflammation, and cardiomyocyte death as occurring in PLA Tg heart tissue. 
 Molecular characterisation suggested accumulation of DNA damage leading to ATM 
mediated NF-κB signalling may initiate inflammation of the myocardium and may also 
contribute to ‘myocardial senescence’. Disruption of gap junction formation via Cx43 
mislocalisation occurred and later structural proteins of the nuclear envelope were misexpressed 
and disorganised, indicating that cardiomyocytes were susceptible to mechanical stress in the 
face of prelamin A accumulation. 
 Immunofluorescence staining of human heart showed that prelamin A accumulated in 
the nuclei of a number of DCM heart biopsies, strongly implicating a role for prelamin A 
accumulation in clinical DCM pathogenesis. Moreover, it was observed that prelamin A was 
expressed, in low levels, endogenously in Wt myocardium and may be a novel component of 
the sarcomere. 
 In conclusion, this thesis provides evidence that nuclear prelamin A accumulation 
occurs in certain settings of DCM pathogenesis which may be a direct consequence of LMNA 
mutations or which may occur downstream of other pathogenic events. In this setting, prelamin 
A may mediate pathology via mechanisms identified in PLA Tg mice.  
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DDR DNA Damage Response 
DSB Double Strand Break 
Dusp Dual specificity phosphatase 
EC Endothelial Cells 
ECM Extracellular Matrix 
EDMD Emery dreifuss muscular dystrophy 
EGR1 Early Growth Response Protein 1 
ERK Extracellular Regulated Kinase 
FACE1 Farnesylated proteins converting enzyme 
FHL1 Four and a Half LIM domain protein 1 
FPLD Familial Partial Lipidodystrophy 
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FTI Farnesyl Transferase Inhibitor 
HCM Hypertrophic cardiomyopathy 
HF Heart Failure 
HFpEF Heart Failure preserved Ejection Fraction 
HFrEF Heart Failure reduced Ejection Fraction 
HGPS Hutchinson Gilford Progeria Syndrome 
IF Intermediate Filament 
IL- Interleukin 
INM Inner nuclear membrane 
JNK Jun N-terminal Kinase 
K+ Potassium 
KASH Klarsich, ANC-1 and Syne homology 
LAP2 α Lamina associated polypeptide 2 alpha 
LGMD1B Limb girdle muscular dystrophy type 1B 
LINC Linkers of nucleoskeleton to cytoskeleton 
LV Left ventricle 
LVH Left Ventricular Hypertrophy 
MAD Mandibuloacral dysplasia 
MAN1 LEM Domain Containing Protein 3 
MAPK Mitogen Activated Protein Kinase 
MCP-1  Monocyte chemotactic protein -1 
MI Myocardial Infarction 
MLC2v Myosin Light Chain 2 ventricular 
MLP Muscle LIM protein 
MMP Matrix metalloproteinase 
MRI Magnetic Resonance Imaging 
mTOR mammalian Target Of Rapamycin 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NE Nuclear Envelope 
Nesprin Nuclear Envelope Spectrin Repeat Protein 
NF-κB Nuclear factor kappa light chain enhancer of activated B cells 
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NFAT Nuclear Factor of Activated T-cells 
NOX NADPH oxidase 
OH Hydroxl radical 
ONM Outer nuclear membrane 
PBS Phosphate Buffered Saline 
PLA Tg Prelamin A Transgenic 
PP Pulse Pressure 
PPAR Peroxisome Proliferator Activated Receptor 
PWV Pulse wave velocity 
RCM Restrictive cardiomyopathy 
RD Restrictive Dermopathy 
RNS Reactive Nitrogen Species 
ROS Reactive Oxygen Species 
RT Reverse Transcription 
RyR Ryanodine Receptor 
SASP Senescence Associated Secretory Phenotype 
SERCA  Sarcoplasmic Endoplasmic Reticulum Calcium ATPase 
Situin  silent mating type information regulation 2 homolog 
SREBP1 Sterol Response Binding Element Protein-1 
SSB Single Strand Break 
SUN Sad1p-UNC84 
TNFα Tumour necrosis factor alpha 
UPS Ubiquitin Proteasome System 
VSMC Vascular smooth muscle cell 
Wnt Wingless-related integration site 
Wt Wildtype 
ZMPSTE24 human homolog Zinc metalloproteinase STE24 
α-MHC Alpha-Myosin Heavy Chain 
β-MHC Beta-Myosin Heavy Chain 
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Chapter 1: Introduction 
 
In the preceeding 15 years, the nuclear envelope (NE), which primarily consists of 
intermediate filament (IF) proteins and other membrane associated proteins that form 
the LInker of Nucleoskeleton to Cytoskeleton (LINC) complex1, has been subject to 
intense scrutiny, in particular the nuclear A-type lamins, lamin A & lamin C. These two 
proteins are the product of the same gene, LMNA, occurring by alternate splicing. 
Whilst lamin C is translated in fully mature form, lamin A is translated as a precursor, 
prelamin A, and undergoes unique enzymatic processing by farnesylated proteins 
converting enzyme1 (FACE1) to yield mature lamin A. This event appears to play a key 
role in the manifestation of disease. The discovery that mutations to the LMNA gene 
result in a variety of ‘premature ageing disorders’ such as Hutchinson Gilford progeria 
syndrome (HGPS), has sparked scrutiny not only from researchers interested in rare 
genetic diseases but also those looking for answers within the field of ageing and age-
related disease. The introduction for this thesis aims to inform the reader of the existing 
dogma of age associated cardiac decline and argue a case for prelamin A within this 
paradigm. 
 
1.1 The Heart: structure and function 
 
Myocardial structure is diverse. The dominant cell type is the cardiomyocyte (CM), 
which constitutes approximately 30% of cells in the heart. Additionally, there are 
endothelial cells, fibroblasts, pericytes, smooth muscle cells and arguably, cardiac stem 
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cells. Moreover, there are a number of extracellular matrix (ECM) components that are 
vital for the structural organisation of the heart and for dealing with load and tension. 
These are primarily glycoproteins and include collagen, laminin and fibronectin2. CMs 
are terminally differentiated cells that are defined structurally by repeating units of 
contractile proteins known as sarcomeres (Fig 1.1) and are connected to neighbouring 
CMs via the sarcolemma (muscle cell membrane) by intercalated discs which comprise 
many junctional proteins and whose role it is to propagate electrical signals and 
facilitate efficient contraction of CMs in a temporally regulated manner, meaning heart 
tissue contraction as a whole is synchronous.  
The sarcomere is made up of thick myosin filaments and thin actin filaments that 
cross-bridge via myosin heavy chain (MHC) heads via the troponin tropomyosin 
complex to initiate contraction. When the cross-bridges are formed, the myosin heads 
act as levers to slide the filaments together, thereby shortening the cytoskeletal 
components of the sarcomere, such as the z-discs, and creating contraction. Relaxation 
occurs when the myosin heads dissociate and the sarcomere returns to normal length3. 
The key regulator of this process is calcium (Ca2+). Increases in intracellular [Ca2+] lead 
to the assembly of the troponin tropomyosin complex whereas dissociation is initiated 
by low [Ca2+]i4. Intracellular calcium concentration is in turn regulated by many 
intricate signalling mechanisms. Membrane depolarisation in CMs usually occurs via 
potassium (K+) ion channels associated with junction proteins known as connexins from 
a neighbouring CM. This initial depolarisation leads to activation of voltage gated Na+ 
channels leading to a rapid depolarisation. Na+ channels subsequently close and K+ and 
L-type Ca2+ channels open. Influx of Ca2+ leads to a phenomenon known as calcium  







Figure 1.1. The sarcomere. An electron micrograph showing the sarcomere: The I-
Band contains only thin actin filaments. The A-Band denotes the region where the thin 
actin filaments and thick myosin filaments overlap, whilst the M-line and Z-discs 
contain cytoskeletal proteins that provide structural compliance for efficient contraction-
relaxation of actin and myosin. 
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induced calcium release (CICR). Within the cytoplasm a structure termed the 
sarcoplasmic reticulum (SR) acts as an internal reservoir for Ca2+ that is segregated 
from the cytoplasm. The SR is safeguarded by the ryanodine receptor (RyR), which is a 
calcium release channel incorporated into the SR membrane. The RyR is activated by a 
transient increase in Ca2+, leading to channel opening and SR Ca2+ release into the 
cytoplasm, which initiates formation of the troponin tropomyosin complex that leads to 
contraction5. Relaxation is governed by Ca2+ reuptake by the SR via the sarcoplasmic 
endoplasmic reticulum calcium ATPase (SERCA)6. The process of electrical signalling 
leading to contraction is known as excitation-contraction coupling and is the focus for 
much research regarding arrhythmia and contractility7.  
Additionally, the role of cytoskeletal components has been studied8. The 
cytoskeleton provides the platform upon which the contractile machinery can exert 
force. As a result these components are critical for the transmission of force across a 
CM or myofiber. Cytoskeletal components include proteins such as titin, desmin, 
muscle lim protein (MLP), myosin and α-actinin. Mutations to all of these can lead to 
dilated cardiomyopathy (DCM)9-13. The NE may also be important to the structural 
integrity and mechanical efficiency of CMs. The NE contains many structural proteins, 
which may provide the structural stability required for transmission of force across the 
nucleus of a CM and contribute to overall mechanical stability in CMs. The importance 
of the NE in CMs is highlighted by the fact that mutations to the genes of NE 
components lamin A/C14, 15, emerin16, 17 and nesprin 1α18 cause DCM phenotypes. 
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1.2 Cardiovascular ageing and heart disease 
 
In the cardiovascular system a number of age related changes to physiology are 
observed. Possibly the first notable change is the increase in arterial impedance or 
‘stiffening of the arteries’. This results in an increased pulse wave velocity (PWV) 
widening of pulse pressure (PP) and an overall increase in blood pressure (BP). 
Subsequently a hypertensive phenotype is observed. This leads to increases in 
mechanical work done by the heart as a result of pressure overload, which is known to 
induce pathological remodelling of the heart such as left ventricular hypertrophy 
(LVH)19-21. Another key age associated change is increasing instability of 
atherosclerotic plaques leading to ischaemic attack and subsequently, myocardial 
infarction (MI) or stroke. Both LVH and non-fatal MI are capable of progressing 
towards cardiac dilatation and heart failure with terminal prognosis. The age-associated 
decline of the heart is summarised in Figure 1.2. 
 
1.2.1 Heart failure 
 
Heart Failure (HF) arises when the heart is no longer able to pump sufficient blood 
through the body to meet the metabolic demands of the respiring tissues. This occurs as 
a result of pathological changes to cardiac structure and function, which can accumulate 
over time, as in the case of LVH and pressure overload or as the result of injury caused 
by ischaemic attack. HF can also arise as an end-point to cardiomyopathies; in which 
case, the disease is the result of CM dysfunction and thought of as primary disease 
rather than secondary. HF is highly prevalent amongst the western population. The   




Figure 1.2. Cardiovascular ageing. In advancing age cardiovascular dysfunction is 
characterised by a variety of age-associated changes to the signalling pathways 
regulating vascular tone and cell cycle leading to pathogenesis and senescence, 
ultimately resulting in stiffened arteries and hypertension. Sustained pressure overload 
(PO) then stimulates hypertrophic remodelling of the heart, characterised by eccentric 
myocyte hypertrophy, interstitial fibrosis and contractile dysfunction. Persistent PO 
causes advanced remodelling and HF. Moreover, mutations to structural proteins in 
CMs lead to DCM. Toxins from dietary intake such as alcohol and from treatment 
regimes such as chemotherapy may also cause DCM associated with ageing.  
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Framingham heart study found that at 40 years of age, lifetime risk for HF for males and 
females is 21% and 20.3% respectively22. Such incidence presents a great strain to the 
health industry and has significant societal implications. Currently there is inadequate 
provision for the treatment of HF; β-blockers, aldosterone antagonists, angiotensin 
converting enzyme (ACE) inhibitors and angiotensin receptor blockers show significant 
efficacy in controlling the mortality and morbidity of some HF patients but only in those 
with reduced systolic function, and furthermore not in all cases23. HF is subdivided into 
two main categories: those who have reduced systolic function (HFrEF) and those with 
preserved systolic function (HFpEF). It is often assumed that patients with HFpEF have 
diastolic dysfunction, which is described as impaired filling of the left ventricle as a 
result of varying factors24 such as impaired relaxation, affecting the ability of the LV to 
fill passively with blood, or from increased filling pressures25, 26.  
 
1.2.2 Left Ventricular Hypertrophy 
 
Age induced dysfunction of the vasculature invariably leads to pathologic cardiac 
events, which characterise the critical disease phenotypes that provide great risk to life, 
crucial to which, is the progressive remodelling of the cardiac tissue known as left 
ventricular hypertrophy (LVH). Pathological LVH is characterised by a chronic decline 
in cardiac output resulting from a gradual decline in contractility as well as an increase 
in impedance of the cardiac tissue, leading to a decrease in diastolic filling and decrease 
in ejection fraction, stroke volume and cardiac output. These changes are mediated by 
interstitial fibrosis, hypertrophy of CMs and decrease in contractile function27. Relative 
to this increase in size, the number of capillaries supplying blood to the CMs has been 
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shown to decrease leading towards a deficit in oxygen supply28. The consequences of 
these pathological changes are severe and lead to a steady decline in cardiac health 
resulting in cardiac dilation and HF (Fig 1.2). There is evidence to suggest that A-type 
lamins play a role in hypertrophic signalling. It has been reported that haploinsuffiency 
of Lmna ameliorates the effects of pressure overload induced hypertrophy in mice29. 
The mechanism identified implies that impaired activation of the mechanosensitive 
gene Egr1, which encodes transcriptional regulator early growth response protein 1, is 
crucial to this phenotype. Additionally, mutation of the lamin binding partner and 
transcriptional regulator, Four and a Half LIM domain protein 1 (FHL1), has been 
implicated in development of a hypertrophy phenotype30. Overall, the cellular signalling 
mechanisms involved in LVH are complex, and therefore beyond the scope of this 




Cardiomyopathies arise as a product of intrinsic and age related dysfunction of the 
CMs. The causes of such events are varied and range from familial mutations of 
structural proteins such as actin, myosin, and A-type lamins, to environmental causes 
such as toxic exposure, e.g. alcohol and chemotherapeutic agents such as doxorubicin. 
Further to this, it has been suggested that DCM occurs late in viral myocarditis, and 
autoimmunity may also lead to DCM32, 33. In most cases, pathological cardiac 
manifestations of these types result in HF. The processes involved are discussed further 
below. 
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Cardiomyopathies have long been classified according to their functional and 
morphological features. It is thought that each classification accurately describes the 
phenotype of disease, and is useful in terms of prognosis and therapeutics34. The 
foremost classifications are dilated, hypertrophic, arrythmogenic right ventricular and 
restrictive, under which several subtypes emerge according to molecular 
characterisation of the disease phenotype35. Often the molecular characterisation in 
question is the presence of a gene mutation, and at the very least, identification of such 
mutations allows us to speculate and investigate the mechanisms for the apparent 
cardiac dysfunction. It is worth noting, however, that there appears to be a great deal of 
heterogeneity with respect to this point, which is highlighted by two known mutations 
to MYH7, the gene encoding sarcomeric β-myosin heavy chain affecting adjacent amino 
acids and leading separately to hypertrophic and dilated cardiomyopathy36.  
 
1.2.3.1 Hypertrophic Cardiomyopathy  
 
An autosomal dominant disease of the heart, hypertrophic cardiomyopathy (HCM) is 
characterised by hypertrophy of the left (and sometimes right) ventricular myocardium 
that is not explained by haemodynamic overload. Unlike the uniform concentric 
hypertrophy seen as a result of pressure overload, hypertrophy is asymmetric and often 
there is involvement of the inter-ventricular septum35. In many cases there is associated 
fibrosis and myocyte disarray underpinning the phenotype. It is associated with high 
prevalence of arrhythmia and is the one of the most common causes of sudden cardiac 
death in young athletes37.  
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 Mechanistically it has been deemed a disease of the sarcomere although it may 
also be associated with AMP kinase (see later). Of 10 genes identified to have causal 
mutations, 9 of them encode sarcomeric proteins38, 39. Of these, the two most important 
encode cardiac myosin-binding protein C (MYBPC3) and β-MHC (MYH7) and account 
for the overwhelming majority of cases40. The remaining 7 genes account for 
approximately 1-5% of cases40. The mutations involved mostly lead to substitution of 
single amino acids, although half of mutations to MYBPC3 are known to cause 
truncations to the protein product and lead to haploinsufficiency, which also underlies 
the phenotypic presentation of HCM41, 42. At the cellular level, increases in contractility 
occur. Analysis of these indicates that altered myosin kinetics and increased calcium 
sensitivity of thin-filaments are key factors43-45. These changes are known to activate 
hypertrophic signalling pathways and also may contribute to the characteristic diastolic 
dysfunction evident in HCM. Furthermore, evidence from a troponin T mutant 
transgenic model suggests that during diastole, SR calcium content is significantly 
elevated46. One hypothesis suggests that dysregulation of calcium handling can 
predispose patients to arrhythmia47 and may also encourage aberrant signalling via 
multiple pathways such as calcineurin nuclear factor of activated T-cells (NFAT) and 
calcium-calmodulin-dependent protein kinase II signalling48.  
 Sarcomeric mutations have been shown to perturb calcium handling via two 
main mechanisms. Firstly, the presence of mutations to troponin T, troponin I and 
tropomyosin increases the affinity of troponin C for calcium49, and mutations to 
cMyBP-C lead to the formation of additional cross-bridges between thick and thin 
filaments which also increase sensitivity to calcium. Troponin is the principal calcium 
buffer in the SR; therefore, increased affinity should increase calcium levels in 
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diastole50, 51. The second mechanism identified suggests that contractile inefficiency 
compromises the energetics of the CM: the formation of cross-bridges between thick 
and thin filaments of the sarcomere requires approximately 70% of the ATP 
consumption of any given CM. HCM mutations in sarcomeric proteins that alter this 
process are hypothesised to confer a deficit in ATP availability and this is postulated to 
have ramifications for other ATP requiring processes within the cell, such as Ca2+ 
uptake via SERCA during diastole, thus potentially contributing to the manifestation of 
diastolic dysfunction that is characteristic in HCM52.  The formation of a myocardial 
energetics hypothesis for HCM is supported by work suggesting that mutations to the γ2 
subunit of AMP-activated protein kinase (AMPK) involved in energy sensing leads to 
HCM53.  
There are a couple of studies showing the involvement of lamins in HCM. In the 
first, HCM appears to be secondary to Familial Partial Lipidodystrophy (FPLD2) 
caused by a missense mutation to LMNA that confers an amino acid substitution at 
residue 59154. Interestingly, this patient was also insulin resistant indicating a 
potentially wider role for lamins in heart disease, as perturbations to lamins may also be 
involved in metabolic syndrome55, 56. Additionally there was a case reported whereby a 
patient with the R644C mutation displayed pathogenicity consistent with HCM57.  
 
1.2.3.2 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 
 
ARVC is characterised by pathological remodelling, primarily of the right ventricle, in 
which myocyte death, inflammation and fibrofatty replacement of the myocardium are 
the main histological features58. In vivo, cardiac imaging shows ventricular wall 
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thinning, dilatation of cardiac chambers and systolic dysfunction. Using magnetic 
resonance it is possible to identify the fibrofatty lesions that pervade the myocardium as 
fat deposits appear as white spots amongst the grey myocardium in T1-weighted fast 
spin echo images. Additionally, injection of gadolinium contrast agent can identify 
fibrotic regions, which present late signal enhancement in recovery sequence images59. 
Alongside the morphological changes to the myocardium, patients are also prone to 
arrhythmia; indeed ARVC is known to be another lead cause of sudden cardiac death 
worldwide60, 61. Furthermore, arrhythmia and sudden cardiac death can occur with 
limited to no pre-existing morphological disturbances, making diagnosis difficult. 
 Due to the nature of mutations identified in ARVC, it has been termed a disease 
of the desmosome62. The desmosome anchors the IFs of one cell to the cytoplasmic 
membrane of another in order to create a lattice structure that provides mechanical 
strength to tissue. Mutations to a number of desmosomal genes have been identified in 
ARVC, including desmoplakin, plakoglobin, plakophilin-2, and desmoglein-263-66. 
Other key mutations have been identified in transmembrane protein 4367 and 
transforming growth factor β368. The molecular mechanisms that regulate the 
progression to ARVC are somewhat unclear, but two main hypotheses have been 
postulated.  Firstly, mutations to the desmosome may compromise the integrity of cell-
cell interactions and as such make the tissue structure, in this case the heart, susceptible 
to mechanical stress leading to cell detachment and necrosis, which may then instigate 
an inflammatory response. In this setting it is thought that fibroadipose deposition is a 
reparative response to injury. Second is the transdifferentiation model, which proposes 
that desmosomal perturbations can dysregulate the Wnt/β-catenin signalling pathway 
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leading to activation of adipogenic and fibrogenic genes and a switch of cell fate from 
CM to adipocyte69, 70. 
 Recently, a number of patients presenting with ARVC who did not have 
mutations to desmosomal genes were found to have LMNA mutations. Interestingly, the 
R644C mutation was again responsible in two of five mutations identified71, 72.  
 
1.2.3.3 Dilated Cardiomyopathy 
 
DCM is characterised by dilation of one, if not both, ventricular chambers. 
Functionally, it is accompanied by a reduction of systolic function and structurally by 
fibrosis of the myocardium and CM death. It can arise as a result of sustained 
ventricular remodelling from pressure overload or as a result of primary causes73. Most 
commonly these come in the form of a mutation to a protein playing a key role in the 
cytoarchitechture of the CM. Indeed, inherited mutations (familial DCM, FDCM) are 
thought to account for up to half of cases, whilst the remaining cases (idiopathic DCM, 
IDCM) are thought to be a result of somatic de novo mutations or external causes such 
as myocarditis74, 75, toxin exposure76, chemotherapy77 and potentially also 
autoimmunity78.  
Where gene involvement is concerned, initial findings suggested that sarcomeric 
mutations were the most important in determining a DCM phenotype, but now many 
mutations affecting cell compartments that are peripheral, or perhaps more pertinently, 
‘accessory’, to the sarcomere have been identified as being equally if not more 
important, such as mutations in genes encoding proteins interacting with the 
sarcolemma and the desmosome (dystrophin), IFs (desmin) and importantly for this 
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thesis, the NE (lamin A/C). Upwards of 40 disease genes have been identified, most of 
which exist as autosomal dominant mutations79. The consequence of having such a 
diverse pool of genes that are causative for DCM is that, mechanistically, there is 
unlikely to be a common cellular process provoking disease, presenting a great 
challenge in terms of therapeutic intervention. 
To a degree, some cellular mechanisms have been elucidated. Mutations to β-
MHC are shown to reduce contractility in DCM, whereas mutations to thin filament 
proteins cause a reduction in Ca2+ sensitivity by attenuating the affinity of troponin to 
calcium. These mutations act to reduce the generation of force in the myocyte. Other 
proteins that are responsible for DCM include cytoskeletal components of the z-disc 
such as cypher80, the costamere (δ-sarcoglycan81, dystrophin82), which links the 
contractile apparatus of the myocyte to the sarcolemma and ECM, and IFs such as 
desmin83, which help link the contractile apparatus to the ECM and also to the nucleus 
via the LINC complex. These mutations are thought to cause a disruption in 
transmission of force throughout the myocyte or may disaffect sensing mechanisms 
possibly involving Titin. Mutations to the Titin gene, TTN, are also now a well-
established cause of FDCM11.  Phospholamban, essentially known as the gatekeeper of 
the SERCA and crucial in regulating the diastolic phase of excitation-contraction 
coupling in CMs, is subject to an unusually common mutation, p.Arg14del, that causes 
DCM with associated arrhythmia84. This mutation inhibits SERCA, resulting in a 
reduction of Ca2+ reuptake in diastole and is probably the means by which ECGs often 
show low voltage. This specific mutation to PLN, the gene that codes Phospholamban, 
is thought to be one of the most common causes of FDCM. Interestingly, the LMNA 
gene is also commonly mutated in DCM. Mutations of the LMNA gene in humans have 
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been shown to result in cardiomyopathies leading to conduction defects resulting in 
arrhythmias leading to sudden cardiac death85. However, the recurrence of common 
DCM causing mutations is much lower; the Universal Mutations Database states that 
there are currently 132 unique DCM causing mutations to LMNA that are known. This 
diversity makes mechanistic analysis challenging, although some DCM causing LMNA 
mutations have been investigated in order to provide some insight into the workings of 
LMNA associated DCM.  
 
1.3 Mechanisms of ageing 
 
1.3.1 Myocardial senescence 
 
Ageing is now recognised as the most potent risk factor for cardiovascular disease 
(CVD). Additionally, levels of DNA damage in vascular smooth muscle cells (VSMC), 
CMs and endothelial cells (EC) increase linearly with age, as do levels of reactive 
oxygen species (ROS). This implies a strong link exists between DNA damage response 
(DDR) and the onset of cellular senescence, defined as the point at which diploid cells 
lose their ability to divide86, and also their ability to respond to external stimuli. It has 
been argued that terminally differentiated cells, CMs for example, despite their lack of 
cell division, may also cease to respond to external stimuli and become ‘senescent’. The 
evidence for myocardial senescence is under intense debate. Classically CMs have a 
very low lifetime turnover, and the regenerative capacity of the heart, particularly in 
adulthood, is poor. Therefore, loss of CM function as a result of senescence is not easily 
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compensated for, unlike that of say, a troublesome epithelial tissue that may be at risk of 
oncogenesis87. Known ageing mechanisms and their potential relevance to cardiac 
ageing will be discussed further. 
 
1.3.2 DNA damage and DNA damage response (DDR) 
 
Genome integrity is under constant threat from daily cellular insults leading to DNA 
damage. DNA repair mechanisms are constantly operating to counter the effect of these 
insults. This relationship of damage and subsequent repair is therefore viewed as a 
normal process in order to maintain cellular homeostasis. Thus, it is widely accepted 
that the stability of genes depends upon DNA repair. DNA damage can occur from 
exogenous sources that include UV and ionizing radiation, environmental chemical 
toxins (e.g. cigarette smoke) and dietary toxins (low density lipoproteins), and 
endogenous sources including ROS or reactive nitrogen species (RNS), which are 
derived from numerous intracellular sites: as products of mitochondrial metabolism; 
from ROS generating enzymes such as NADPH oxidase (NOX); or RNS generating 
enzymes such as uncoupled nitric oxide synthase (NOS)88. The modifications made 
include DNA adducts, and single (SSB) and double strand breaks (DSB). This has led to 
the notion that DNA damage itself plays little role in pathogenesis and that often the 
accumulation of DNA damage which drives senescence and disease is due primarily to 
defective DNA repair mechanisms.  
At a molecular level DNA repair occurs by a DDR pathway driven by a 
collective of sensors, transducers and effectors89. When DNA becomes damaged it is 
detected by DNA damage binding proteins, or sensors, that can recognise the lesions or 
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the chromatin reorganisations occurring as a result of the damage. Such proteins include 
the Mre11-Rad50-Nbs1 complex, which detects DSBs90, and the 9-1-1 complex that 
detects SSBs91. The principle transducers of DNA damage response are the Ataxia-
telangiectasia mutated gene product known as ATM, and the ATR (ATM and Rad3-
related). Both belong to the phosphatidylinositol 3-kinase-like family of 
serine/threonine kinases (PIKK)92. ATM/ATR are able to influence, via various 
phosphorylations, a number of ‘effector’ or cell-cycle regulating proteins such as 
checkpoint kinase 1 and 2 (ChK1/2) and the tumour suppressor proteins p53, p21 and 
p16 which induce cell-cycle arrest in G1 and G2/M phases when activated93-95, which 
are associated with development of senescence96, 97. In DDR, inhibition of the cell cycle 
paves the way for enzymatic repair of DNA. For example, base excision repair utilises 
DNA glycosylase to remove the damaged base leaving an abasic site, which is cleaved 
by apurinic or apyrimidinic endonucleases before it is fully repaired by DNA 
polymerase and DNA ligase98, 99. Overall, the importance of DDR for ageing paradigms 
can be extracted from work showing that when key mediators of DSB repair are absent 
in mice, they experience a premature senescence phenotype. For example, when the 
genes encoding the DSB repair proteins, ECCR1 and Ku86, are deleted in mice, the 
resulting phenotype is one of growth retardation and senescence100, 101. In the 
myocardium, the importance of DDR in pathological settings is an emerging field, with 
DDR mechanisms recently shown to be part of the adaptive response to myocardial 
infarction102. Interestingly, recent findings also suggest that DDR is responsible for the 
post natal loss of proliferative capacity of CMs103.  
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1.3.3 Reactive oxygen species 
 
ROS can arise from exogenous sources such as ionizing radiation (IR) but the most 
important for disease are derived endogenously and arise as part of cellular processes. It 
is widely accepted that the primary source of endogenous ROS production in cells is the 
mitochondria. During xenobiotic metabolism, the electron transport chain produces 
ROS that are released into the cytosol, primarily as by-products of complex I (NADH 
dehydrogensase) and complex III (ubiquinone-cytochrome c reductase)104. However, it 
is thought that there are several other enzyme systems that make a significant 
contribution to redox potential by ROS generation. Amongst these is the NOX family of 
enzymes. NOXs were the first identified proteins whose primary function it was to 
generate ROS105. Since their identification, many studies have shown their importance 
in several ‘redox signalling’ paradigms, a significant portion of which have identified 
key roles for Nox1, 2 and 4 in the development of cardiovascular dysfunction in 
response to stress106-108.  
The effects of ROS on nuclear DNA are well established109. Oxidative 
modifications to DNA are almost exclusively achieved by hydroxyl radicals and do not 
occur directly by O2- or H2O2. However, O2- and H2O2 can be efficiently converted to 
OH• via the Fenton reaction110.  Modifications induced by hydroxyl radical attack 
include SSBs and DSBs, base modifications such as thymine glycol and 8-oxo-2-
deoxyguanosina (oxo-8-dG), which lead to GT transition mutations111, 112.  
The importance of ROS and DDR in cardiac pathology can be seen in the 
context of doxorubicin cardiotoxicity. Doxorubicin is the most commonly used member 
of the anthracycline group of cancer chemotherapeutic agents and is known to lead to 
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DCM up to 10 years after initial treatment113, 114. Doxorubicin is capable of directly 
intercalating with DNA to induce irreparable DSBs but also produces large amounts of 
ROS. Furthermore, evidence suggests that doxorubicin cardiotoxicity is regulated by 
ROS dependent activation of DDR leading to ATM dependent phosphorylation of p53 
and subsequent CM apoptosis115.   
 
1.3.4 Senescence associated secretory phenotype 
 
The senescence associated secretory phenotype (SASP) is the term ascribed to a 
paradigm in which cells that have undergone cellular senescence are able to contribute 
to the regulation of the surrounding tissue microenvironment by the production and 
secretion of soluble factors such as cytokines, chemokines, hormones and proteases and 
insoluble factors that comprise the ECM such as fibronectin, laminin and collagen116. 
The secretion of these factors creates a physiochemical gradient, which, depending on 
the tissue model, have the potential to affect cell differentiation117, stimulate epithelial 
and endothelial cell motility118 and induce leukocyte recruitment119. It is well 
established that cellular senescence is a safeguard against cancerous proliferation of 
damaged cells120. However, the discovery that senescent cells exhibit a secretome121, 
and subsequently have an active role within tissue environments, has led to the 
establishment of the SASP paradigm, evidence for which suggests that the detriments 
outweigh the benefits. Therefore, it seems that senescence is a double-edged sword 
capable of arresting tumorigenesis and being procarcinogenic; this contradictory 
response is part of an evolutionary model known as antagonistic pleiotropy122. 
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 A key aspect of SASP is the specificity with which it operates. There is a 
specific subset of secreted factors, which create a molecular signature for SASP. The 
main players include the pro inflammatory IL-6, IL-8 (CXCL-8), MCP-1 and MMP-3 
(plus many more), whilst some are noticeably absent from any senescence response, e.g. 
IL-2,-4,-10,-11,-12, which are interestingly, anti-inflammatory cytokines. As such, the 
SASP is deemed a pro inflammatory response116.  
 The SASP has not been actively investigated in cardiac tissue, but the science is 
transferable. Persistent DNA damage, such as that seen in chemotherapy mediated 
DCM, is capable of activating ATM, which is crucial in senescence associated IL-6 
secretion119. Moreover, pathogenic changes to the myocardial milieu are known to 
induce immune responses that are regulated by myocyte signalling and involve nuclear 
factor kappa light chain enhancer of activated B cells (NF-κB) mediated secretion of 
cytokines, such as IL-6, MCP-1 and TNF-α123 which, as previously stated, are heavily 
implicated in the SASP.  
 Prelamin A accumulation has also been linked with activation of the SASP. 
Studies of VSMCs subject to ectopic prelamin A overexpression showed a SASP like 
profile that was associated with DNA damage and induction of vascular calcification124. 
Furthermore, studies in Zmpste24-/- mice, in which mice are null for the prelamin A 
processing enzyme Zmpste24/Face1 and subsequently accumulate prelamin A, indicate 
that prelamin A is capable of inducing activation and nuclear translocation of the 
transcriptional regulator NF-κB, which consequently leads to transcription and secretion 
of SASP mediators IL-6, TNF-α and CXCL-1125. Interestingly, the mechanism of NF-
κB activation is non-canonical and mediated by ATM activation. Finally, modulation of 
NF-κB signalling caused by perturbations to the NE has also been reported126.  
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1.3.5 Other ageing mechanisms 
 
Telomere length, regulated by the enzyme telomerase, is a well known indicator of 
cellular age127. In the heart, age dependent modulation of telomerase activity has been 
reported128, and low telomerase is thought to be a risk factor for CVD129, 130. Telomerase 
activation and telomere attrition have been reported in human hearts131-133, whilst 
telomerase deficient mice (Terc-/-) display significant telomere erosion and subsequently 
succumb to ventricular dilation and heart failure134.  
 Several lines of investigation have identified the importance of the lamina in 
telomere dynamics135 and arrangement136. Moreover, the mutated form of prelamin A 
expressed in children with HGPS, Progerin, has been shown to induce telomere 
dysfunction in fibroblasts137. 
Many other mechanisms have been associated with cardiac ageing and may 
contribute positively or negatively to a cardiac senescence phenotype. Sirtuins, for 
example, are thought to confer lifespan extension properties when upregulated and have 
been shown to be cardioprotective, as well as linked to prelamin A138-145. 
 Caloric restriction famously confers lifespan extension benefits in a number of 
models146. Two primary targets by which caloric restriction elicits its effects are by 
inhibiting Insulin and Insulin like growth factor (IIS) signalling and Protein kinase 
B/mammalian Target of Rapamycin (Akt/mTOR) signalling. Activated mTOR 
signalling is thought to mediate downstream repression of the stress response pathway 
known as autophagy, which is crucial for the clearance of cell debris. Crucially, IIS, 
Akt/mTOR and autophagy are implicated in heart disease phenotypes147 and 
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accumulation of prelamin A and progerin has been implicated in the dysregulation of 
these pathways148-150.  
 
1.3.6 Summary of ageing mechanisms 
 
There are many mechanisms associated with ageing per se, and evidence suggests that 
despite the obvious caveat that the myocardium is terminally differentiated, many of 
these are likely to be involved in the phenotypic and pathological changes that occur in 
ageing myocardium.   
 
1.4 The nuclear envelope in health and disease 
1.4.1 The nuclear envelope 
 
As noted above, aspects of the NE have become the focus of ageing research. The 
stimulus for this has come from the discovery that a number of clinically distinct 
diseases, many exhibiting features of premature ageing and DCM, arise as a result of 
mutations in proteins that comprise and/or maintain the NE17, 151-155.  
The NE (Fig 1.3) primarily consists of an outer nuclear membrane (ONM) and 
an inner nuclear membrane (INM) that are separated by a ~50 nm luminal gap known as 
perinuclear space (PNS). These two lipid membranes serve to provide a physical barrier 
between the nucleoplasm and cytoplasm, thus facilitating compartmentalisation of the 
nuclear environment. Additionally, the NE is punctured with nuclear pore complexes 
(NPCs), which facilitate the trafficking of macromolecules across the NE. Structurally, 
the ONM is continuous with the endoplasmic reticulum (ER) with which it shares many   





Figure 1.3 The nuclear envelope in CMs. The nuclear envelope provides a physical 
barrier for nuclear compartmentalisation and a platform for communication between the 
nucleus and cytoskeletal domains via a group of proteins termed the LINC complex. 
The outer nuclear membrane (ONM) contains the KASH domain proteins, nesprins, 
which bind to cytoplasmic filament proteins such as actin. The inner nuclear membrane 
(INM) contains SUN proteins and LEM domain proteins that connect the KASH domain 
to the nuclear lamina, consisting of lamins A, C and B. In CMs, it is thought that the NE 
is connected to the sarcomere by the LINC complex via CH domains in the N-termini of 
nesprins and also via plectin and desmin. The LINC complex plays a key role in 
nuclear integrity and is also thought to regulate transcription, DDR and mitosis. 
Mutations to LINC proteins are known to causes a plethora of disease phenotypes 
known as laminopathies, often characterised by premature ageing or cardiomyopathy.   
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of the same membrane proteins including FACE1 and KASH domain proteins such as 
nesprins, which also contain calponin homology domains and bind with cytoplasmic 
actin, thereby providing a link to the cytoplasmic domain156-159. In contrast, the INM has 
a set of distinct membrane associated proteins that include lamina associated 
polypeptide 2 (LAP 2), emerin and MAN1 (collectively termed the LEM domain 
proteins)160 and SUN proteins, which bind the KASH domains and mediate physical 
communication between nesprins and the lamina161. The nuclear lamina is a meshwork 
of proteins lining the nuclear interface of the INM, and consists of type V IF proteins 
known as A- and B-type lamins, which form parallel coiled-coiled dimers and head to 
tail dimers to produce a large network that covers the entire INM162. The predominant 
A-type lamins are lamin A and lamin C and are alternative splice products of the same 
gene, LMNA163. Unlike lamin A, lamin C is translated as a mature protein, whereas 
lamin A is translated as a precursor, prelamin A, which must undergo a number of 
modifications before becoming mature lamin A164. B-type lamins are lamin B1, arising 
from the LMNB2 gene, and lamins B2 and B3 from the LMNB3 gene165. Whilst A-type 
lamins are thought to be specific to differentiated cell types, B-type lamins are thought 
to be present ubiquitously166. The sequential tethering of these NE spanning proteins is 
thought to be crucial for rapid physically mediated communication to the nucleus from 
the cytoplasmic and extracellular environment and is known as the linker of 
nucleoskeleton to cytoskeleton (LINC) complex1.  
The current dogma stipulates that the NE is crucial for mechanical stability, 
mechanical signalling, transcriptional regulation and DDR. The importance of the NE is 
highlighted by DCM causing mutations in genes of NE components emerin and lamin 
A/C that lead to uncoupling of the nucleoskeleton from the cytoskeleton under 
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mechanical stress167. Additionally, Lmna-/- and Sta-/-  (STA encodes emerin) fibroblasts 
show impaired mechanotransduction in single cell models of mechanical stretch168, 169. 
It has also been shown that the NE may be able to detect perturbations in force and 
convert these perturbations into adaptive or pathological gene expression responses126, 
170, 171. Finally, it is well documented that disrupting the nuclear lamina leads to large 
increases in DNA damage and inhibition of repair172-174. The consequences for 
disrupting these processes can be seen in cases of mutations to lamina-associated genes, 
which lead to pathological outcomes that have come to be known as laminopathies.  
 
1.4.2 Laminopathies 
It has been postulated that rare genetic conditions leading to premature ageing may give 
insights into normal ageing mechanisms148. There are to date at least 13 known disease 
phenotypes arising from mutations to the LMNA gene including Werner syndrome175, 
Emery-Dreifuss muscular dystrophy176 and the classical premature ageing disorder, 
HGPS177 (Table 1.1). Furthermore, as previously mentioned, a search on the Universal 
Mutation Database brings up 132 unique mutations believed to be responsible for 
causing DCM (http://umd.be/LMNA/).  
 
1.4.3 Mechanistic basis of laminopathies 
1.4.3.1 Genotype phenotype correlations 
Genotype phenotype correlations are often useful tools for aiding the elucidation of 
pathogenic mechanisms in the clinic. For example, mutations to ZMPSTE24 have been  





Table 1.1 Laminopathies 
Disease Gene Reference 
Atypical Werner syndrome  LMNA Chen et al178 
Charcot-Marie-Tooth disease LMNA De Sandre-Giovannoli 
et al179 
Dilated Cardiomyopathy LMNA Charniot et al180 
Emery-Dreifuss muscular dystrophy EMD (X-linked), LMNA 
(autosomal dominant) 
Bonne et al152 
Familial partial lipidodystrohy of the 
Dunningan type FPLD 
LMNA Cao et al153 
Hutchinson-Gilford progeria syndrome LMNA, ZMPSTE24 Eriksson et al155 
Limb-girdle muscular dystrophy LMNA Muchir et al181 
Lipoatrophy with diabetes, hepatic 
steatosis, hypertrophic cardiomyopathy 
and leukomelanodermic papules 
(LDHCP) 
LMNA Caux et al182 
Mandibuloacral dysplasia with type A 
lipodystrophy (MADA) 
LMNA Novelli et al183 
Mandibuloacral dysplasia with type B 
liodystrophy (MADB) 
LMNA Agarwal151 
Restrictive Dermopathy ZMPSTE24 Navarro184 
 
  
 On the role of prelamin A in the heart  
 
 43 
shown to correlate to disease severity. Mutations that caused a complete loss of function 
to FACE1 led to the neonatally fatal disease restrictive dermopathy (RD), whereas 
mutations in which there was residual FACE1 activity led to less severe disease types, 
such as atypical HGPS and mandibuloacral dyslasia (MAD)185. However, in the case of 
LMNA, the picture is not so clear. There are a subset of Laminopathies which are caused 
by a few ‘hot spot’ mutations which lead to specific phenotypes and are likely to share 
mechanistic traits186. These include classical HGPS, Werner syndrome, Charcot- Marie-
Tooth disorder, and MAD. However, the more common laminopathies, which are 
primarily striated muscle disorders, e.g. autosomal EDMD, limb girdle muscular 
dystrophy (LGMD1B) and DCM, are caused by seemingly indiscriminate and 
promiscuous mutations which present fewer clues as to the mechanisms involved. For 
example, mutations that cause DCM have been found in all 12 exons of the LMNA gene 
(http://www.umd.be/LMNA/, search in “mutations” using terms “phenotypic group”, 
“contains”, “DCM”). Moreover, mutations that cause DCM can also cause EDMD, 
LGMD1B and FPLD in separate individuals or can lead to any of these diseases with 
associated DCM. The level of pleiotropy seen with some of these mutations is unusual. 
Indeed, one curious mutation to the LMNA gene, R644C, displays extreme phenotypic 
diversity in the clinic187. These findings suggest that epigenetic or other extrinsic factors 
may be important in disease pathogenesis and/or progression where lamins are 
concerned. Discussed herein are examples of the efforts made to solve the pathways of 
disease in the cases of HGPS, which has a consistent genotype phenotype link, and 
DCM, which does not. 
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1.4.3.2 Prelamin A processing and HGPS 
HGPS patients are asymptomatic until around 2 years of age. From this point the 
disease progresses quickly. Phenotypically, patients display loss of subcutaneous fat, 
brittle skin, prominent scalp veins, micrognathia, convex nasal profile, hair loss and 
skeletal dysplasia188-192. These features compelled Hutchinson, in 1886, to report that 
his patient, a 3½ year old boy, ‘presented a very peculiar withered, old-mannish 
look’193. Subsequently, HGPS patients die in the second decade of life primarily due to 
cardiovascular complications, usually in the form of an ischaemic event, a myocardial 
infarction or stroke. The disease is highly tissue specific, affecting mainly skin, bone 
and muscle. At a cellular level, the HGPS phenotype is typified by the presence of a 
protein termed progerin, the mutated form of the lamin A/C precursor, prelamin A194. 
Normally, prelamin A is processed by four post-translational steps to produce mature 
lamin A (Fig 1.4). This process begins with farnesylation (or isoprenylation) of a C-
terminal cysteine thiol residue of a motif known as a CaaX box, which denotes the final 
four amino acids of the C-terminus195. This is followed by endoproteolytic cleavage of 
the remaining three amino acids of the C-terminus, known as AAXing, by a CaaX 
endoprotease, exposing the farnesylated cysteine residue196. Following AAXing the 
cysteine thiol is then further processed with the addition of a carboxyl methyl group by 
methyltransferases197. The final step is an upstream proteolytic cleavage of 18 amino 
acids between Tyrosine at position 646 and Leucine at position 647 in the amino acid 
sequence which releases mature lamin A198, a step which is believed to be required for 
lamin A insertion into the nuclear lamina197, 199, 200. It has been discovered that this step  






Figure 1.4. Prelamin A is processed by four post-translational modifications to 
produce mature lamin A. Firstly, farnesylation of the C-terminal cysteine from the 
CAAX motif occurs, which is followed by cleavage of the remaining three amino acids, 
then carboxymethylation of the cysteine, and finally cleavage of the entire farnesyl 
carboxymethylated tail. Mature lamin A is then inserted into the nuclear lamina to 
provide structure and mediate nuclear signalling.  
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is mediated and performed exclusively by the zinc metalloproteinase FACE1 
transcribed from the ZMPSTE24 gene201. Furthermore, FACE1 is also capable of 
performing the initial AAXing of the CaaX motif preceding carboxymethylation. In 
HGPS, the final enzymatic cleavage is abolished and the peptide remains permanently 
farnesylated, meaning it cannot be inserted efficiently or completely into the nuclear 
lamina202. In the most common form of HGPS, this occurs because of a single 
nucleotide C>T transition mutation in the LMNA gene, which confers no change to 
amino acid sequence (LMNA G608G), but that creates a donor splice site in exon 11 
leading to a 50 amino acid deletion containing the FACE1 cleavage site155, 203, 204. The 
resulting truncated prelamin A mutant protein has been termed ‘progerin’. It is also the 
case that loss of function mutations to ZMPSTE24 lead to prelamin A accumulation and 
can also drive HGPS phenotypes in humans205. Consequently, cells expressing high 
levels of progerin or prelamin A display nuclear morphology defects, disorganised 
heterochromatin distribution and massive increases in DNA damage172-174. It is 
hypothesised that increases in DNA damage are caused by defective recruitment of 
DNA repair factors due to unstable heterochromatin caused by lamina disruption206, 207. 
Moreover, disruption to the lamina and subsequently the LINC complex is thought to 
have deleterious effects on mechanical coupling of cell compartments and subsequently 
lead to structural instability and susceptibility to mechanical load and stress208. 
Additionally, disruption to the lamina may impede mechanical signalling and regulation 
of mechano sensitive gene transcription208. Current understanding suggests that these 
may underlie most of the pathological processes of HGPS.  
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1.4.3.3 What attempts at therapeutic intervention have taught us about HGPS  
 
A popular theory within the field of premature ageing suggests that accumulation of the 
farnesyl lipid anchor is central to accelerated ageing. This notion formed the basis for 
the development of treatments for progeroid syndromes with a group of compounds 
known as farnesyl-transferase inhibitors (FTIs). In vitro, FTIs lead to an almost 
complete rescue of the nuclear morphology defects associated with progerin/prelamin A 
accumulation and successfully delay the onset of senescence209, 210. Such findings 
prompted clinical trials for FTIs in progeria but have not led to a definitive cure211. It 
has been postulated that the low efficiency of FTI treatment is due to redundancy. In the 
event of farnesyl inhibition, the mutated progerin protein undergoes alternative 
gerangeranyltransferase mediated prenylation212. In this study, the authors show that 
combination treatment with aminobisphosphonates and statins ameliorate the progeria 
phenotype and increase longevity in a mouse model of human ageing. In light of these 
findings numerous models of progerin and prelamin A accumulation in various stages 
of processing have been developed. The Fong laboratory in California has performed 
much of the work to tease out the pathological significance of this. They have 
developed and tested an array of knockin/knockout mouse models in order to elucidate 
the role that prelamin A processing has in causing premature ageing diseases. In 
summary, Zmpste24-/- mice have no FACE1 expression, meaning the cleavage of 
prelamin A cannot occur. Consequently mice exhibit progeria like phenotypes213, 214.  
This has been phenocopied by a model of HGPS knock-in mice (LmnaHG/+) and both 
these pathological presentations have been partially ameliorated by FTI treatment in 
vivo215-217. This indicated that the farnesyl tail of prelamin A was key to progeroid 
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phenotypes. Therefore, to further assess the role of the farnesyl lipid in progeroid 
syndromes, further knock-in models were developed. Non-farnesylated progerin 
(LmnanHG/+) unexpectedly led to progeria, suggesting that the farnesyl lipid was not as 
important to the development of premature ageing as initially thought218. However, a 
later model of non-farnesylated prelamin A (LmnanPLAO) failed to validate this 
observation as the mice were normal with regard to premature ageing but instead 
developed cardiomyopathy219. In light of this, another non-farnesylated progerin model 
(LmnacsmHG/+) was developed220 in which the mutation was a deletion of isoleucine from 
the CaaX motif (CSM) rather than the switching of the cysteine for serine (SSIM) as 
was the case for LmnanHG/+mice. This model led to complete amelioration of progeroid 
symptoms that once again supported the argument for FTI treatments but at the same 
time further increased the complexity of the pathological paradigm. Along with these, 
Fong et al have also made a lamin A only221 model which bypasses normal prelamin A 
processing, and a lamin C only222 model in which mice appear completely normal. 
These are interesting developments for the field of HGPS and premature ageing 
disorders because there appears to be some redundancy with regard to the A-type 
lamins, which brings into question the evolutionary purpose of prelamin A 
processing223. Additionally, this perhaps strengthens an argument for the toxic effects of 
mutant lamins and unprocessed prelamin A in a dominant negative manner. Indeed a 
cross of Zmpste24-/- and Lmna+/- mice leads to a reduction in prelamin A accumulation 
and amelioration of the progeroid phenotype and highlights the toxic nature of prelamin 
A224. These models are summarised in Table 1.2. 
The current questions regarding the use of FTIs to treat HGPS are aimed at 
establishing why they do not completely abolish the symptoms. For example, whilst  
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Table 1.2. Overview of phenotypes associated with mouse models 










Normal at birth, develop Muscular Dystrophy and severe systolic dysfunction, 
live to 5-6 weeks225, 226 
 












Only prelamin A made, which is subsequently processed by ZMPSTE24 to 
lamin A; apparently normal219 
 














Non-farnesylated prelamin A and unprocessed by ZMPSTE24; cardiomyopathy 











Progeroid phenotype—some reported cardiac manifestations at 16 weeks214 
 
 
















CSIM motif changed to SSIM; progeroid phenotype – subsequently die at 16 
weeks218 
 
CSIM motif changed to CSM; apparently normal220 
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FTIs rescue nuclear morphology defects, they do not prevent accumulation of DNA 
damage172 and with increasing evidence pointing towards DDR in the onset of cellular 
senescence, the use of FTIs as a stand alone therapeutic is becoming increasingly 
questionable. Further elucidation of the pathways that result in pathogenesis is required 
to build a theoretical basis for successful treatment regimes, which would likely be 
combination therapies.  
 
1.4.3.4 Mechanistic insight into LMNA associated DCM 
 
As mentioned above, the importance of A-type lamins for cardiac health has been 
highlighted by the frequency of LMNA mutations that lead to cardiomyopathic 
presentation in the clinic. Moreover, HGPS patients were observed to suffer 
cardiomegaly and cardiac dilatation towards the end of life228, and in a separate study 
HGPS patients who survived to older ages were observed to display cardiac remodeling 
and atrial enlargement229. Additionally, a number of animal models with modified Lmna 
genes have given detailed insight into the possible pathological mechanisms that arise 
from LMNA mutations. These are discussed below.  
 
1.4.3.4.1 LmnaH222P/H222P mice 
 
In the heart, many LMNA mutations have been shown to cause a variety of 
cardiomyopathies in humans230, 231. Of these, the LMNA mutation H222P has been 
extensively assessed in vivo using LmnaH222P/H222P knock in mice232. Whilst these mice 
are born seemingly normal, at 16 weeks they display a classical DCM progression 
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leading to heart failure and death in males at 5-9 months and in females at 7-13 months. 
These mice experience a reduction in cardiac function (EF and FS) as well as cardiac 
fibrosis, which is thought to be triggered by increased nuclear translocation of Smad 
proteins and activation of TGFβ signalling232. Furthermore, elevation of ANP mRNA 
expression and dysregulation of myosin light chain 2 (MLC-2) and β-MHC mRNA 
expression indicates heart failure233.  
Biochemical analysis of the heart tissue suggests that mitogen activated protein 
kinase (MAPK) signalling is activated in these hearts, specifically the extracellular 
signal regulated kinase (ERK1/2) and c jun N-terminal kinase (JNK) branches of 
MAPK signalling. Pharmacological regulation of these pathways showed that a number 
of pathological mechanisms associated with DCM could be retrieved. Inhibition of JNK 
and ERK1/2 in mice significantly improved LV functional parameters, led to a 
reduction in fibrosis and collagen mRNA expression, normalised Myosin light chain 
(MLC) mRNA expression, and improved survival234-236. Moreover, the clinical 
relevance of activated ERK1/2 signalling in DCM has been confirmed in post mortem 
analysis of LMNA associated DCM cardiac tissue expressing alternative mutations, 
LMNA ΔK261 and LMNA IVS9 + 1g>a237, and provides a potential therapeutic lead as 
Selumetinib, an ERK1/2 inhibitor, which is currently undergoing trials for treatment of 
cancer, currently reports improved survival rates and minimal adverse effects238. 
Additional analysis suggests a role for dual specificity phosphatase 4 (Dusp4), which is 
elevated in LmnaH222P/H222P mice. Conditional overexpression of Dusp4 leads to DCM 
similar to that of LMNA associated DCM and mechanistically results in activation of the 
Akt/mTOR signalling pathway and subsequently, negatively regulates autophagy239. 
Treatment of the LmnaH222P/H222P mice with an inhibitor of mTOR, temsirolimus, 
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subsequently led to activation of autophagy, coupled with amelioration of cardiac 
decline240  
 
1.4.3.4.2 Lmna-/- mice 
 
The observation that autophagic activity is impaired is mimicked in global Lmna-/- 
mice241, which die between 6-8 weeks of age because of DCM and heart failure225. 
Moreover, intervention with the mTOR inhibitor rapamycin significantly improves 
cardiac function and survival in Lmna-/- mice, further strengthening the argument for 
mTOR signalling in LMNA associated DCM. Currently, modulation of Akt/mTOR 
signalling provides the most promising way forward for the treatment of LMNA 
associated DCM242, 243.  
Hearts of Lmna-/- mice also manifest a variety of other mechanistic traits that are 
important to consider. Phenotypically, Lmna-/- mice have irregular patterns of heart 
tissue histology and skeletal muscle dystrophy226 and succumb to severe systolic 
dysfunction225. Detailed cardiac characterisation has shown Lmna-/- CMs to be 
mechanically unsound. They have nuclear morphology defects and appear to undergo 
disruption of the LINC complex via nesprin1α leading to uncoupling of the nucleus 
from the cytoskeleton resulting in mechanical instability and defective force 
transmission in CMs244. Additionally, the IF protein desmin, which serves to link 
sarcolemma to the sarcomere and also the sarcomere to the nucleus, is also heavily 
mislocalised in these mice and further supports this hypothesis225. Moreover, nuclear 
import of the lamin binding partner, sterol response element binding protein 1 
(SREBP1) appears to be decreased along with peroxisome proliferator activated 
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receptor γ (PPARγ) expression. Activation of hypertrophic genes appears to be 
attenuated, and the suggestion is that Lmna-/- mice are unable to adapt to DCM 
progression with compensatory hypertrophy, which accounts for the speed of disease 
progression and short lifespan. Another key observation in Lmna-/- mice is that they also 
exhibit disorganisation and loss of connexins in the myocardium which would cause 
inhibition of cardiac conduction and may contribute to reduced force of contraction245, 
246 
 
1.4.3.4.3 LmnaN195K/N195K mice 
 
The lamin A N195K mutation is known to cause DCM with conduction defects in 
humans247. LmnaN195K/N195K mice developed DCM with associated conduction defects 
and died at 2-3 months old as a result of arrhythmia248. This was associated with 
increases in ANP and BNP as well as increased interstitial fibrosis and abnormal 
desmin localisation. Moreover, LmnaN195K/N195K mice experience loss of Connexins 40 
and 43, which accounts for reduced contractility and arrhythmia. Conduction defects 
could also be explained by an observed reduction in mRNA of HF1b/Sp4, a 
transcription factor that is important in the development of the cardiac conduction 
system249.  
  
1.4.2.3.4 LmnaΔK32/+ mice  
 
A crucial problem with many of the model systems of LMNA associated DCM is that 
most only show phenotypic changes when the mutation is homozygous, whereas in the 
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clinic, LMNA disease mutations are almost always heterozygous, leading to autosomal 
dominant phenotypes. Recently however, LmnaΔK32/+ mice were investigated and found 
to be pathogenic250. Deletion of lysine at position 32 in the lamin A amino acid 
sequence is known to cause severe congenital muscular dystrophy phenotypes in 
humans251. Interestingly, these mice presented with a DCM manifestation that occurred 
in a stepwise fashion with two distinct pathomechanisms resulting in death between 35 
and 70 weeks. The first mechanism observed that ‘toxic’ accumulation of ΔK32-lamin 
was avoided by degradation but led to a resultant decrease in lamin A/C expression, 
which, it was believed, began the process of cardiac remodelling and DCM. Secondly, 
the authors observed that after DCM was established, lamin A/C levels normalised. This 
was coupled with dysfunction of the ubiquitin proteasome system (UPS) and an 
increase in ΔK32-lamin, thereby worsening the dominant negative effect of ΔK32-
lamin.  
 
1.4.2.3.5 LmnaMHC-M371K mice 
 
Another study that has circumvented the autosomal dominant problem looked at 
LmnaMHC-M371K mice. M371K substitution in the amino acid sequence of lamin A was 
shown to cause EDMD in humans252. In the mouse model, mutant DNA was 
incorporated onto the MHC promoter, creating a cardiac specific overexpression model 
in which wildtype lamins were unaffected. These mice had a very low survival ratio of 
0.07 and those that did survive succumbed between 2-7 weeks from cardiac defects253. 
The implications of this study are that accumulation of the mutant M371K-lamin is 
toxic even in the presence of endogenous wildtype lamins.  
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1.4.2.3.6 Other lamin associated models with cardiac defects 
 
Other lamina associated models with cardiac presentation include Lmna+/- mice, which 
have early onset cardiac conduction system (CCS) disease and late onset DCM227, 
which could be alleviated by exercise and β-blockers254. LmnaL530P/L530P mice were 
progeric and also showed a cardiac phenotype255. Zmpste24-/- mice showed fibrosis and 
lymphocytic infiltration of the myocardium and observed thinning of the ventricular 
wall, suggestive of cardiomyopathy214. Another study of interest showed that 
accumulation of non-farnesylated prelamin A led to DCM in mice expressing a 
homozygous ‘non-farnesylated prelamin A only’ allele219. This is interesting because 
the data imply that different stages of prelamin A processing may lead to diverse 
cellular responses.   
 
1.5 The special case of prelamin A 
1.5.1 The role of prelamin A in normal ageing 
 
The most compelling evidence for the role of prelamin A in normal ageing comes from 
recent work done by Ragnauth et al who postulated that prelamin A acccumulation may 
have real implications for the biology of normal ageing256. Indeed they showed that 
prelamin A accumulation is a signature of senescence in VSMCs. Furthermore, this 
accumulation is initiated not by changes in prelamin A but by a downregulation of 
FACE1 activity, which is mediated by oxidative stress. Additionally, by inhibiting 
FACE1 using siRNAs in early passage (young) VSMCs, prelamin A accumulation can 
accelerate senescence phenotypes and disrupt mitosis. Finally, analysis of aged VSMCs 
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displaying increased levels of prelamin A showed increases in DNA damage signalling 
suggesting that prelamin A induced DNA damage, which was confirmed by comet 
assays. Importantly, it is thought that oxidative stress may play a role in regulating 
FACE1 activity although the precise mechanism is unknown. Evidence from a study 
which looked at fibroblasts isolated from young, old and centenarian patients supports 
this notion257. Cells assessed from old and young patients that were subject to 
replicative stress were found to accumulate prelamin A and became senescent, whilst 
centenarian cells accumulated prelamin A but did not become senescent. Furthermore, 
young and old cells subject to oxidative stress experienced decreased FACE1 
expression and increased prelamin A expression, a response that was attenuated in 
centenarian cells. Additionally, in young and old cells that were allowed to recover from 
stress, expression levels returned to pre-treatment levels. These observations, coupled 
with the fact that prelamin A accumulation in centenarians is not associated with 
senescence, suggests that prelamin A accumulation is an adaptive response. The 
hypothesis that senescence is an adaptive response in order to combat the oncogenic 
hegemony associated with advancing age is not a new idea, but these data suggest that 
prelamin A accumulation is part of the mechanism. Another study investigated 
Zmpste24 mosaic mice, which were null for Zmpste24 on the autosomal Zmpste24 locus 
(Chromosome 4) but had an extra copy of Zmpste24 placed on the X chromosome at the 
Hprt locus. Consequently, animals accumulated prelamin A in half of cells whilst the 
other half produced wildtype lamin A. The results were intriguing. Contrary to the 
original Zmpste24-/- model, mice were long lived, despite expressing prelamin A. The 
mechanism put forward by the authors was that non-progeric cells rescued the 
phenotype of progeric cells and that, as such, cell-extrinsic mechanisms were crucial in 
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the development of progeroid syndromes. Additionally, the authors discovered that 
prelamin A expression in these mice was anti-oncogenic, as they found that prelamin A 
was capable of preventing metastasis and therefore identified ZMPSTE24/FACE1 as a 
target for cancer treatment258.  
 In summary, the paradigm that emerges suggests that the accumulation of 
prelamin A may be intended to be an adaptive response to confer resistance against 
cancer phenotypes. However, the acute implications for prelamin A accumulation are 
deleterious as they cause cellular senescence.  
 
1.5.2 Is there a role for prelamin A in heart disease?  
 
Evidence for a prelamin A centric role in cardiac disease is beginning to emerge. 
Clinically, HGPS patients have been shown to display a cardiac phenotype228, 229. 
Furthermore, in a mouse model of HGPS, LmnaG609G/G609G mice259 showed compelling 
evidence for cardiac dysfunction as the mice developed bradycardia between 9-15 
weeks coupled with a prolonged QRS complex, suggesting an inhibition of ventricular 
depolarisation. However, these mice did not appear to develop DCM. As mentioned 
above, Zmpste24-/- mice, which accumulated prelamin A, although not yet subjected to a 
detailed cardiac characterisation, showed evidence of myocardial disruption214. 
Furthermore, LmnanPLOA mice, which accumulated non-farnesylated prelamin A, led to 
DCM in vivo219. Moreover, DCM causing mutations have been shown to accumulate 
prelamin A in a variety of systems. In vivo, LmnaMHC-M371K mouse heart tissue expressed 
unprocessed prelamin A intermediates253, whereas in isolated cell cultures, viral 
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transduction and expression of the R89L lamin mutant prevented prelamin A 
processing260.  
It is well established that global accumulation of prelamin A leads to premature 
ageing but, considering the current dogma that laminopathies are essentially a subset of 
premature ageing disorders, it is curious that researchers have never explored the notion 
of myocardial senescence in models of LMNA associated DCM. The observation that 
mTOR signalling plays a key role in LMNA associated DCM (mTOR is a famous 
ageing pathway) supports a myocardial senescence paradigm and, incredibly, there have 
been no published observations regarding DNA damage accumulation in LMNA models 
of DCM. Many of the DCM models show nuclear morphology defects and some show 
heterochromatin disorganisation. These phenotypic features are also observed in HGPS 
and are associated with the accumulation of DNA damage, and it is thought these 
processes underlie the premature senescence paradigm.  
The pleiotropic effects of single LMNA mutations, such as the R644C mutation 
for example187, suggested that external factors may be important in the establishment of 
disease, a hypothesis which is now backed by evidence which implies that cells with 
prelamin A variants are susceptible to environmental stresses258. The nature of these 
stresses may influence pathogenesis. Finally, if one considers this evidence and the 
notion that dilatation of the cardiac chambers is an end stage process of progressive 
heart disease, often occurring as a product of age, it could be postulated that LMNA 
associated DCM is a form of premature cardiac ageing.  
 In summary, current evidence displays a variety of nuanced cardiac 
manifestations arising from defective prelamin A processing. Moreover, DCM observed 
in the setting of LMNA mutations may be a pathologic end point of a senescence-like 
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phenotype. Focussed investigation is needed to confirm the importance of prelamin A 
accumulation in cardiac pathogenesis.  
 
1.6 Aims of thesis 
 
To study the significance of prelamin A accumulation, we decided to utilise a system of 
targeted transgenesis to assess the impact of prelamin A in cardiac tissue of mice. The 
human L647R-prelamin A variant, which has a mutation at the FACE1 cleavage site 
and cannot be processed to yield mature lamin A, has been studied extensively by viral 
transduction in vitro124, 256. In our study it was placed into the ROSA26 locus and driven 
by the ventricular myosin light chain (MLC2v) promoter for CM specific expression. In 
doing so, the autosomal Lmna locus remained unaffected and lamin A/C expression was 
maintained. Using this model I aimed to: 1) Characterise the functional significance of 
prelamin A accumulation in the heart in vivo; 2) Use in situ/ex vivo techniques to 
identify morphological and histological traits in order to elucidate a cellular phenotype; 
3) Utilise fluorescence microscopy and biochemical assays to elucidate potential 
pathogenic mechanisms for prelamin A induced DCM.  
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Chapter 2: Materials and Methods 
2.1 Materials 
All reagents and solutions are detailed in table or list format below; materials and 
machines are incorporated within the Methods text. 
Table 2.1 Reagents 
Laboratory reagents Source Catalogue 
number 
30% Bis-Acrylamide solution  BioRad 161-0158 
5x buffer & RNase inhibitor kit  Promega M1705 
Ammonium Persulfate (APS) Bio-Rad 161-0700 
BDM (2,3-Butanedione monoxomine) Sigma-Aldrich B0753 
Biotin-16-dUTP Roche 11388908910 
Bovine Serum Albumin (BSA) Sigma-Aldrich A4503 
Bromophenol Blue  Sigma-Aldrich 11,439-1 
Chloroform Sigma-Aldrich C2432 
Citrate Buffer Vector Laboratories H-3300 
Cobalt Chloride, Hexahydrate Sigma-Aldrich 255599 
Collagenase, Type II Worthington 4167 
Coomassie G-250 stain Bio-Rad 161-0786 




DC Protein Assay Bio-Rad 500-0113, 500-
0114 
DEPC-treated water  Invitrogen 750023 
Di-methyl formamide Sigma-Aldrich D4551 
Disodium Phosphate (NaHPO4) Sigma-Aldrich S5136 
DMSO (dimethyl sulfoxide) Sigma-Aldrich D8418 
DNase I Sigma-Aldrich AMPD1 
dNTPs master mix  Promega NU-0010-10 
DPX mountant VWR International 360292F 
Dulbecco’s Modified Eagle’s Medium  Sigma-Aldrich D5671 
Earl’s Balanced Salt solution (EBSS) Sigma-Aldrich E6267 
Enhanced Chemiluminescent (ECL) kit  Pierce 32106 
Eosin Raymond A Lamb 
Ltd 
Lamb/100d 
Ethanol (CH3CH2OH, EtOH) Sigma-Aldrich E7023 
Ethidium Bromide Sigma-Aldrich E1510 
Ethylenediaminetetra-acetic Acid (EDTA)  Sigma-Aldrich E5134 
Foetal Bovine Serum (FBS)   Sigma-Aldrich F7524 
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Gelatin Sigma-Aldrich G1393 
Glucose VWR 101174Y 
Glutaraldehyde (EM grade) Agar Scientific R1314 
Glycine  Fisher Scientific BP381-500 
Harris’ Haematoxylin Raymond A Lamb 
Ltd 
Lamb/230d 
Heparin Leo Laboratories PL 0043/0041R 
HEPES  Sigma-Aldrich H4034 
HEPES Sigma-Aldrich H3375 
Hiperfect transfection reagent  Qiagen 301707 
Hydrogen Chloride (HCl)  Sigma-Aldrich 320331 
Isofluorane Abbott B506 
Isopentane Sigma-Aldrich M32631 
Isopropanol (C3H8O) Sigma-Aldrich I9516 
L647R-LMNA Adenovirus In-House - 
M-MLV Reverse Transcriptase  Promega M1701 
M199 media  Sigma-Aldrich M4530 
Magnesium Sulphate (MgSO4) Sigma-Aldrich M-2643 
Manganese chloride (MnCl2) Sigma-Aldrich 244589 
Methanol (CH3OH,MeOH)  Sigma-Aldrich 322415 
Milk (dried skimmed) Marvel Any good corner 
shop 
Monopotassium Phosphate (KH2P04) Sigma-Aldrich P5655 
Mowiol  Calbiochem 475904 
NP-40 alternative Calbiochem 492016 
Oligo (dT) primers Promega C1101 
Optimal cutting tempaerature (OCT) 
compound 
Sakura finetek 4583 
Pancreatin Sigma-Aldrich P3292 




Paraformaldehyde powder  Sigma-Aldrich P6148 
PBS tissue culture grade Sigma-Aldrich D1408 
Penicillin-Streptomycin-Glutamine 
solution  liquid 
Invitrogen 10378-016 
Pentobarbital Animalcare 1409CE102 
Phosphate buffered saline (PBS) tablets Oxoid BR0014G 
phosphomolydbic acid Sigma-Aldrich HT153 
Picric acid Sigma-Aldrich P6744 
Potassium Chloride (KCl) Sigma-Aldrich P5405 
Potassium hexacyano-ferrate (II) 
Trihydrate 
MP Biomedicals 152560 
Potassium hexacyano-ferrate (III) MP Biomedicals 152559 
Potassium Hydrogen Carbonate Sigma-Aldrich P9144 
primers (ZMPSTE24) Qiagen QT00024627 





Protease Inhibitor Cocktail Sigma-Aldrich P8340 
Protein standards (Precision Plus ProteinTM 
Dual Colour Standards 
Bio-rad 161-0374 
PVDF membrane (Immobilon-PTM) Millipore IPVH00010 
Random Primers  Promega C1181 
RNA STAT-60™ AMS Biotechnology 
Ltd 
CS-110 
RNase away  Molecular 
Bioproducts 
7003 
SDS Fluka Analytical 05030 
Sirius red (Direct Red 80) Sigma-Aldrich 365548 
Sodium Cacodylate, Trihydrate Sigma-Aldrich C0250 
Sodium Chloride (NaCl)  Sigma-Aldrich S7653 
Sodium Chloride (NaCl) Sigma-Aldrich S5886 
Sodium Citrate, Trihydrate Sigma-Aldrich A4034 
Sodium fluoride (NaF) Sigma-Aldrich 201154 
Sodium Hydrogen Carbonate Sigma-Aldrich S5761 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich S6508 
SYBR green qPCR master mix  Eurogentec RT-SY2X-
03+NRWOUB 
Taurine Sigma-Aldrich T-8691 
TEMED Bio-Rad 161-0801 
Terminal transferase (TdT) Roche 03333566001 
Triton-X 100  Sigma-Aldrich X100 
TrizmaTM base Sigma-Aldrich T6066 
Trypsin (phenol red free) 10x Invitrogen 15400-054 
Trypsin 1x-EDTA solution Sigma-Aldrich T3924 
Tween 20 Sigma-Aldrich P2287 
Urea Sigma-Aldrich U6504 




Xylene Sigma-Aldrich 534056 
β-Mercaptoethanol (C2H6OS, βME) Sigma-Aldrich M6250 
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Table 2.2. Antibodies used for this investigation. WB = western blot, IF = 










CD45 Abcam 1:1000 1:100 - 
Cleaved Caspase3 Cell Signaling 9661 1:1000 - - 
Cleaved LC3 II Abgent AP1805a 1:500 - - 
Connexin 43 Zymed 71007 1:100 1:100 - 
Desmin Dako M0760 1:100 1:100 - 
Emerin  Leica Biosystems 
NCL-Emerin 
1:500 - - 
GAPDH Sigma-Aldrich 
G8795 
1:1000 - - 
KDEL Enzo life sciences 
ADI-SPA-827 
1:2500 - - 
Lamin A/C (N-18) Santa Cruz 
Biotechnology sc-
6215 
1:1000 - - 
Lamin B1 Abcam ab16048 1:1000 1:1000 - 
Myomesin B4 E.Ehler (homemade) 1:1000 1:100-200 - 
Nesprin 1α N3 Homemade 1:1000 - - 
Nesprin 2 N3 Homemade 1:1000 1:100  - 
p-H2AX Cell signalling 9718 1:1000 1:1000 - 
p16  Cell signalling 4824 1:1000 - - 
p21  Cell signalling 2947 1:1000 - - 
p53 Cell signalling 9282 1:1000 - - 
p65 Santa cruz 
Biotechnology sc-
372 






1:200 1:1000 1:250 
SUN 2 Abcam ab65447 1:100 1:100 - 
Zmpste24/FACE1 Novus Biologicals 
NB100-2388 
1:200 1:100 - 
α-actinin Sigma-Aldrich 1:1000 1:250 - 






1:10,000 - - 
Secondary 
Antibodies 










Invitrogen A-11055 - 1:1000 - 
Anti-goat Alexa 
fluor 568 





1:5000 - - 
Anti-mouse Alexa 
488 
Invitrogen A11004 - 1:1000 - 
Anti-mouse Cy3 Jackson Laboratories 
715-150-150 





1:5000 - - 
Anti-rabbit Alexa 
fluor 488 









kit (see reagents) 
- - 1:500 
IRdye 800 Anti-
goat 
LICOR 926-32214 1:15000 - - 
IRdye 800 Anti-
mouse  
LICOR 926-32210 1:15000 - - 
IRdye 800 Anti-
rabbit 
LICOR 926-32211 1:15000 - - 
IRdye680 Anti-
rabbit 
LICOR 926-68073 1:15000 - - 
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2.1.1 Solutions  
(final concentrations dissolved in ddH2O, unless otherwise stated) 
 
1x Phosphate buffered Saline (PBS) 
1 PBS pellet/100ml ddH2O 
1x Phosphate Buffered Saline with Tween (PBS-T) 
 1xPBS, 0.001% Tween-20 
1x Tris Buffered Saline (TBS) 
 50 mM Tris-HCl pH 7.5, 150 mM NaCl   
1x Tris Buffered Saline with Tween (TBS-T) 
 1x TBS, 0.001% Tween-20 
1x Transfer Buffer  
 25 mM Tris, 192 mM glycine, 10% methanol 
1x Running Buffer 
 25 mM Tris, 192 mM glycine, 0.1% SDS 
1x Tris-Acetate-EDTA (TAE) Buffer 
 40 mM Tris-acetate, 1 mM EDTA 
5x SDS-PAGE sample loading buffer (10 ml) 
60 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01% 
bromophenol blue 
ADS Buffer  
116 mM NaCl, 20 mM HEPES, 1 mM NaH2PO4, 5 mM Glucose, 5.4 mM KCl, 
0.8 mM MgSO4 -> pH=7.35 (NaOH). Filter sterilized. 
Agarose gel 
 1.5% molecular grade agarose, 1x TAE 
Blue Wonder Sample loading buffer 
3.7 M urea, 134.6 mM Tris pH 6.8; 5.4% SDS; 2.3% NP-40; 4.45% beta-
mercaptoethanol; 4% glycerol and 6 mg/100 ml bromophenolblue 
Enzyme reagent 
 4 % Terminal transferase (TdT) in TdT storage buffer  
Enzyme Solution (75 ml) 
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61.5 mg Collagenase (300 U/mg), 45.0 mg Pancreatin in 75 ml ADS buffer 
>Filter sterilized. 
Formalin solution 
 4% Paraformaldehyde (w/v) in 1x PBS 
Label reagent 
 0.4% Biotin-16-dUTP in TdT reaction buffer 
Maintenance Media (500 ml) 
400 mL DMEM #D5671, 100 ml Medium 199 #M2154, 5 ml 
Pen/Strp/Glutamine 100x 
Membrane blocking buffer 
 5% milk, 1x TBS-T 
Mowiol Mounting Media (25 ml) 
32 μM Mowiol, 2.67 M Glycerol 6ml ddH2O. Mix and leave ON. Add 13 ml 0.2 
M TRIS pH 8.5, Stir at 50°C until dissolved. 
Physiological saline solution (PSS) 
113 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 0.6 mM Na2HPO4, 0.6 mM 
KH2PO4, 12 mM NaHCO3, 10 mM KHCO3, 30 mM Taurine, 10 mM HEPES. 
Plating medium 
340 ml DMEM #D6546, 85 ml Medium 199 #M2154, 50 ml Horse serum, 25 
ml Non-Heat inactivated FBS, 5 ml Pen/Strp/Glutamine 100x. 
Radioimmunoprecipitation (RIPA) buffer (100 ml) 
 100 μl NP-40, 0.5% Sodium deoxycholate, 100 μl 10% SDS, 98.4 ml 1x PBS 
SDS-PAGE Stacking Gel (5%) 
331 mM Bis-acrylamide, 62.5 mM Tris pH 6.8, 0.1% APS, 0.1% SDS, 0.01 % 
TEMED 
SDS-PAGE Resolving Gel (8%) 
525 mM Bis-acrylamide, 375 mM Tris pH 8.8, 0.1% APS, 0.1% SDS, 3.4 mM 
TEMED 
SDS-PAGE Resolving Gel (10%) 
641 mM Bis-acrylamide, 375 mM Tris pH 8.8, 0.1% APS, 0.1% SDS, 3.4 mM 
TEMED 
SDS-PAGE Resolving Gel (12%) 
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778 mM Bis-acrylamide, 375 mM Tris pH 8.8, 0.1% APS, 0.1% SDS, 3.4 mM 
TEMED 
SDS-PAGE Resolving Gel (12%) 
973 mM Bis-acrylamide, 375 mM Tris pH 8.8, 0.1% APS, 0.1% SDS, 3.4 mM 
TEMED 
Senescence associated β-Galactosidase solution 
 40 mM Citric acid/NaP, 5 mM KFeCN II, 5 mM KFeCN III, 150 mM NaCl, 2 
mM MgCl, 0.1% X-Gal. 
Stop wash buffer 
 300 mM NaCl, 30 mM Na3C6H5O7. 
TdT reaction buffer 
 25 mM Tris-HCl, 200 mM C2H7AsO2, 0.25 mg/ml BSA, 1 mM CoCl2. 
TdT reaction mixture 
 10% Enzyme reagent in label reagent 
TdT storage buffer 
 60 mM K2HPO4, 150 mM KCl, 1 mM 2-mercaptoethanol, 0.5% Triton X-100, 
50% glycerol. >pH 7.2 HCl 
X-Gal solution 
 2% X-Gal (anhydrous) in Dimethylformamide. 
 
  




2.2.1 In vivo studies 
2.2.1.1 Generation of cardiac specific prelamin A transgenic mice 
 
All procedures were performed in accordance with the Guidance on the Operation of the 
Animals (Scientific Procedures) Act, 1986 (UK Home Office). Our laboratory has 
previously shown that transduction of a viral plasmid vector containing uncleavable 
prelamin A leads to premature senescence of VSMCs35. The construct contains a 
mutated LMNA sequence resulting in the translation of a protein containing an arginine 
at position 647 in place of leucine, (L647R-LMNA) which is normally present in the 
wild type amino acid sequence. This allows the first cleavage step and prenylation to 
take place but not the final cleavage step, therefore resulting in a permanently 
farnesylated prelamin A protein. The toxic nature of this protein in vitro led to the 
hypothesis that in vivo expression would lead to a phenotype representative of 
premature ageing. Therefore, in collaboration with Taconic artemis GmbH, a 
conditional transgenic system was devised to assess the in vivo effects of uncleavable 
prelamin A expression. The system involves recombinase mediated cassette exchange 
(RMCE) of the Rosa26 gene whereby L647R-LMNA cDNA is inserted into an exchange 
vector containing a neomycin resistance gene, a strong CAGGS promoter sequence and 
a STOP cassette flanked by loxP sites (Fig 2.1). Electroporation into the embryonic 
stem (ES) cells of C57BL/6 mice led to site-specific recombination by the recombinases 
F3 and FRT. Neomycin resistant clones that had undergone RMCE were selected. After 
administration of hormones, superovulated BALB/c females were mated with BALB/c   









Figure 2.1. Generation of cardiac-specific L647R LMNA transgenic mouse line. 
Modified from: “Targeted Transgenic Mouse Models” (URL: 
http://www.taconic.com/CMGS/TransgeneExpression/TargetedTransgenesis). SA: 
Splice Acceptor site, pA: Polyadenylation signal, STOP: Transcription termination site, 
CAGGSprom: CAG promoter, neoR/HygR: Neomycin/Hygromycin B resistance gene. 
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males. Blastocysts were isolated from the uterus at 3.5 days post coitum (dpc) for 
microinjection. Blastocysts were placed in a drop of DMEM with 15% FCS under 
mineral oil. A flat tip, piezo actuated microinjection-pipette with an internal diameter of 
12-15 µm was used to inject 10-15 targeted C57BL/6NTac ES cells into each 
blastocyst. After recovery, 8 injected blastocysts were transferred to each uterine horn 
of 2.5 dpc, pseudopregnant NMRI females. Chimerism was measured in chimeras (G0) 
by coat colour contribution of ES cells to the BALB/c host (black/white). Highly 
chimeric mice were bred to strain C57BL/6 females.  
 
2.2.1.2 Genotyping  
 
For genotyping, DNA was isolated from ear biopsies by incubation in 300 μl 50 mM 
NaOH at 95°C for ~5 min followed by vortexing and addition of 25 μl Tris-HCL pH 8. 
Genotyping for transgene identification was achieved with primers (Table 2.3) designed 
to identify the wildtype Rosa26 and L647R-LMNA modified Rosa26 alleles 
simultaneously. PCR was achieved with 5 μmol primers (1 μl 100 μmol stock solution), 
2 μl DNA, 10 μl of 2x PCR master mix containing dNTPs, MgCl, 2x buffer 
concentration and loading dye, made up to 20 μl with ddH2O. The contents of the 
reaction were mixed by pipetting up and down in a 0.2 ml thin-walled PCR tube and 
subjected to the following thermal cycling parameters: initial denaturation 95°C 1 min, 
denaturation 95°C 30 seconds*, annealing 60°C 30 seconds*, extension 72° 1 min*, 
final extension 72°C 10 min, cooled to 4°C indefinitely (*repeated for 35 cycles). PCR 
products were separated by agarose gel (containing 5x10-5 % ethidium bromide) 
electrophoresis and PCR products were visualised using UV detection. Mice positive  











Table 2.3 List of PCR primers used in this investigation for genotyping 
Primers Sequence (5’-3’) Amplicon size (bp) 
PLA Tg F – GTGGATGCTGAGAACAGGC 
R –TCCACCTGGTCCTCATGC 
Wt Rosa26 – 377 
Modified Rosa26 – 200 
Cre F – TGCCAGGATCAGGGTTAA 
R – CCCGGCAAAACAGGTAGTTA 
200 
GAPDH F – CGTAGACAAAATGGTGAAGG 
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for the transgene were selected for breeding with mice expressing Cre recombinase. 
Identification of offspring was achieved by performing two separate PCRs: one to 
identify carriage of the transgene and one to identify Cre recombinase (Table 2.3). Mice 
positive for both the transgene and Cre were selected as experimental (PLA Tg) 





Echocardiography was performed using a Vevo 2100 imaging system with a 30 MHz 
linear transducer specially designed for small animal studies (VisualSonics, USA). 
Echocardiography was performed with 5% isofluorane fast induction of anaesthesia 
followed by maintenance of 1-1.5% isoflurane anaesthesia for 4 week old mice and 
2.5% isofluorane for 2 week old mice, which was vaporized in 100% oxygen delivered 
at 1.5-2 liters/min. Heart rate was kept at ~400-450 beats per minute while respiratory 
rate was ~100 breaths per minute. Body temperature was ~36.5±1°C. 
 
2.2.1.4 Magnetic Resonance Imaging (MRI) of hearts 
 
Cardiovascular MRI was performed by Dr Andrea Protti on a 7 Tesla (T) horizontal MR 
scanner (Varian Inc., Palo Alto, CA) with mice in the prone position. The gradient coil 
had an inner diameter of 12 cm, the gradient strength was 1000 mT/m (100 G/cm), and 
rise-time was 120 ms. A quadrature transmit/receive coil (RAPID Biomedical GmbH, 
Germany) with an internal diameter of 39 mm was used. Anesthesia was maintained 
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with 1.5% isoflurane/98.5% oxygen and body temperature was maintained at 37°C 
using a warm air fan (SA Instruments, Stony Brook, NY). The ECG was monitored by 
means of two metallic needles placed subcutaneously in the front paws. A pressure-
transducer for respiratory gating was placed on the animal abdomen. To synchronize 
data acquisition with the ECG and to compensate for respiratory motion, simultaneous 
ECG triggering and respiration gating (SA Instruments) were applied. 
 
2.2.1.5 Harvesting of mouse heart 
 
Mice were anaesthestised with 2% isofluorane. When unconscious, mice were removed 
from the anaesthesia chamber and subject to cervical dislocation. Mice were then laid 
on their back and secured to a dissection surface (cork or polystyrene). The chest cavity 
was then opened and held back with a hemostat. Prior to harvesting, a syringe was 
clamped approximately 1 metre above the dissection surface. It was fitted with plastic 
tubing capable of servicing the dissection area, which was in turn fitted with a needle at 
the end. The syringe was filled with a salt solution containing 5% KCl and 0.9% NaCl 
capable of arresting the heart in diastole. The reasoning for having a raised reservoir 
was to, in some way, mimic the perfusion pressure of blood flow into the heart and to 
maintain a consistent pressure and therefore preserve cardiac anatomy. The hearts were 
injected with the needle and the stop-cock turned to on. The hearts were perfused until 
they had ceased beating and were pale, indicating efficient removal of blood from the 
hearts. The hearts were excised and washed in cold PBS. They were blotted with tissue 
to remove excess fluid and then weighed (wet weight). The lungs were also excised, 
washed and weighed; the right hind limbs of the mice were removed; and the 
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gastrocnemius was trimmed from the tibia and the tibia was measured using calipers for 




Mice were subject to observation and weighed regularly. When it became apparent that 
the phenotype of the PLA Tg mice was failure to thrive and premature death, it was 
decided that when the weight of a mouse fell below 75% of its Wt littermates, it was 
deemed to be suffering the maximal threshold of pain permitted on the project license 
and was culled. The age was recorded and used for Kaplan-Meier survival analysis. 
Post-mortem morphometry analysis was performed using heart and lung weight as well 
as tibia length. 
 
2.2.1.7 Tissue fixation and processing 
 
Post-PBS washing, tissue was placed in 1% Formalin solution at 4°C. Tissue was 
washed once in PBS and then placed into processing cages in 75% Ethanol. Tissues 
were subject to dehydration protocol and mounted in wax blocks. They were stored at 
room temperature for future use. 
 
2.2.1.8 Tissue cryopreservation 
 
Upon dissection and excision from the chest cavity, hearts were cryopreserved by 
immersion in isopentane whilst simultaneously immersing the container in liquid 
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nitrogen. Upon cessation of the gaseous plume emitted from the container of 
isopentane, the hearts were presumed frozen and transferred to a cryotube. The tubes 
were stored at -80°C. 
 
2.2.2 Ex vivo studies 
2.2.2.1 Human heart specimens 
 
Human specimens were obtained by Dr Elisabeth Ehler from The University of Sydney, 
Australia via St Vincent’s Hospital (Hospital Research Ethical Committee approval 
#H03/118; University of Sydney ethical approval #12146). Human materials were used 
in accordance with the ethical guidelines of King’s College London (College Research 
Ethical Committee 04/05-74; REC reference 12/EM/0106) and the current UK law. 
 
2.2.2.2 Sectioning of tissue mounted in wax blocks 
 
Wax blocks were kept at -20°C for 1 hour prior to sectioning. A water reservoir was pre 
heated to 45-50°C. Upon removal from the freezer, the blocks were mounted onto a 
microtome rotary sectioner and slices were cut 7-10 μm thick. Slices were transferred to 
the water reservoir to allow any creases or folds to smooth out. The slices were then 
mounted onto high quality polylysine or superfrost slides and allowed to air dry on a 
surface heated to 45°C.  
  
 On the role of prelamin A in the heart  
 
 76 
2.2.2.3 Sectioning of cryopreserved tissue 
 
Tissue was removed from storage at -80°C and warmed to -20°C for approximately 1 
hour. Tissue was then mounted onto the stage of a cryostat with OCT compound and 
allowed to equilibrate to the ambient temperature of the cryostat for 5 min; for cutting 
heart tissue or skeletal muscle, the stage temperature was set to -22°C and the knife was 
set to -20°C. The sections were then cut to 10 μm thick and mounted onto high quality 
polylysine or superfrost slides. The sections were allowed to air dry for approximately 1 
hour and then stored at -80°C. 
 
2.2.2.4 Indirect immunofluorescence of cryosectioned tissue 
 
Sections were allowed to dry completely and fixed by immersion, in a coplin jar, in pre 
cold 100% methanol at -20°C for 5 min or 4% formalin for 10 min RT. Sections were 
washed 2x5 min in PBS. Sections were permeabilised in 0.5% NP-40 for 3 min RT and 
washed 3x5 min in PBS. Sections were blocked in 3% serum originating from a species 
to which the antibody was not raised against for 1 hour RT. Primary antibody was 
diluted appropriately in blocking solution applied to the sections and incubated in a 
humidified chamber overnight at 4°C. Sections were washed 3x5 min in PBS and 
secondary antibody conjugated to a fluorophore was diluted as appropriate, applied to 
the sections and incubated in the dark in a humidified chamber for 1 hour RT. DAPI 
was added 1:10,000 for 5 min at the end of the incubation for visualisation of nucleic 
structures. Sections were washed 3x5 min in PBS in the dark and then mounted in 
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mowiol mounting media and allowed to dry in the dark overnight. Antibody dilutions 
can be found in Table 2.2. 
 
2.2.2.5 Homogenisation of Tissue  
 
Cryopreserved heart tissue was homogenised by placement into a pre-liquid nitrogen 
cooled steel chamber (Independent metal worker) followed by crushing administered by 
a pre-liquid nitrogen cooled stainless steel rod (Independent metal worker) and rubber 





Whole cell lysates were made by scraping cells into 100-150 µl RIPA lysis buffer and 
transferring to clean sterile tubes. Lysates were incubated for 5 min on ice. A protein 
assay was then performed to determine protein concentration and lysis buffer and/or 4x 
sample buffer was added to give a concentration of 1.5-2 mg/µl accordingly. 
Alternatively, tissue samples were homogenised using the ‘rod-in-chamber’ technique 
and 200 μl blue wonder sample buffer was added. The tubes were heated to 85°C for 5 
minutes. A chamber was prepared with an SDS gel of 10% acrylamide concentration. 
20µl was then loaded into each well of the gel. The proteins were separated at 150 mV. 
Transfer was achieved in wet conditions. The proteins were subject to electrophoretic 
transfer onto PVDF membranes that had been incubated in methanol for 20 seconds and 
then washed in distilled water. The transfer conditions were 65 Amps at 4°C ON. The 
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membrane was blocked for 1 hour with 5% Milk in TBS-T. Primary antibodies were 
added (Table 2.2) with TBS-T/5% milk and incubated overnight at 4°C. The membrane 
was washed 3x5 min with TBS-T. The blots were then incubated in secondary antibody 
coupled to horseradish peroxidise for 1 hour at room temperature or secondary antibody 
conjugated to a fluorophore for 1 hour. The blots were again washed with TBS-T and 
bound antibody was detected by ECL plus western blotting analysis system. Signals 
were detected by exposure to X-ray film. In the case of fluorophore conjugated 
secondary antibodies, an Odyssey® scanning detection system (LI-COR Biosciences, 
U.S.A) was used to detect signals. Western blots were quantified using ImageStudio™ 
software (LI-COR Biosciences, U.S.A). 
 
2.2.2.7 Extraction of RNA from tissue samples 
 
200 μl RNA stat-60™ was placed onto the homogenate and allowed to freeze. The 
pellet was removed, placed into a cryo-tube and allowed to thaw, and an additional 800 
μl of RNA stat-60™ was added. The homogenate was kept at room temperature for 5-
10 min to allow dissociation of nucleoprotein complexes. The samples were then frozen 
overnight at -80°C and thawed the following day. After thawing, 0.2 ml of chloroform 
was added, and then the tubes were closed tightly and shaken vigorously for 15+ 
seconds. The samples were left to incubate for 2-3 min RT. The homogenate was then 
centrifuged at 12,000 g for 10 min at 4°C. After centrifugation, two phases were 
discernable: a lower red phenol chloroform phase and a colourless upper aqueous phase. 
The upper aqueous phase containing uncontaminated RNA was carefully pipetted and 
transferred to a fresh tube and mixed with 500 μl of isopropanol. Samples were 
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incubated for 10 min RT and then centrifuged at 12,000 g for 5 min at 4°C. After 
centrifugation, a white pellet containing RNA remained. The supernatant was then 
carefully removed and the pellet washed once with 75% ethanol and vortexing. The 
pellets were centrifuged at 7,500 g for 5 min at 4°C and the supernatant discarded. The 
pellets were allowed to air-dry before solubilisation in 30 μl of DEPC treated water. 
RNA yield was determined by Nanodrop ND 1000 (Labtech International).  
 
2.2.2.8 Making complementary DNA from RNA 
 
2 μg RNA was diluted into 10 μl of double distilled (dd) H2O. 0.3 μl Oligo dT primer, 
0.3 μl random primer and 1μl dNTPs was added to this and heated to 65°C and then 
cooled to 4°C in a thermocycler. 4 μl 5x Buffer, 3.9 μl DEPC-treated H2O and 0.5 μl 
reverse transcriptase (M-MLV) was added and samples were heated in a thermocycler 
to 25°C for 10 min, 37°C for 50 min and cooled to 4°C. After the reaction, the samples 
were diluted to 100 μl total volume for qPCR. 
 
2.2.2.9 Quantitative (q)PCR 
 
qPCR was carried out using the ΔCt and standard curve methods. When the ΔCt method 
was used the primers had been pre-validated and were part of a standard protocol for the 
lab.  
  9 μl cDNA was added to 10 μl 2x Sybr green PCR master mix and 5 μmol of 
forward and reverse primers (Table 2.4). Cycling parameters were 94°C for 15 seconds, 
followed by single-step annealing and extension at 60°C for 1 min (35 cycles).   









Table 2.4 List of qPCR primers used in this investigation 
Primers Sequence (5’-3’) 
ANP F – CGTGCCCCGACCCACGCCAGCATGGGCTCC 
R –GGCTCCGAGGGCCAGCGAGCAGAGCCCTCA 
BNP F –AAGGGAGAATACGGCATCATT 
R – ACAGCACCTTCAGGAGATCCA 
α-MHC F – CAGAGATTTCTCCAACCCAGCTGCG 
R – AGTCAGCCATCTGGGCGTCCG 
β-MHC F –AGCAGCAGTTGGATGAGCGACT 
R – CCAGCTCCTCGATGCGTGCC 
GAPDH F – CGTGCCGCCTGGAGAA 
R – CCCTCAGATGCCTGCTTCAC 
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Reactions were carried out in a Corbett RotorGene-3000. The cycle threshold (Ct) was 
determined manually as an arbitrary point during the linear phase of amplification and 
mRNA expression was quantified as a ratio of GAPDH expression. mRNA expression 




Tissue samples were fixed in 4% PFA and dehydrated overnight. The samples were 
then embedded in wax blocks and cut to sections of 6 µM thickness and mounted on 
glass slides (superfrost plus, VWR International). Slides were baked at 60°C overnight. 
Tissue samples were rehydrated by incubation in xylene for 2x5 min and then sequential 
incubation in decreasing concentrations of ethanol (EtOH) 100%, 96% (3 min), 75%, 
50% 25%, ddH2O (1 min). Antigen unmasking was then achieved by heating the 
samples in a citrate buffer in a conventional vegetable steamer (Russell Hobbs) for 15 
min. The lid was removed and samples allowed to cool for approximately 30 min. The 
samples were washed in TBS-T for 3x5 min followed by incubation in 3% H2O2 for 10 
min. The samples were washed 2x5 min in TBS-T followed by 2x5 min in ddH2O. 
Sections were then blocked 1 hour in normal goat or rabbit serum depending on the 
specifications of the primary antibody. Sections were washed 3x5 min in TBS-T and 
incubated overnight at 4°C. Primary antibodies were added as appropriate for 1 hour, 
RT. Sections were washed as before and secondary antibodies (Table 2.2) were added 
for 1 hour, RT. Sections were washed 3x5 min in TBS-T then incubated with ABC 
reagent (containing avidin DH and biotinylated horseradish peroxidase). The sections 
were washed 3x5 min in TBS-T then subject to incubation with the peroxidase substrate 
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solution DAB until the desired stain intensity had developed. Slides were lightly 
counterstained with eoisin’s hematoxylin (1 min) washed briefly with acid alcohol and 
cleared with sequential ethanol incubations (50, 75, 96, 100%) and xylene, and then 
mounted with DPX. 
 
2.2.2.11 Haemotoxylin and Eosin staining 
 
Heart sections were subject to a haematoxylin and eosin staining procedure. After 
rehydration, sections were washed under running tap water for 5 min, and then placed in 
Harris’ haematoxylin solution for 5 min. The sections were then washed under running 
tap water until the water ran clear followed by differentiation in acid alcohol. The 
sections were again placed under running tap water for 5 min and then stained with 
eosin solution for 3 min. The sections were dunked 5 times in tap water and then subject 
to dehydration in ethanol and clearance in xylene. Coverslips were mounted using DPX 
and allowed to dry overnight.  
 
2.2.2.12 Picro-sirius red staining 
 
Tissues were processed and rehydrated as previously described. After rehydration, 
slides were left under running tap water for 10 min. Slides were left in ddH2O for 5 min 
followed by a 30 second incubation in 0.2% phosphomolybdic acid. Slides were rinsed 
in ddH2O and then left in 1% Sirius red solution for 90 min. Slides were washed 2x2 
min in acidified ddH2O (0.05% acetic acid) followed by a 15 min incubatation in Picric 
acid. Slides were rinsed several times in ddH2O followed by dehydration by sequential 
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ethanol treatment: 25%, 50%, 75%, 96% (1 min each) 100%, (2x3 min) xylene, (2x5 
min) Glass coverslips were mounted with DPX and allowed to dry overnight. 
 
2.2.2.13 Senescence associated β-Galactosidase assay 
 
Hearts were cryosectioned into 5mm thick slices and mounted onto superfrost slides. 
Sections were allowed to dry for 30-60 min. Senescence associated β-Galactosidase 
(SA-β-Gal) staining solution was freshly made and applied to each heart section so that 
they were generously submerged (approx. 50 μl per heart section). The slides were 
incubated in a heavily humidified chamber overnight (approx. 16h) at 37°C. The slides 
were washed 2x5 min in PBS and once in 100% methanol for 2 min, the heart sections 
were then viewed and photographed under brightfield microscopy. 
 
2.2.2.14 TUNEL staining 
 
Deparaffinised sections were digested in 20 μg/ml proteinase K solution at 37°C for 10 
min and washed 3x5 min in PBS. Sections were then incubated in 3% H2O2 for 10 min 
RT to block endogenous peroxidase activity and washed 3x5 min in PBS. Sections were 
then pre-incubated in TdT reaction buffer for 10 min RT and then incubated in TdT 
reaction mixture for 1 hour at 37°C in a humidified chamber. Sections were then 
washed in stop wash buffer for 10 min RT and rinsed in PBS-T 3x5 min. Sections were 
incubated with streptavidin-HRP for 20 min RT. Sections were incubated in DAB 
chromagen solution for 1-10 min (until brown staining appeared) and left under running 
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tap water for 5 min. Coverslips were mounted with DPX and allowed to dry for 2 hour 
or overnight (ON).  
 
2.2.2.15 Transmission Electron Microscopy (TEM) 
 
2 and 4 week old mice were injected intraperitoneally with heparin (5000 u/kg body 
weight). This was followed by intraperitoneal injection of 50mg/kg body weight of 
sodium pentobarbital to induce terminal anaesthesia. The chest cavity was opened and 
secured with a hemostat. The left ventricle was injected with a needle connected via a 
pump to a reservoir of pre-wash buffer. Flow rate of the pump was adjusted as to 
perfuse mouse heart at a pressure between 90-100 mmHg with pre-wash buffer. Pre-
wash buffer was a standard physiological tyrode solution containing 10mM BDM to 
arrest the heart in diastole and 2.5% PVP to replace the protein content of blood, 
thereby maintaining colloidal pressure and preventing haemorrhage at vascular sites in 
the heart. By taking these measures, it was hoped that the cardiac ultrastructure would 
remain as intact as possible. Following prewash, the hearts were perfused with fixative 
solution containing 2% Glutaraldehyde and 2% Paraformaldehyde until 20ml of fix had 
been perfused. Hearts were dissected and the mid left ventricle was isolated and cut for 
further processing. Samples were dehydrated through a graded series of ethanol washes 
and embedded in epoxy resin. Semithin sections (0.2 μm) were stained with toluidine 
blue for light microscopy examinations and were used to guide sampling for TEM 
studies. Thin sections (0.09 μm) were collected on 150-mesh copper grids and double 
stained with uranyl acetate and lead citrate for examination under TEM (H7650, 
Hitachi, Tokyo, Japan). Dehydration, sectioning, and staining were kindly performed by 
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Dr Gema Vizcay at the Centre for Ultrastructural Imaging (CUI), King’s College 
London. 
 
2.2.3 In vitro studies 
2.2.3.1 Isolation of neonatal rat CMs 
 
Sprague dawley rat pups at 1-2 days old were individually subject to cervical 
dislocation, whereupon they were decapitated. Scissors were then used to open the chest 
cavity, the heart dissected out and placed in a 7ml bijous tube containing ADS buffer. 
After the hearts (approx. 11-12) were collected in the bijous tubes, they were finely 
diced using sharp scissors. Once the hearts were cut into small pieces, the ADS buffer 
was drained carefully in order not to discard any heart tissue and washed once in ADS 
buffer. The heart tissue pieces were then transferred to a 50 ml falcon tube using a 
sterile plastic pasteur pipette and subjected to an initial enzymatic digest in 5 ml of 
enzyme solution for 5 min at 37°C. The enzyme solution containing collagenase and 
pancreatin in ADS buffer was filter sterilized before use. After the initial digest, the 
heart tissue was resuspended 30 times using a sterile plastic pasteur pipette. The tissue 
was allowed to settle and the supernatant was removed carefully and discarded. The 
tissue was then subject to a second digest of the same parameters except that the 
supernatant was retained and placed into a 50 ml falcon tube containing 20 ml of plating 
medium. The digest was repeated and the supernatant collected in the same tube of 
plating medium as previously. The tube of plating medium was then passed through a 
cell strainer and spun at 1000 rpm RT for 5 min to pellet the cells. The cells were 
resuspended in 10 ml of plating medium and kept at 37°C. This process was repeated 
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twice more, at which point all tissue was adequately digested. After the final spin, the 
contents of the three falcon tubes containing plating medium and cells were combined 
in a T75 tissue culture flask and incubated for 1 h at 37°C, 5% CO2 to allow fibroblasts 
to adhere to the plastic surface. After 1 h, NRCs which did not adhere to tissue culture 
plastic were removed and plated at approximately 400,000 per 10cm well of tissue 
culture dishes which had been pre coated with gelatin for at least 1 h 37°C. The cells 
were left overnight to adhere and the plating medium was replaced the following day 
with maintenance medium. 
 
2.2.3.2 C2C12 Cell Culture 
 
C2C12 mouse myoblasts are a cell line originally derived from dystrophic mouse 
skeletal muscle261. They were maintained in culture using DMEM with 20% FBS and 
antibiotics (PenStrepGlut) and kept at 37°C, 5% CO2. They were grown to 80% 
confluence before passaging which occurred approximately every second day. To 
passage, cells were washed once in DPBS and then covered with 2.5 ml trypsin-EDTA 
for 5 min 37°C to lift cells from the tissue culture plastic. The cells were quenched with 
7.5 ml DMEM 10% FBS and reseeded on fresh flasks at 1:10 dilution.  
 To induce the formation of myotubes, cells were grown to 60% confluency and 
then incubated with DMEM containing 2% Horse serum at 37°C 5% CO2 for several 
days. Cells were observed daily for the formation of myotubes, the characteristics of 
which include a distinct change in morphology from rounded to spindle like cells and 
the presence of multi nuclei within the spindle like cells. 
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2.2.3.3 Viral transduction of L647R LMNA plasmid 
 
NRCs were kept in serum free maintenance media in 35x10 mm dishes. Cells were 
counted and Adenoviral constructs containing mutated L647R-LMNA DNA were 
applied to the media with a multiplicity of infection of 5 viruses per cell for 
immunofluorescent staining readouts, and 10 viruses per cell for western blotting.  
 
2.2.3.4 Indirect immunofluorescence of isolated cell cultures 
 
Cells were grown on glass coverslips and fixed in 4% paraformaldedhyde (PFA) for 10 
min or in methanoacetone for 2 min, and then washed three times in PBS. Cells fixed in 
formaldehyde were then permeabilised in 0.2% NP40 for 2 minutes and washed three 
times in PBS. Cells were then incubated for 1 h with 1% BSA in PBS at room 
temperature to prevent non-specific binding. The coverslips were incubated with 
primary antibodies (Table 2.2) overnight 4°C or for 1 h RT and then washed in PBS. 
They were then incubated with fluorescent secondary antibodies (Table 2.2) 1 hour RT 
and then DAPI diluted 1:10,000 5 min RT to visualise nucleic structures. The coverslips 





Immunohistochemical and general tissue staining was analysed by brightfield light 
microscopy using an Axioskop 2 microscope (Carl Zeiss MicroImaging, NY). Images 
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were acquired using Volocity Software (PerkinElmer Inc, USA). Immunofluorescence 
was analysed using widefield fluorescence microscopy whereas images were captured 
using a Leica SP5 confocal microscope (LeicaMicrosystems, UK). Confocal images 
were processed in Photoshop CS3 (Adobe) and minimal adjustments to brightness and 





All in vivo and ex vivo data of PLA Tg mice compared to Wt were analysed using the 
Student’s unpaired T-test for normal distribution. Where assymetric distribution of data 
occurred the nonparametric Mann-Whitney test was applied. For the analyses of body 
weights at 4 weeks versus 5 weeks, a paired t-test was selected. Kaplan-Meier survival 
curves were assessed by the log-rank Cox-Mantel test. C2C12 studies were subject to 
One-Way ANOVA with Tukey’s post-test. Values were expressed as means ± the 
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Chapter 3: Characterisation of a model of CM specific expression of 




Currently, a role for prelamin A accumulation has neither been specifically identified 
nor rigorously investigated in the context of heart pathology. The rationale for doing so 
in this study is supported by several slightly disparate lines of investigation, which 
converge on a hypothesis of prelamin A associated heart dysfunction. Accumulation of 
prelamin A is known to cause nuclear abnormalities and disruption of the LINC 
complex. It is thought that this underlies the mechanism by which disease occurs. The 
broadest association is with models showing disruption of the LINC complex such as in 
Lmna-/- mice, which develop systolic dysfunction and heart failure at 8 weeks old225. 
Additionally, some LMNA mutations that cause DCM have been rigorously investigated 
in mouse models, which lead to cardiomyopathic phenotypes resulting in attenuated 
survival232, 248, 250, 253. Although these studies were not carried out in the context of 
prelamin A accumulation, evidence suggests that prelamin A accumulation can occur in 
the presence of some of these LMNA mutations253, 260. Furthermore, there is evidence 
that older HGPS patients exhibit cardiac abnormalities228, 229, whilst a mouse model of 
HGPS, LmnaG609G/G609G, indicates a cardiac conduction deficiency phenotype259 and 
Zmpste24-/- mice display histological abnormalities of the myocardium214. 
 To further investigate the role that prelamin A plays in heart disease, I utilised a 
mouse model of targeted transgenesis to the ROSA26 locus of human LMNA cDNA 
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containing a missense mutation leading to a change in the amino acid sequence that 
prevented cleavage by Zmpste24, which was designed to cause accumulation of 




3.2.1 MLC2v-Cre mediated recombination of the floxxed Rosa26L647R-LMNA 
transgene results in prelamin A accumulation in CMs of mice 
 
In order to obtain experimental mice, it was necessary to mate mice carrying the 
Rosa26L647R-LMNA transgene to mice expressing the MLC2v promoter linked cre 
recombinase. MLC2v is a part of the contractile machinery of myocytes and is 
postulated to be specifically expressed in CMs of the ventricle, making it ideal to drive 
cardiac specific expression of transgenes. After the mice were born, they were 
genotyped by PCR and agarose gel electrophoresis (Fig 3.1A & B). Mice carrying the 
transgene that also expressed cre recombinase were deemed to be prelamin A transgenic 
(PLA Tg) mice. Mice that contained only the transgene were selected as ‘wildtype’ 
(Wt) littermates. This ‘Wt’ control would ensure that any phenotypic changes could not 
be ascribed to merely possessing a transgene on the Rosa26 locus. The remaining mice 
with neither a transgene nor cre expression, and mice with only cre expression were not 
used for the study and culled as surplus. Genotypic analysis of n= 242 pups showed that 
the presence or expression of the transgene did not affect Mendelian birth ratios (Fig 
3.1C).  
  






Figure 3.1. Transgenic mice were born in the expected Mendelian ratios. DNA 
was extracted from ear biopsies and then amplified by PCR using primers designed to 
ampify (A) the modified Rosa26 allele 200bp (Tg) and wildtype Rosa26 allele (Wt) 
500bp and (B) cre recombinase 200bp and GAPDH 300bp. (C) Genotype ratios were 
expressed as a percentage of the total number of mice, which were born in the 
expected Mendelian pattern of 1:1:1:1. N=242  
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Cardiac specific expression of prelamin A protein in the heart was confirmed by 
western blotting of whole tissue lysates using lamin A/C C-20 antibody (detects 
prelamin A only) (Fig 3.2A). Immunohistochemistry showed nuclear rim localisation of 
accumulated prelamin A in PLA Tg mouse heart sections (Fig 3.2B). 
 
3.2.2 Mice that accumulate cardiac specific prelamin A fail to thrive and succumb 
by 6 weeks of age with apparent cardiac phenotypic abnormalities 
 
Due to the short life span of other Lmna mouse models, PLA Tg mice were initially 
observed; at birth and then also upon weaning, mice appeared normal. Shortly after 
weaning, PLA Tg mice appeared smaller (Fig 3.3A & B). From weaning, mice were 
weighed every second day to reveal that PLA Tg mice reached peak weight at 30 days 
old (12.2 g ± 0.6) and experienced weight loss thereafter. Comparatively, at 30 days old, 
Wt littermates were 13.8 g ± 0.6 and continued to experience steady growth after this 
timepoint (Fig 3.3C). At 35 days old, PLA Tg mice were 11.9 g ± 0.9 compared to Wt 
17.1 g ± 0.8. Failure of PLA Tg mice to thrive was subsequently coupled with poor 
survival rates (Fig 3.3D). Kaplan-Meier analysis showed that the range of survival for 
PLA Tg mice was between 29 and 38 days, whilst the Wt littermates all survived to 80 
days of age at which point the study was ended. Log-rank Mantel-Cox test for PLA Tg 
compared to Wt returned a P value of <0.0001 indicating statistical significance. 
Previous studies investigating Lmna mouse models have also reported phenotypic 
differences between genders262. Here, gender comparison showed median survival of 33 
days for male compared to 32.5 for female mice. Log-rank Mantel-Cox test returned a  
  









Figure 3.2. MLC2v Cre mediated recombination led to the expression of prelamin 
A exclusively in the myocardium. (A) Immunohistochemical staining with prelamin A 
antibody showed nuclear rim localisation of prelamin A in PLA Tg hearts only Scale bar 
= 30 μm. (B) Western blotting of whole tissue lysates showed cardiac specific 
expression of prelamin A in PLA Tg hearts. N=1/group. 
  








Figure 3.3. PLA Tg mice failed to thrive and died between 5-6 weeks of age. 
Representative photographs of Wt and PLA Tg mice at 4 weeks of age are shown in 
panels (A) and (B). (C) Longitudinal analysis of body weight shows that PLA Tg mice 
failed to grow past 4 weeks of age. *P>0.05 N=6/group (D) Kaplan-Meier survival 
analysis shows death of PLA Tg mice occurs between 5 and 6 weeks of age. Log-rank 
Mantel-Cox test was performed to show P<0.001 for PLA Tg mice compared to 
wildtype, N=6/group  
 On the role of prelamin A in the heart  
 
 95 
P value of 0.85, indicating that there were no statistical differences between male and 
female survival of PLA Tg mice.  
 Because of the presentation of a phenotype and because mice were still viable, it 
was decided that characterisation of the phenotype should be carried out on 4 week old 
mice. Tissue was harvested and morphometric analysis carried out. Upon excision, 
hearts were photographed. PLA Tg hearts were noticeably larger in size compared to 
Wt and appeared to be dilated (Fig 3.4). 4 week body weights were recorded for male 
and female mice. Male PLA Tg mice were 11.96 g ± 0.46 which was significantly less 
than 15.23 g ± 0.59 for Wt controls (Fig 3.5A). Female PLA Tg mice were 10.71 g ± 
0.38 compared to 12.8 g ± 0.38 for Wt controls (Fig 3.5A). Post mortem wet heart 
weight for male PLA Tg mice was 106.2 ± 10.5 compared to 96.7 ± 9.9 for Wt. Female 
PLA Tg were 93.1 ± 8.6 compared to 79.1 ± 5.6 for Wt (Fig 3.5B). There were no 
statistical differences between groups. Heart weight to body weight ratios were derived 
(mg, heart weight/g, body weight) to show values for male mice of 8.34 ± 0.66, which 
were significantly higher compared to 5.78 ± 0.23 for Wt. Female PLA Tg mice also 
had a significantly higher ratio of 9.34 ± 1.18 compared to 5.35 ± 0.23 for Wt (Fig 
3.5C). Because of fluctuations in body weight between Wt and PLA Tg cohorts, it was 
decided that heart weights should be normalised to the potentially more reliable 
parameter, tibia length. Tibia lengths for male PLA Tg mice were 10.13 mm ± 0.23 
compared to Wt 10.07 mm ± 0.19. Tibia length for female PLA Tg mice was 10.30 mm 
± 0.15 compared to 10.00 ± 0.08 for Wt (Fig 3.5D). There were no statistical 
differences between Wt and PLA Tg cohorts. Heart weight to tibia length ratio was 
derived (mg, heart weight/mm, tibia length). In male PLA Tg mice (9.25 ± 0.40), the 
ratio was slightly elevated compared to Wt (8.29 ± 0.53) with no statistical significance.   








Figure 3.4. At 4 weeks of age, PLA Tg hearts were larger than Wt hearts. Hearts 
were excised and photographed and revealed that PLA Tg hearts (right) were much 
larger than Wt hearts (left). 
  




Figure 3.5. At 4 weeks, morphometric analysis showed that heart weight was not 
significantly different in PLA Tg hearts compared to Wt. Post mortem analysis of 
morphological parameters was performed by recording body weight, heart weight and 
tibia length. Graphs show: (A) Nominal increases in heart weight in male and female 
PLA Tg hearts compared to Wt; (B) Significantly decreased body weight in PLA Tg 
mice compared to Wt; (C) The ratio of body weight/heart weight was significantly 
increased in PLA Tg mice compared to Wt; (D) Tibia length was consistent between Wt 
and PLA Tg mice; (E) Ratio of heart weight/tibia length was nominally increased in PLA 
Tg mice but was not significant, **P<0.01, ***P<0.001, N= 6/group  
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This was also the case for female PLA Tg mice (8.16 ± 0.74) compared to Wt (6.80 ± 
0.80) (Fig 3.5E).  
 
3.2.3 Functional assessment of the cardiac phenotype shows a marked decline in 
contractility of the myocardium with evidence of myocardial remodelling in mice 




Measurement of cardiac function by ultrasound (Echocardiography) is now a reliable 
and relatively inexpensive tool for preclinical analysis of rodent cardiac function263. 
Moreover, echocardiography has been used to assess cardiac function in several 
relevant studies. For example, Lmna-/- and LmnaH222P/H222P mice had depressed cardiac 
function, whereas LmnaG609G/G609G mice did not exhibit depressed systolic or diastolic 
function, but did show altered ventricular depolarisation when assessed by ECG. 
 In this study, 2 dimensional long-axis B-mode images of the left ventricle were 
analysed in favour of 1 dimensional longitudinal M-mode images because the increased 
spatial resolution seen with B-mode images was deemed to be more important in 
assessing LV parameters, particularly in the setting of isofluorane anaesthesia which has 
a depressive effect on heart rate, meaning the superior temporal resolution of M-mode 
analysis could be somewhat negated. 
 Again, males and females were separately assessed. Firstly, structural 
parameters were analysed. Interventricular septal thickness in systole (IVS;s) and 
diastole (IVS;d) was nominally, but not significantly, reduced in PLA Tg males and 
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females compared to their Wt counterparts. Left ventricular internal diameter in diastole 
(LVID;d) showed a trend towards an increase in male and female PLA Tg hearts 
compared to their Wt counterparts but was not statistically significant. Left ventricular 
internal diameter in systole (LVID;s) was significantly increased in PLA Tg males (3.37 
mm ± 0.14) compared to Wt (2.30 mm ± 0.10) P<0.001 and PLA Tg females (3.36 mm 
± 0.18) compared to Wt (2.26 mm ± 0.22) P<0.01. Moreover, in male mice, left 
ventricular posterior wall thickness in diastole (LVPW;d) was significantly decreased in 
PLA Tg mice (0.57 mm ± 0.03) compared to Wt (0.69 mm ± 0.04) P<0.01 and though a 
decrease was also seen in PLA Tg female mice compared to Wt, it was not statistically 
significant, P=0.075. Left posterior wall thickness in systole (LVPW;s) was 
significantly reduced in male PLA Tg mice (0.65 mm ± 0.04) compared to Wt (0.80 
mm ± 0.02) P<0.01 and female PLA Tg mice (0.59 mm + 0.03) compared to Wt (0.70 
mm ± 0.04) P<0.05. Area of the LV in systole (Area;s) was significantly increased in 
both PLA Tg males (16.83 mm2 ± 1.16) compared to Wt (10.62 mm2 ± 0.52) P<0.001 
and PLA Tg females (17.00 mm2 ± 1.24) compared to Wt (9.81 mm2 ± 1.21) P<0.01. 
Area in diastole was not significantly different between Wt and PLA Tg for male and 
female mice. These findings are displayed in Table 3.1 and Figure 3.6. 
Next functional parameters were analysed. Ejection fraction (EF), the proportion 
of the end diastolic volume ejected from the LV at the end of systole, was measured. In 
male PLA Tg mice, EF was found to be significantly reduced (19.56 % ± 5.44) 
compared to Wt (60.61 % ± 2.51) and also for female PLA Tg mice (14.92 % ± 1.70) 
compared to Wt (60.28 % ± 4.62). Fractional shortening (FS) was measured. FS is the 
degree of shortening of the left ventricle diameter between end-diastole (EDD) and end-
systole (ESD) and is defined as (EDD-ESD)/EDD. FS was significantly decreased in   





Table 3.1. B-mode Echocardiographic analysis of hearts in long axis 
orientation showed significant cardiac dysfunction in PLA Tg hearts at 4 
weeks old 
  
Values expressed as mean±SEM, N=6/group, *P<0.05, **P<0.01, ***P<0.001, NP=No 
significance 
IVS = Interventricular septum 
LVID = Left ventricular internal diameter 
LVPW = Left ventricular posterior wall  










Figure 3.6. Heart chamber size appeared increased in 4 week old PLA Tg hearts. 
Representative B mode images of the LV long axis from echocardiography movies 
used to analyse cardiac function showing that chamber size was increased in 
transgenic hearts during the systolic phase of contraction, supporting the analysed 
data from Table 3.1.    
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male PLA Tg mice (7.19 % ± 2.26) compared to Wt (15.77 % ± 1.99) P<0.05 and also 
in female PLA Tg mice (7.58 % ± 0.73) compared to Wt (18.11 % ± 1.99) P<0.01. 
Volumetric parameters were analysed and showed that there was a minor but non 
significant increase in left ventricular end diastolic volume (LVEDV) in PLA Tg hearts 
of male and female mice compared to Wt. Left ventricular end systolic volume 
(LVESV) of male PLA Tg hearts (38.90 μl ± 4.16) was significantly increased 
compared to Wt (17.33 μl ± 1.49) P<0.01 and also in female PLA Tg hearts (39.84 μl ± 
4.51) compared to Wt (15.80 μl ± 2.96) P<0.01. Accordingly, stroke volume (SV) was 
decreased in male PLA Tg hearts (9.10 μl ± 2.53) compared to Wt (26.40 μl ± 1.21) 
P<0.001 and also in female PLA Tg hearts (7.32 μl ±1.44) compared to Wt (22.12 μl ± 
1.43) P<0.001. There was no difference in heart rate between Wt and PLA Tg groups in 
male and female mice. Cardiac output was measured and found to be significantly 
attenuated in male PLA Tg mice (4.13 ml/min ± 1.07) compared to Wt (12.00 ml/min ± 
0.51) P<0.001 and also in female PLA Tg mice (3.28 ml/min ± 0.53) compared to Wt 




MRI utilises strong magnetic fields to excite hydrogen atoms and then detects the 
frequency emitted in order to build images of organs of interest in human anatomy, 
including the heart. Cross sectional images of the ventricular chambers were acquired 
and analysed for some of the functional parameters that were assessed with 
echocardiography. MRI is thought to be more accurate than echocardiography because, 
unlike 2D echocardiography, it does not rely on geometric assumptions in order to make 
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quantified analyses. No gender comparison was made during MRI studies. Volumetric 
parameters were assessed and revealed that LVEDV was significantly elevated in PLA 
Tg mice (48.47 μl ± 2.54) compared to Wt (32.45 μl ± 2.03) P<0.001. LVESV was also 
significantly higher in PLA Tg mice (35.27 μl ± 3.34) compared to Wt (11.13 μl ± 1.15) 
P<0.001. Accordingly, SV was significantly attenuated in PLA Tg mice (13.20 μl 
±1.13) compared to Wt (21.30 μl ± 1.38) P<0.01. Moreover, EF was significantly lower 
in PLA Tg mouse hearts (28.05 % ± 3.61) compared to Wt (65.87 % ± 2.59) P<0.001 
(Fig 3.7). Representative images are shown in Figure 3.8. 
 
3.2.4 Post mortem analysis of chest cavity and modulation of mRNA markers 
indicate heart failure was the cause of mortality in PLA Tg mice 
 
Heart failure (HF) has been shown to exhibit a specific molecular signature. Modulation 
of α- (decrease) and β- (increase) isoforms of myosin heavy chain mRNA264 coupled 
with increases in atrial natriuretic peptide and brain natriuretic peptide mRNA are 
reliable markers of HF. Moreover, transudative pleural/pericardial effusions, whereby 
excessive fluid penetrates into the pleural space, are caused by elevated filling pressures 
in the heart, and are a reliable indicator of HF265. 
 To test this, mice were sacrificed and the chest cavity was carefully dissected, 
observed and photographed. It was clear to the eye that a colourless fluid had penetrated 
the pleural cavity in PLA Tg mice and not in Wt (Fig 3.9).  
 Next, quantitative PCR (qPCR) was performed to test for mRNA markers of HF. 
Primers for α-MHC, β-MHC, ANP, and BNP were used to amplify cDNA of Wt and 
PLA Tg heart tissue. Wt values were normalised to those of GAPDH for control  





Figure 3.7. At 4 weeks of age, cardiac function was attenuated in PLA Tg hearts 
compared to Wt. MRI was used to assess cardiac function in Wt and PLA Tg hearts. 
Analysis of MRI images showed: (A) ejection fraction is attenuated in PLA Tg mice;(B) 
LV end-diastolic volume; and (C) LV end-systolic volume are increased in PLA Tg 
mice, whilst (D) Stroke volume is attenuated. (E) LV mass is not significantly different in 
PLA Tg hearts compared to Wt. Values expressed as mean±SEM, **P<0.01, 
***P<0.001, N=5/group of mixed gender cohorts  







Figure 3.8. Cardiac MRI showed that heart chambers were larger in PLA Tg mice 
compared to Wt. Representative MR images of the short axis of the heart showing 
that cardiac chambers of PLA Tg hearts appear larger than Wt (arrows) and support 
the analysed graphical data from Figure 3.7.  










Figure 3.9. Transudative pleural effusion in PLA Tg mice indicated heart failure at 
4 weeks of age. Mice were sacrificed and the chest cavity was carefully dissected 
open and photographed to show the accumulation of clear liquid in the pleural space of 
PLA Tg but not Wt hearts, indicating heart failure in PLA Tg mice.  
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purposes and adjusted to 1.  PLA Tg values were expressed as fold change compared to 
Wt. α-MHC mRNA levels were significantly decreased in PLA Tg hearts (0.41 fold 
change ± 0.11) compared to Wt (1.0 ± 0.11) P<0.05. β-MHC mRNA in PLA Tg hearts 
was 38.07 ± 16.02 fold greater than Wt (P<0.05). ANP mRNA was 23.55 ± 11.09 fold 
greater in PLA Tg hearts compared to Wt (P<0.05). Finally, BNP mRNA levels were 
19.01 ± 11.74 fold greater in PLA Tg hearts compared to Wt (P<0.05) (Fig 3.10). 
 
3.2.5 Histological examination of hearts shows post mortem dilatation of cardiac 
chambers, myocardial disarray, and evidence of fibrotic remodelling of cardiac 
tissue in PLA Tg mice 
 
Haemotoxylin and Eosin staining was performed on 4 week old ventricular long axis 
and short axis cross sections and viewed with low power light microscopy to reveal that 
dilatation of the ventricular chambers had occurred in PLA Tg hearts compared to Wt 
(Fig 3.11 & 3.12). High power light microscopy of the same H&E stained hearts 
showed myocardial disarray and nucleic infiltration, assumed to be of a lymphocytic 
lineage (Fig 3.13). 
 Sirius red staining was viewed using light microscopy. A large proportion of the 
myocardium had been replaced by fibrotic regions in PLA Tg hearts compared to Wt 
(Fig 3.14). These sections were also viewed under circular polarised light, which 
preferentially detects abnormally cross-linked collagen fibers, which occur in fibrotic 
remodelling and was quantified using colour threshold analysis to show that PLA Tg   







Figure 3.10. Analysis of mRNA markers indicated heart failure in 4 week old PLA 
Tg hearts compared to Wt. qPCR was performed to assess mRNA markers of heart 
failure and showed: (A) α-MHC mRNA is significantly decreased; (B) β-MHC is 
significantly increased; (C) ANP is significantly increased; and (D) BNP is significantly 
increased in PLA Tg hearts compared to Wt, indicating heart failure. Values expressed 
as mean±SEM, *P<0.05, N=3/group  







Figure 3.11. At 4 weeks, cardiac chambers were dilated and the myocardium 
appeared thinner in PLA Tg hearts compared to Wt in the long axis view. H&E 
staining was performed on long axis sections of paraffin embedded Wt (left) and PLA 
Tg (right) hearts and viewed under low power light microscopy to reveal that cardiac 
chambers were dilated in PLA Tg hearts compared to Wt. Moreover, substantial 
thinning of the myocardium appears to have occurred in PLA Tg hearts. Scale bar = 
2mm  




Figure 3.12. At 4 weeks, cardiac chambers were dilated and the myocardium 
appeared thinner in PLA Tg hearts compared to Wt in the short axis view. H&E 
staining of paraffin embedded cross sections of Wt (left panels) and PLA Tg (right 
panels) hearts was performed and viewed with low power light microscopy and showed 
dilatation of cardiac chambers and thinning of the myocardium in PLA Tg hearts 
compared to Wt. Scale bar = 2mm  




Figure 3.13. Myocardial structure was disrupted in hearts of 4 week old PLA Tg 
mice compared to Wt. H&E staining of paraffin embedded heart cross sections was 
viewed under high power light microscopy and showed that, whilst Wt heart sections 
present expected myocardial histology (left panelling), PLA Tg hearts have myocardial 
disarray and clustering of nuclei in the myocardium (right panelling), indicative of 
pathological leukocyte invasion. Scale bar = 30μm   




Figure 3.14. At 4 weeks, hearts accumulating prelamin A developed interstitial 
fibrosis whereas Wt hearts did not. Picrosirius red staining was performed on 
paraffin embedded heart cross-sections of Wt (left panelling) and PLA Tg (right 
panelling) mice. PLA Tg hearts appeared to have significantly more bright red staining 
than Wt indicating the presence of fibrosis. Scale bar = 60 μm  
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mice (2.324 % ± 0.135) have more abnormally linked fibres than Wt (0.568 % ± 0.218) 
P<0.001 (Fig 3.15). Images of the cardiac ultrastructure were obtained and confirmed 
this finding as PLA Tg hearts showed many regions punctuated with collagen-style 
filamentous structures indicative of fibrosis, whereas Wt hearts did not (Fig 3.16). 
Additionally, cardiac MRI of patients with DCM associated LMNA mutations has 
shown that the majority have myocardial fibrosis when late gadolinium enhancement is 
performed266. Indeed, myocardial inversion recovery sequences in late gadolinium 
enhancement showed a significant increase in R1 values in the myocardium of PLA Tg 
mice (1.960 1/sec ± 0.068) compared to Wt (1.620 1/sec ± 0.66) (Fig 3.17).  
 
3.2.6 Immunofluorescence staining, western blotting and electron microscopy 
indicates infiltration of leukocytes into myocardial tissue of PLA Tg mice 
 
Lymphocytic infiltration into cardiac tissue has been reported in Zmpste24-/- mice as 
defined by H&E staining and histological observation. In the current study, it was 
observed that a similar histopathological phenotype was presented. To confirm that 
inflammatory cells were present in the myocardium of PLA Tg mice, indirect 
immunofluorescence staining of cryopreserved heart sections using an antibody to 
CD45 was performed. CD45, also known as common leukocyte antigen (CLA), is 
present on the cell surface of all cells of lymphocytic lineage and is therefore a reliable 
marker for inflammation. It was observed that PLA Tg mice appeared to have larger 
populations of CD45+ cells accumulating in the myocardium compared to Wt (Fig 
3.18). This was then quantified by cell counting to reveal that there were indeed   




Figure 3.15. Polarised light microscopy showed evidence of fibrosis in the hearts 
of 4 week old PLA Tg mice. Picrosirius red stained heart sections were viewed under 
polarised light to reveal birefringence associated with fibrotic lesions was significantly 
increased in PLA Tg hearts compared to Wt as quantified by colour threshold analysis 
with volocity® software. Values expressed as mean±SEM, ***P<0.001, N=3/group, 
Scale bar = 60 μm  





Figure 3.16. Interstitial Fibrosis of PLA Tg hearts was evident in the cardiac 
ultrastructure of 4 week old mice. Perfusion fixed hearts were processed and 
stained for TEM. Evidence for fibrosis was clear in PLA Tg hearts (right panelling), 
identifiable as filamentous thread like structures, shown here within the confines of the 
red borders. Wt hearts (left panelling) showed no evidence of this. Scale bar = 2 μm 
  













Figure 3.17 Increased myocardial tissue enhancement indicated the presence of 
fibrosis in PLA Tg mice hearts. Anaesthetised mice were subject to MRI before and 
after intraperitoneal (i.p.) injection of Vasovist (Vasovist, Bayer Schering Pharma AG, 
Berlin, Germany), a gadolinium-based contrast agent. T1-weighted sequences were 
analysed to assess the R1 values of blood and myocardium. (A) R1 (relaxation) values 
for the blood and myocardium before injection of Vasovist. Similar values were 
achieved in Wt and PLA Tg mice. (B) R1 values 30 minutes after injection of Vasovist. 
R1 values were non-significantly increased in blood, while a significant difference was 
found in the myocardium. This is indicative of a higher accumulation of the contrast 
agent in the myocardium, and likely to be related to the presence of diffuse fibrosis. 
Values expressed as mean±SEM, *P<0.05, **P<0.01, N=6/group of mixed gender 
cohorts 
  






Figure 3.18. Prelamin A accumulation led to leukocytic invasion of the 
myocardium at 4 weeks of age. Cryopreserved heart cross-sections were co-stained 
with antibody to CD45 (green) and myomesin (red) and viewed with fluorescence 
microscopy to show that PLA Tg hearts (second bottom row) appeared to have many 
more CD45 positive cells within the myocardium than did Wt hearts (second top row). 
Cryopreserved spleen (top row) was used as positive control for the CD45 antibody 
whereas serum IgG was used as a negative control. Scale bar = 20 μm  
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significantly more cells in PLA Tg hearts (171.9 cells per field of view ± 19.73) 
compared to Wt (46.98 ± 6.54) P<0.01 (Fig 3.19A). Western blotting of whole tissue 
lysates confirmed that there was a general increase in CD45 protein expression in PLA 
Tg hearts compared to Wt (Fig 3.19B & C). Additionally, upon observation of the 
cardiac ultrastructure it was clear that there were activated leukocytes present in the 
interstitium of PLA Tg myocardium but not in Wt myocardium (Fig 3.20).  
 
3.2.7 Cell death 
 
The TUNEL assay labels unrepaired DNA breaks thereby enabling the detection of 
fragmented DNA, which is a classical response in apoptosis pathways. Here, TUNEL 
assay and cell counting was performed on wax-mounted heart sections to reveal that 
PLA Tg mice hearts (21.27 cells per field of view ± 3.30) had significantly more 
TUNEL positive nuclei than Wt hearts (2.7 ± 0.91) (Fig 3.21). 
 Caspase 3 is a key mediator in the apoptosis pathway, therefore western blotting 
of whole tissue lysates was performed to show that caspase 3 was not expressed in PLA 
Tg or Wt heart tissue (Fig 3.22), suggesting that apoptosis may not have been 
contributing to the observed increased TUNEL positivity. 
  








Figure 3.19. Quantification of CD45 microscopy confirmed an increase in CD45 
positive cells and total CD45 protein expression in PLA Tg hearts compared to 
Wt. (A) CD45 positive cells per field of view on 63x magnification were counted by eye 
and revealed that there were significantly more CD45 positive cells in PLA Tg 
myocardium than Wt. Values expressed as mean±SEM, **P<0.01, N=3 /group, 20 
randomly selected fields of view from each section were counted. (B) CD45 antibody 
was used to probe western blots of whole tissue lysates from hearts to show (C) 
increases in CD45 expression in PLA Tg hearts compared to Wt according to 
densitometric analysis. N=3/group 
  







Figure 3.20. Leukocytes were present in hearts that accumulated prelamin A at 
the ultrastructural level. Perfusion fixed hearts were processed and stained for 
viewing with TEM. Presence of morphologically distinct dendritic leukocytes was 
observable in PLA Tg myocardium (bottom four panels) but not in Wt myocardium. 
Scale bar = 500 nm 
  




Figure 3.21. Prelamin A accumulation led to myocardial cell death. (A) Paraffin 
embedded cross sections were subject to TUNEL staining and viewed under light 
microscopy to show a perceived increase in TUNEL positive (brown staining) cells in 
PLA Tg (bottom right panel) compared to Wt (bottom left). Shown also are IgG 
negative control (top left panel) and DNAse treated positive control sections (top right). 
Scale bar = 30 μm (B) Number of TUNEL positive cells per field of view at 40x 
magnification were counted and showed a significant increase in the number of TUNEL 
positive cells in PLA Tg hearts compared to Wt. Values expressed as mean±SEM, 
**P<0.01, N=3/group; 10 randomly selected fields of view from each section were 
counted.  













Figure 3.22. Cell death in hearts accumulating prelamin A was independent of 
Caspase 3 activation. Caspase 3 antibody was used to probe western blots of whole 
tissue lysates from Wt and PLA Tg hearts to show that caspase 3 was not expressed in 
Wt or PLA Tg hearts. C2C12 mouse myoblasts were treated with staurosporin (SSP 
C2C12) and run as a positive control for caspase 3 expression. 
  





3.3.1 Targeted transgenesis of L647R LMNA to the Rosa26 locus and Cre 
recombinase mediated stop cassette removal results in prelamin A accumulation in 
the nuclei of CMs 
 
Initial characterisation of the targeted transgenesis model suggested that the system that 
was chosen to study prelamin A accumulation in the heart was efficient in achieving 
this aim. According to genotyping, mice were born in the expected Mendelian ratios and 
prelamin A was expressed exclusively in the hearts of PLA Tg animals. Moreover, it 
was shown that prelamin A accumulated in the nuclear rim of myocytes, as it does in 
premature ageing disorders, and laid the foundations to elucidate the biological 
significance of this potentially pathological process.  
 
3.3.2 Cardiac specific prelamin A accumulation leads to a severe DCM and HF 
phenotype in PLA Tg mice 
 
The Lmna mouse models present with a variety phenotypes. The most severe are the 
Lmna-/- mice, which succumb to HF at 8 weeks of age. Survival of LmnaG609G/G609G and 
Zmpste24-/- mice is approximately 3 months and the LmnaH222P/H222P mice survive to 
older ages still. At birth and up to weaning, PLA Tg mice appeared morphologically 
normal compared to Wt control mice. Soon after weaning, it became quickly apparent 
that mice accumulating prelamin A failed to thrive and died in a very short window of 
time. Although post-mortem assessment of PLA Tg mice heart weight to tibia length 
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ratios was not statistically significant compared to Wt, there was an incremental 
increase in both males and females indicating that remodelling of the heart may have 
occurred. This finding was supported by echocardiographic measurement of myocardial 
tissue walls, the dilated appearance of the heart upon excision and myocardial wall 
thinning evident in PLA Tg hearts compared to Wt as defined by histological staining. 
Echocardiographic analysis also showed that cardiac function was dramatically 
compromised in PLA Tg mice with enormously attenuated EF and FS values compared 
to their Wt counterparts. Interestingly, this DCM phenotype, which was ultimately fatal 
after 5 to 6 weeks of age, closely mimics the pathophysiological and survival phenotype 
observed in Lmna-/- mice, indicating that disruption of the lamina may be a key feature 
of pathogenesis. Data obtained from the MRI analysis of cardiac function reinforced the 
finding that cardiac function was severely attenuated. Indeed MRI analysis tended to 
agree with the echocardiographic analysis with regard to all but one parameter. LVEDV 
was much greater in PLA Tg hearts when measured by MRI compared to 
echocardiography indicating a more pronounced dilatation of the PLA Tg heart. It is 
difficult to attribute this difference to any specific aspect; however, in our study echo 
analysis was performed on a single 2D long-axis sections of the LV whereas MRI 
analysis was performed on a series of 2-D cross-sections. Therefore the echo analysis is 
based on much less spatial information, and may potentially underestimate the 
remodelling occurring in PLA Tg hearts in the cross-sectional plane. Another key 
feature of this model was progression to HF, which was shown by qPCR analysis of HF 
markers, and evidenced also by transudative pleural effusion.  
 Histological examination of hearts in related models of disease are 
phenotypically varied. LmnaN195K/N195K mice have mildly dilated hearts and Lmna-/- 
 On the role of prelamin A in the heart  
 
 125 
hearts are heavily dilated, whilst neither model shows any sign of disruption to the 
myocardial architecture on closer inspection. LmnaH222P/H222P and Zmpste24-/- mice 
present with myocardial disarray and fibrotic lesions, whilst hearts from Zmpste24-/- 
mice also appear to have lymphocytic infiltration into the myocardium. Histological 
examination of PLA Tg mice revealed myocardial disarray, and clustering of nuclei, 
which was confirmed by assessment of CD45 expression and TEM as leukocytic 
invasion of the myocardium. Sterile inflammation of the myocardium, a scenario in 
which the tissue becomes inflamed without any external source of pathogen, as in 
myocardial infarction, has been identified in the pathogenesis of heart failure267. 
Potentially, it can arise from damaged mitochondrial DNA, which escapes degradation 
and activates toll-like receptors in the heart, leading to an immune response and 
recruitment of leukocytes to the heart, and implicates metabolism and defective 
autophagic mechanisms268.  
Picrosirius red staining and TEM confirmed that severe fibrosis had occurred in 
the setting of prelamin A accumulation at 4 weeks of age. Cardiac MRI of contrast-
injected mice also indicated the presence of diffuse fibrosis in the myocardium of PLA 
Tg mice further suggesting that significant cardiac remodelling was occurring in the 
setting of prelamin A accumulation. The importance of remodelling of the ECM cannot 
be overstated in heart failure paradigms. The elasticity of the myocardium is crucial to 
the heart’s role as a pump and whilst remodelling is thought to occur as a reparative and 
adaptive response initially, the long-term effects are unequivocally detrimental and 
contribute greatly to congestive heart failure. 
Another facet to be associated with DCM and heart failure is myocyte death. 
Cell death is thought to characterise end-stage DCM phenotypes presenting with 
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thinning of the myocardium3. Moreover, Lmna+/- mice experience DCM phenotypes and 
cardiac conduction disease as a result of apoptosis in the AV node tissue as defined by 
TUNEL assay and caspase-3 detection227. Additionally, Lmna-/- mice also show cell 
death on TUNEL staining225. To assess this, TUNEL staining was performed and gave a 
positive result that indicated that cell death occurred in PLA Tg hearts. However, 
Caspase 3, a commonly used marker for apoptosis, was negative. The implications of 
these somewhat contradictory results are that cell death is occurring, but not by 
apoptosis, meaning the CMs could be undergoing necrosis. Indeed the idea of apoptosis 
in DCM is a controversial one269. As previously stated, TUNEL labels unrepaired DNA 
‘nick ends’ which are present as a result of the DNA fragmentation that often occurs 
during cell death. A potential pitfall of the TUNEL technique is that it is possible that 
unrepaired double strand breaks are also labelled and may in fact be an indicator of 
severe DNA damage as well as cell death. A previous study that focussed on this 
problem concluded that TUNEL is not a reliable indicator of cell death in DCM hearts 
and rather is an indicator of increased DNA repair activity270, a point that is worth 
highlighting when considering that DNA damage accumulation is a hallmark of 
prelamin A/progerin accumulating diseases.  
In summary, cardiac specific accumulation of prelamin A led to a multi-faceted 
pathological response involving remodelling of the myocardium via interstitial fibrosis, 
sterile inflammation and potentially cell death, which resulted in severe systolic 
dysfunction reminiscent of DCM, heart failure, growth retardation and ultimately led to 
death at 5-6 weeks of age. Comparisons to existing models are summarised in Table 3.2. 
As an aside, disease progression in PLA Tg mice mimics the progression of clinical 
HGPS, whereby infants appear normal and only begin to show symptoms after 2 years 
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of age, after which point children suffer retarded growth and rapid ageing of selective 
tissues and organs including the cardiovascular system. Moreover, rapid cardiac decline 
is seen in HGPS patients a matter of weeks before death228, and suggests that intrinsic 
cardiac decline may occur in hearts of progeria patients independent of vascular 
changes.  
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Table 3.2. Phenotypic comparison of existing models of LMNA associated 
DCM.  
Model Survival Heart 
pathology 


















































- - - + 
MLC2v-PLA Tg 






+ + + + 
LmnaMHC-M371K and MLC2v-PLA Tg models are specific for the heart whereas the 
remaining models are tissue non-specific and are expressed in all cells of the 
respective model. 
+ = Yes, - = No, ? = unknown 
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Chapter 4: Molecular characterisation of mice accumulating CM 




Models of LMNA associated disease have reported a variety of pathways to which 
pathogenesis may be attributed. These include mechanical, transcriptional, DNA 
damage, cell cycle, MAPK signalling, mTOR signalling and autophagy.  For example, 
Lmna-/- mice have a distinct DCM-like phenotype involving reduction in contractility of 
the myocardium. LMNA deficiency has been associated with a number of cellular events 
including disruption of the LINC complex and the cytoskeleton which may impair 
mechanical coupling in the myocytes leading to reduction in force225, 244. Moreover, 
inhibition of mechanotransduction and altered signalling has been reported in in vitro 
models of LMNA deficiency126, 168, 170. In addition, AKT/mTOR signalling is thought to 
be elevated in Lmna-/- mice241. AKT/mTOR signalling has also been implicated in the 
pathogenesis of DCM in LmnaH222P/H222P mice240. Interestingly, defective autophagic 
responses were also reported in these mice, and may be linked to mTOR signalling. 
Another defect reported in LmnaH222P/H222P mice, LmnaN195K/N195K mice, which have 
DCM, as well as Lmna-/- mice, is mislocalisation and loss of connexins. In the heart, 
connexins are membrane bound ion channels that link the cytoplasmic domains of 
adjacent CMs, thus playing a vital role in propagating electrical signals from one CM to 
the next, enabling efficient and synchronous contraction of the myocardium. Loss of 
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connexins, particularly Cx43, has been associated with the cardiac conduction defects 
seen in Lmna-/- and LmnaH222P/H222P mice245, 246, 248.  
 Zmpste24-/- mice have not been studied in detail in the context of heart disease. 
Although it is clear that there are histological abnormalities in the myocardium, it is not 
yet clear whether there is an overt cardiac phenotype. However, extensive systemic 
characterisation of the model shows an obvious progeroid-like phenotype and many 
molecular pathways have been identified in the pathogenesis of these mice. Zmpste24-/- 
mice are senescent and exhibit defective DNA repair mechanisms271, altered p53 
signalling272, ageing like epigenetic patterns273, deregulated miRNA repression274, 
mitochondrial dysfunction275, inhibition of somatotrophic signalling149, 276 and systemic 
inflammation125.  
Genomic instability is a hallmark feature of progeroid disorders and can be 
shown as accumulation of DNA damage markers in the nuclei of cells. The current 
dogma suggests that this is due to faulty DNA damage repair mechanisms caused by 
destabilisation of the lamin scaffold. Lamins are thought to be crucial in chromatin 
arrangement and in facilitating optimal positioning for DNA damage repair. In the 
presence of prelamin A/progerin variants, the lamina is disorganised and 
heterochromatin cannot be positioned optimally leading to defective recruitment of 
DNA damage repair factors207. Moreover, cell cycle regulators are key mediators in the 
onset of senescence. Activation of p53 occurs in order to stall the cell cycle in G1/2 
phase to allow DNA damage to repair before the cell continues through to DNA 
synthesis or mitosis. It is thought that persistent DNA damage can lead to constitutive 
p53 activation and permanent cell cycle arrest. Reports suggest that this occurs via 
ATM dependent phosphorylation of p5394, 277, 278. Expression and activation of p53 has 
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been linked to the ageing phenotype seen in Zmpste24-/- mice272. Moreover, whilst CMs 
are post mitotic, activation of p53 has been observed in CMs and is thought to regulate 
pathogenic pathways279. Additionally, activation of p16 and p21 has also been identified 
as potentially senescence inducing in many cell types280-283. These many pathways 
which regulate disease are not exclusive and may occur in tandem with each other and 
may even be co-dependent. In this chapter, the phenotype of the PLA Tg mice is 





4.2.1 Prelamin A accumulation causes expression changes in nuclear envelope 
proteins and mislocalisation of the intermediate filament protein, desmin 
 
Prelamin A accumulation is known to disrupt the NE and cause changes to LINC 
complex proteins and our current model displays phenotypic similarities to Lmna-/- 
mice. Therefore, the LINC complex and cytoskeletal components of the myocyte were 
assessed in PLA Tg mice.  
 Western blotting of ventricular tissue lysates was performed and prelamin A was 
detectable only in PLA Tg heart lysates (Fig 4.1). The LINC complex proteins, lamins 
A, C and B1, appeared to be significantly increased in PLA Tg hearts compared to Wt. 
Emerin expression did not change between Wt and PLA Tg whilst SUN2 was decreased 
in PLA Tg hearts (Fig 4.1). Antibody to nesprin 1α (N3) showed that an isoform 
corresponding to ~95kDa was absent in PLA Tg hearts whilst nesprin 2 also appeared to   












Figure 4.1. Expression of inner nuclear membrane associated proteins was 
dysregulated in 4 week old hearts of mice accumulating prelamin A. A) Ventricular 
tissue lysates were western blotted and membranes probed with antibodies for INM 
proteins prelamin A (C20), lamin A/C (N18), lamin B1, emerin and SUN2. GAPDH was 
used as loading control. B) Densitometric analysis showed that, as expected, prelamin 
A was increased in PLA Tg hearts. Significant increases were also apparent in lamin A 
and C and lamin B1. SUN2 significantly decreased in PLA Tg hearts tissue compared 
to Wt. Emerin remained unchanged. Values expressed as mean±SEM, *P<0.05 
***P<0.001, N=3/group 
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undergo an isoform switch as there was a significant increase in the 75kDa band in PLA 
Tg compared to Wt (Fig 4.2). Expression of desmin was significantly increased in PLA 
Tg hearts compared to Wt. Expression of sarcomeric myomesin was unchanged 
between Wt and PLA Tg mice, whilst α-actinin was significantly decreased in PLA Tg 
compared to Wt (Fig 4.2). 
 Next, cryopreserved heart sections were subject to immunofluorescence staining 
for LINC associated and cytoskeletal proteins. Prelamin A (C-20 antibody) staining 
confirmed that prelamin A was present in the nuclear rim of PLA Tg but not Wt CMs 
(Fig 4.3). Lamin A/C was localised to the nuclear rim of CMs in Wt and PLA Tg 
myocytes, whilst the number of lamin A/C positive nuclei appeared increased in PLA 
Tg hearts (Fig 4.4). Many of these nuclei were located within the interstitium of the 
myocardium, which also appeared more pronounced compared to Wt, indicating the 
presence of another cell type. Moreover the lamin A/C staining was more intense in 
interstitial cells compared to CMs. Lamin B1 was also distributed at the nuclear rim of 
CMs and interstitial cells in both Wt and PLA Tg hearts (Fig 4.5). Desmin distribution 
appeared more disparate in PLA Tg hearts compared to Wt. Whilst displaying the 
sarcomeric staining expected, the clear perinuclear localisation seen in Wt was largely 
absent in prelamin A positive nuclei and staining was also weaker at intercalated discs 
(Fig 4.1). Moreover, it appeared that desmin occasionally accumulated in a random, 
non-specific manner in the cytoplasmic domain of CMs. Staining for cytoskeletal 
components of the sarcomere showed that myomesin localisation was unchanged 
between PLA Tg and Wt heart sections (Fig 4.4 & 4.5), whilst α-actinin localisation 
was also unaffected – although there was some indication that staining was less intense 
  










Figure 4.2. Expression of outer nuclear membrane proteins, intermediate 
filament proteins and cytoskeletal components of the sarcomere was 
dysregulated in 4 week old hearts that accumulate prelamin A. A) Ventricular 
tissue lysates were western blotted and the membranes were probed for antibodies to 
nesprin 1, nesprin 2, desmin, myomesin and α-actinin. B) Densitometric analysis 
showed that nesprin 1 expressed lower levels of the 95kDa isoform in PLA Tg heart 
compared to Wt. A nesprin 2 isoform of molecular weight 75kDa was significantly 
increased in PLA Tg hearts. Desmin significantly increased in PLA Tg hearts and α-
actinin significantly decreased when compared to Wt. Myomesin showed a trend 
towards a decrease in expression in PLA Tg mice. Values expressed as mean±SEM, 
*P<0.05, **P<0.01, N=3/group 
  








Figure 4.3. Prelamin A was localised to the nuclear rim and desmin appeared to 
show a more perinuclear localisation in PLA Tg hearts. Cryopreserved heart cross 
sections were subject to immunofluorescence staining with prelamin A (green) and 
desmin (red) antibodies, and viewed under fluorescent light. Prelamin A accumulated 
in the nuclear rim of PLA Tg mice mice and not Wt (green arrow). In PLA Tg hearts, 
desmin accumulated in aggregates at perinucler regions and sarcolemmal regions 
(dashed red arrows) compared to Wt, which showed localisation to the sarcomere and 
intercalated discs (red arrows). Sections stained with serum IgG were used as negative 
controls. Scale bar = 20 μm 
  








Figure 4.4. Lamin A/C was localised to the nuclear rim and nucleoplasm in all 
cells in the heart and myomesin was localised to the sarcomere in Wt and PLA 
Tg mice. Cryopreserved heart sections were subject to immunofluorescence staining 
with lamin A/C (green) and myomesin (red) antibodies and showed that myomesin was 
localised to the sarcomere in both Wt and PLA Tg mice with no observable differences. 
Lamin A/C was localised to the nuclear rim and nucleoplasm in CMs. Heart sections 
from PLA Tg mice appeared to have more lamin A/C positive nuclei than Wt within the 
myocardium which gathered in regions between the myomesin staining indicative of 
interstitial clusters of cells (within the ellipse). Sections stained with serum IgG were 
used as negative controls. Scale bar = 20 μm 
  









Figure 4.5. Lamin B1 localised to the nuclear rim in all cells of the myocardium in 
Wt and PLA Tg mice but appeared to be less intense in PLA Tg CMs. 
Cryopreserved heart sections were subject to immunofluorescence staining with lamin 
B1 antibody (green) and myomesin (red). Lamin B1 was localised to the nuclear rim in 
all cells but was was more intense in the nuclei of cells in the interstitium than the CMs. 
There appeared to be fewer CMs and more interstitial cells in PLA Tg mice compared 
to Wt (within the ellipse). Myomesin was used as a CM marker. Sections stained with 
serum IgG were used as negative controls. Scale bar = 20 μm 
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and less sharp (Fig 4.6). Interestingly, in Wt sections, prelamin A appeared to co-
localise with α-actinin at the sarcomere, a feature which has not before been observed 
(Fig 4.6) and discussed in chapter 7. 
 
4.2.2 Prelamin A accumulation causes misshapen nuclei and disruption to 
perinuclear organisation in CMs 
 
It has been well reported that aberrant expression of lamins or lamin mutants has a 
deleterious effect on nuclear structure and results in nuclear morphology defects. 
Moreover, prelamin A accumulating diseases also report a loss of heterochromatin in 
affected nuclei, although this has not been shown in CMs. 
To ascertain whether this occurs in prelamin A accumulating CMs, hearts were 
perfusion fixed and processed for electron microscopy. As expected, nuclei were often 
misshapen in PLA Tg hearts compared to Wt (Fig 4.7) and also underwent a loss of 
heterochromatin from the nuclear periphery. It was also possible to visualise an 
increased space between the nuclear membrane and the sarcomeres. This was also 
evident even in nuclei of PLA Tg hearts that were not misshapen. In contrast, the 
structure of the sarcomeres appeared unaffected in PLA Tg compared to Wt. 
  









Figure 4.6. Prelamin A co-localised with α-actinin at the sarcomere in Wt hearts, 
whilst α-actinin staining intensity decreased in PLA Tg hearts. Cryopreserved 
heart cross sections were subject to immunofluorescence staining with prelamin A 
(green) and α-actinin (red) antibodies. Prelamin A appeared to colocalise with α-actinin 
at the sarcomere in Wt hearts to create a yellow colour in the merge (identified by 
arrows). In PLA Tg hearts, prelamin A localised to the nuclear rim as previously shown 
(arrows). Concomitantly, α-actinin staining was less intense and more diffuse in PLA 
Tg hearts compared to Wt. Sections stained with serum IgG were used as negative 
controls. Scale bar = 20 μm  
  




Figure 4.7. Prelamin A accumulation led to nuclear morphology defects, loss of 
heterochromatin and disruption of the nuclear membrane-sarcomere junction. 
Perfusion fixed hearts were processed and stained for TEM. The sarcomere 
organisation and nuclear morphology was normal in Wt hearts as was the appearance 
of heterochromatin (dark spots within the nucleus). Comparatively, PLA Tg nuclei were 
often dysmorphic with a loss of heterochromatin especially at the nuclear periphery. 
The distance between the sarcomere and nuclear membrane appeared to be 
increased in PLA Tg hearts (highlighted here with red border lines and red arrows) 
compared to Wt, which had no observable space between the nuclear membrane and 
sarcomere (yellow arrows). Scale bar = 500 nm  
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4.2.3 Prelamin A accumulation leads to mislocalisation and aberrant expression of 
Cx43 
 
To ascertain whether Cx43 expression in the heart was affected in the setting of 
prelamin A accumulation, cryopreserved heart sections were subject to 
immunofluorescence staining using an antibody directed towards Cx43. Wt hearts 
showed intense staining that was clearly localised to intercalated discs, whilst Cx43 was 
disrupted in PLA Tg hearts, localising within cytoplasmic regions of CMs in a random 
manner (Fig 4.8A). Moreover, there appeared to be less Cx43 staining in PLA Tg 
hearts. Western blotting of whole tissue lysates confirmed that Cx43 showed a trend 
towards down regulated expression in PLA Tg hearts compared to Wt (Fig 4.8B & C). 
 
4.2.4 Prelamin A accumulation leads to an increase in DNA damage marker γ-
H2AX in CMs 
 
In order to assess whether DNA damage was present in CMs that accumulated prelamin 
A, cryopreserved heart sections were subject to indirect immunofluorescence staining 
using an antibody directed towards phosphorylated-Histone 2AX (γ-H2AX). During 
DNA damage response, phosphorylation of H2AX is one of the earliest events in the 
DDR and acts as a sensor that initiates downstream effectors such as ATM. As such, it 
is an ideal marker for DNA damage accumulation in the current model. As expected, it 
was observed that γ-H2AX foci were increased in CMs of PLA Tg hearts compared to 
Wt. It was obvious that many more nuclei expressed γ-H2AX foci with many more γ-
H2AX foci per nucleus (Fig 4.9A). Furthermore, western blotting of whole tissue   




Figure 4.8. Prelamin A accumulation led to mislocalisation and loss of Cx43 in 
PLA Tg myocardium. (A) Cryopreserved heart cross sections were subject to 
immunofluorescence staining with Cx43 (green) and myomesin (red) antibodies. In Wt 
myocardium, Cx43 was localised to the intercalated discs with strong staining intensity 
(white arrows). Comparatively, Cx43 localisation was erratic and non specific within the 
cytoplasm of PLA Tg myocytes. Scale bar = 20 μm (B) Ventricular tissue lysates were 
western blotted and the membrane was probed with Cx43 antibody. There appeared to 
be a reduction in Cx43 expression in PLA Tg hearts compared to Wt. (C) Densitometry 
showed an incremental but non-significant decrease in Cx43 expression. Values 
expressed as mean±SEM, N=3/group  





Figure 4.9. Prelamin A accumulation led to an increase in γ-H2AX foci and 
protein expression in PLA Tg hearts. (A) Cryopreserved heart cross sections were 
subject to immunofluorescence staining with γ-H2AX (green) and myomesin (red) 
antibodies. There were more γ-H2AX positive nuclei in PLA Tg myocardium compared 
to Wt and the number of γ-H2AX foci in the nuclei was also increased. Scale bar = 20 
μm  (B) Ventricular tissue lysates were western blotted and the membrane was probed 
with γ-H2AX antibody and showed that γ-H2AX expression was significantly increased 
in PLA Tg hearts compared to Wt. Values expressed as mean±SEM, *P<0.05, 
N=6/group  
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lysates showed a small, although significant, increase in γ-H2AX expression (Fig 4.9B 
& C). 
 
4.2.5 Myocardium of hearts accumulating prelamin A express senescence 
associated β galactosidase 
 
Accumulation of large amounts of DNA damage leading to permanent stalling of the 
cell cycle has been implicated in the onset of stress induced premature senescence 
(SIPS). Senescent cells are known to express elevated levels of lysosomal β-
galactosidase that can be detected at pH 6.0 as opposed to pH 4.0284. The theory behind 
detection of β-gal at suboptimal pH is that enzyme expression is thought to be orders of 
magnitude greater in senescent cells compared to healthy cells, owing to the 
accumulation of damaged non degradable macromolecules in senescent cells285. 
Although SA-β-gal has never been shown in heart tissue sections, prelamin A 
accumulation in cell cultures of fibroblasts and VSMCs, both endogenous and ectopic, 
is known to result in expression of SA-β-gal124, 256. 
 Thinly sliced (5 μm thick) cryopreserved heart sections were stained with β-
galactosidase staining solution to reveal that PLA Tg hearts expressed large amounts of 
SA-β-gal whereas Wt hearts did not express SA- β-gal (Fig 4.10). 
  





Figure 4.10. Prelamin A accumulation led to the expression of the senescence 
associated β-galactosidase in PLA Tg hearts. 5 μm thick cryopreserved heart cross 
sections were subject to staining with senescence associated β-galactosidase staining 
solution and viewed under light microscopy. SA-β-Gal positive staining (blue) was 
observed in PLA Tg but not Wt hearts. Disruption of the myocardium was also 
apparent in PLA Tg hearts as the tissue sections were punctured with holes. Scale bar 
= 60 μm  
 On the role of prelamin A in the heart  
 
 146 
4.2.6 Expression of the cell cycle regulators appears unaffected by accumulation of 
prelamin A 
 
In order to assess the role of cell cycle regulators, western blotting of whole tissue 
lysates was performed and showed that tumour suppressor protein p53 and the cyclin 
dependent kinase inhibitors p21 and p16 were barely detectable in all tissue lysates. 
C2C12 myoblasts treated with 1μM doxorubicin for 3 hours were used as a positive 
control and showed strong expression of p53, p21 and p16. There appeared to be no 
observable difference between Wt or PLA Tg hearts (Fig 4.11). 
 
4.2.7 The unfolded protein response (UPR) and autophagy are not activated in the 
setting of prelamin A accumulation 
 
Accumulation of toxic matter in cells is dealt with by stress response systems in which 
macromolecules are subject to proteosomal, lysosomal and autophagosomal 
degradation. The events preceding degradation involve stress sensing and labelling 
mechanisms including the unfolded protein response (UPR) and autophagy. During the 
UPR, chaperones such as Grp78 and Grp94 bind unfolded proteins and label them for 
degradation286, whilst activation of autophagy is associated with the lipidation status 
and cleavage of LC3287.  
 To assess whether the UPR was activated in the setting of prelamin A 
accumulation, western blotting of whole tissue lysates was performed using KDEL 
antibody, which detects Grp78 and 94. Neither Grp78 nor Grp94 were detectable in Wt 
or PLA Tg heart tissue (Fig 4.12A). Finally, to assess autophagy, western blotting of   










Figure 4.11. Expression of senescence associated cell cycle regulators 
was unaffected by accumulation of prelamin A in the heart. Ventricular 
tissue lysates were western blotted and membranes probed with p53, p21 and 
p16 antibodies. Expression levels were very low for p53, p21 and p16, with no 
observable differences between Wt and PLA Tg hearts. N=3/group 
  







Figure 4.12. Accumulation of prelamin A in CMs did not activate ER stress or 
autophagic response pathways in PLA Tg mice hearts. Ventricular tissue lysates 
were western blotted and the membrane was probed with (A) KDEL antibody for 
detection of ER stress response chaperones Grp78 and Grp94. Expression of Grp78 
and Grp94 remained unchanged between Wt and PLA Tg mice. Tunicamycin treated 
C2C12 myoblasts were used to positively control for this experiment. (B) The 
membrane was probed with antibody to cleaved LC3B II to assess activation of 
autophagy. Levels of LC3 II were barely detectable in Wt and PLA Tg mice, with no 
observable difference between groups. C2C12 myoblasts that were serum starved for 
2 h in EBSS were used to positively control for this experiment. N=3/group  
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whole tissue lysates was performed with antibody to cleaved LC3II. Neither Wt nor 
PLA Tg heart tissue expressed cleaved LC3 II (Fig 4.12B). These results suggest that 
these stress pathways do not form part of the mechanism of pathogenesis associated 
with prelamin A accumulation in PLA Tg mice. 
 
4.2.8 NF-κB signalling appears to be activated in hearts of mice that have 
accumulated prelamin A in a CM specific manner 
 
Taking into account the strong inflammatory cell invasion seen in PLA Tg hearts, an 
emerging pathway associated with DNA damage and inflammation has been reported, 
which suggests that activation of the transcription factor NF-κB, a master regulator of 
inflammatory genes, can be driven, in a non-canonical pathway, by upstream activation 
of ATM288. NF-κB is a heterodimeric complex, potentially consisting of p65 (also 
termed Rel A) and p50. Subunits Rel B, cRel and p52 are also capable of forming NF-
κB complexes289. NF-κB complexes are present in inactive forms in the cytoplasm 
bound to IκBα, which together form an inhibitory complex. Activation is initiated by 
phosphorylation of IκBα by upstream secondary messengers, which then dissociates 
from NF-κB, leaving NF-κB free to translocate to the nucleus and regulate gene 
transcription. ATM dependent activation begins with translocation of the NF-κB 
essential modulator (NEMO) to the nuclear domain from the cytoplasmic domain. 
Phosphorylation and activation of ATM leads to subsequent phosphorylation of NEMO 
and translocation out of the nucleus, where activation of the IKK complex occurs, 
leading to phosphorylation of IκBα, dissociation from NF-κB, and nuclear 
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translocation290. Importantly, prelamin A accumulation has already been identified in 
activating this pathway systemically125. 
 To test whether NF-κB signalling was activated in an ATM dependent manner 
in hearts accumulating prelamin A, western blotting of whole tissue lysates from 4 week 
old hearts was performed using antibodies to phospho-ATM (pATM), IκBα, phospho-
IκBα and p65. There was a clear and significant (P<0.001) increase in pATM 
expression in hearts of PLA Tg mice compared to Wt (Fig 4.13). IκBα showed two 
bands and indicated a trend in which there was a decrease in the smaller weight band 
(non-phosphorylated) and an increase in the higher weight band (phosphorylated) in 
PLA Tg mice compared to Wt (Fig 4.13). This finding was confirmed when phospho-
IκBα also displayed a trend towards increased expression in PLA Tg hearts compared to 
Wt (Fig 4.13). Finally, a significant (P<0.05) increase in p65 was observed in PLA Tg 
hearts compared to Wt (Fig 4.13). 
 In order to assess whether NF-κB translocated to the nucleus in the setting of 
prelamin A accumulation, cryopreserved heart sections were subject to 
immunofluorescence staining using p65 antibody and viewed using fluorescence 
microscopy. Whilst expression levels were clearly increased in PLA Tg mice compared 
to Wt, p65 did not necessarily localise to the nucleus, as much of the p65 staining 
remained in the cytoplasmic domain of CMs (Fig 4.14).  
 In order to study this pathway further, CMs isolated from rat hearts were 
transduced with a virus containing a Flag-tagged LMNA-L647R construct. 
Immunofluorescence co-staining with Flag and p65 antibodies showed that many Flag 
positive cells expressed p65 in their nuclei or in peri nuclear regions, whereas non  
  












Figure 4.13. Accumulation of prelamin A led to activation of ATM dependent NF-
κB signalling. (A) Ventricular tissue lysates were western blotted and probed with the 
antibodies: phosphorylated ATM/ATR substrate, IκBα, phosphorylated IκBα and p65 
subunit of the NF-κB complex. (B) Densitometry showed that in PLA Tg hearts 
compared to Wt, p-ATM/ATR was significantly increased; IκBα appeared to be slightly 
but not significantly decreased; and p-IκBα also showed a trend for increased 
expresssion. p65 was significantly increased in PLA Tg myocardium compared to Wt. 
N=3/group 
  










Figure 4.14. NF-κB subunit p65 was increased in hearts that accumulated 
prelamin A. Cryopreserved heart sections were subject to immunofluorescence 
staining using NF-κB subunit p65 (green) and myomesin (red) antibodies. P65 was 
present at very low levels in Wt tissue, whereas PLA Tg sections displayed abundant 
staining. Localisation appeared to be exclusive to CMs as defined by myomesin 
staining, although the patterning and localisation within the CMs appeared 
indiscriminate and difficult to define. Scale bar = 20 μm 
  






Figure 4.15. NF-κB subunit p65 localised to the nucleus in isolated CMs 
transduced with prelamin A. CMs isolated from rat hearts were subject to 
transduction with an adenovirus containing flag tagged uncleavable prelamin A DNA. 
Control cells were transduced with an empty EGFP vector adenovirus. Cells were 
subjected to immunofluorescence microscopy using NF-κB subunit p65 and flag 
antibodies. Flag-prelamin A localised to the nucleus in transduced cells. NF-κB subunit 
p65 was localised to the nucleus or in perinuclear regions in prelamin A transduced 
cells and were diffuse in the cytoplasm in EGFP transduced cells, suggesting prelamin 
A induces p65 translocation to the nucleus. Scale bar = 10 μm 
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transduced cells or cell transduced with an empty viral vector (EGFP control) had 




4.3.1 Accumulation of prelamin A leads to disruption of the LINC complex, which 
may be a potential cause of contractile deficiency 
 
The mechanical relationship between the cytoplasmic and nuclear domains via the 
LINC complex is thought to be crucial to cell homeostasis. It is postulated that certain 
cell types must be mechanically compliant in order to fulfil their function, meaning that 
the nucleus must be mechanically sound and coupled effectively to other cytoskeletal 
components of the cell. Disruption to these linkages and loss of coupling would 
therefore result in structural instability and reduction in force transmission, potentially 
having deleterious effects on a range of processes from cell motility to muscle 
contraction, depending on cell type291. Moreover, it has been established that these 
mechanical links can detect external signals such as sound or flow or mechanical 
stresses and perturbations such as stretch and activate transcriptional responses much 
more rapidly than soluble second messengers are able to and are actively involved in 
controlling cell responses292, 293.  
Data from this chapter indicate that in PLA Tg hearts that have accumulated 
prelamin A, LINC complex protein expression is dysregulated, as lamins A & C 
appeared to be increased as did lamin B1. Interestingly, cleavage of lamins was not 
apparent in PLA Tg mice. Cleavage of lamins is an established marker for apoptosis294, 
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and this observation supports the assertion made in chapter 3 that despite positive 
TUNEL staining, apoptosis was not apparent. Localisation of lamin A/C and lamin B1 
was in the nuclear rim as expected, although there were many more lamin A/C and 
lamin B1 positive nuclei in PLA Tg myocardium, presumably belonging to invasive 
leukocytes. Disruption of expression and localisation to SUN domain proteins is known 
to occur in the setting of HGPS295 and MADA296. Decreased SUN2 in PLA Tg hearts 
compared to Wt is consistent with these observations. Neprins 1 and 2, for which the 
antibodies detect multiple isoforms, appeared to undergo a switch with regard to the 
dominant isoforms that were expressed in PLA Tg heart tissue compared to Wt. PLA 
Tg heart tissue appeared to undergo a loss of a 95 kDa band in the nesprin 1 
immunoblot, which could correspond to the muscle specific isoform nesprin 1α, and 
corroborates with previous findings from Lmna-/- mice suggesting loss of this isoform 
occurs in the setting of lamina disruption244. Additionally, PLA Tg heart tissue 
underwent an increase in a 75 kDa nesprin-2 isoform, which is interesting because the 
opposite occurred in an in vitro mutational analysis of S143F-LMNA DNA, which is 
known to cause progeria phenotypes297. SUN2 and nesprins were inefficiently detected 
on cryosections and as such were inconclusive (not shown).  
Desmin expression was greatly increased in PLA Tg hearts and appeared to 
become localised in cytoplasmic aggregates compared to Wt, which localised at 
intercalated discs, the sarcomere and the perinuclear domain. Indeed, desmin has been 
previously shown to aggregate in DCM and heart failure phenotypes and may be part of 
a common mechanism or response downstream of causative mutations in DCM 
pathogenesis298-300.  
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The expression of sarcomeric proteins, myomesin and α-actinin, was decreased 
in PLA Tg hearts and, although the general localisation of myomesin and α-actinin 
appeared unaffected, α-actinin staining appeared less intense and more diffuse. As yet, 
more work is needed to see how these observations fit into the PLA Tg pathogenic 
model.  
Interestingly, it was observed that prelamin A localised with α-actinin at the 
sarcomere in Wt heart sections, a novel finding, which was not apparent in PLA Tg 
heart tissue. If valid, one could speculate that prelamin A is a novel component of the 
sarcomere. Therefore, disruption to this complex by pathological expression of prelamin 
A may disrupt the finely tuned balance of protein expression and localisation required 
for normal sarcomere function and potentially complicate the analysis of this model. 
This phenomenon is explored in more detail in chapter 7. Furthermore, closer inspection 
of PLA Tg tissue sections by way of ultrastructural imaging suggested that PLA Tg 
nuclei were often dysmorphic and the nuclear membrane appeared to have become 
untethered from the sarcomere even in nuclei that were non-dysmorphic. It may be the 
case that accumulation of IF proteins in PLA Tg CMs reported above is an adaptive 
response in order to compensate for the disruption created by the expression of prelamin 
A. Further investigation is required.  
To summarise, taken with the observations in chapter 3 showing that 
contractility of the myocardium in PLA Tg mice was deficient, these results provide 
compelling evidence for the view that disruption of the LINC complex leads to 
mechanical uncoupling of the nucleus from the cytoskeleton and a reduction in force 
transmission across the CMs leading to a global reduction in contractility of the 
myocardium.  
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4.3.2 Deregulation of Cx43 
 
Another reason for the reduction in contractility of hearts that accumulated prelamin A 
was the reduction in expression and mislocalisation of Cx43 observed. Connexins, 
Cx43 in particular, are localised to gap junctions in the myocardium and vital in 
propagating electrical signals between CMs to facilitate synchronised excitation of 
related regions of the heart. Loss of Cx43, therefore, is likely to lead to attenuated 
electrical signalling and muted excitation-contraction coupling responses in the 
myocardium and therefore, reduced contractility.  
 
4.3.3 Molecular responses to stress and senescence 
 
Studies in isolated HGPS patient fibroblasts have shown that a hallmark of prelamin 
A/progerin accumulating diseases is the increase in DNA damage markers thought to be 
caused by defective DDR mechanisms. This chapter showed that DNA damage is also 
increased in the nuclei of CMs by detection of increased γ-H2AX foci and expression 
and supports the idea that accumulation of prelamin A at the nuclear rim also causes 
accumulation of DNA damage and may be a crucial part of disease pathogenesis in the 
heart. Sustained activation of DDR is thought to be the initial trigger in establishing a 
senescence phenotype, which, according to SA-β-gal staining, was also evident in PLA 
Tg myocardium. 
 Previously, the association between prelamin A, senescence and DNA damage 
led investigators to hypothesise that the accumulation of DNA damage could lead to 
activation of cell cycle regulators such as p53 and cause permanent arrest of cell cycle, 
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thus facilitating the senescence. This chapter showed that expression of cell cycle 
regulators p53, p21 and p16, which are known to inhibit cell cycle during the DDR, 
were unchanged in the myocardium of PLA Tg hearts compared to Wt, suggesting that 
the senescence-like phenotype occurs independently of cell cycle regulators. Expression 
levels of cell cycle regulators were barely detectable in PLA Tg or Wt heart tissue 
lysates, and this observation perhaps questions the role of cell cycle regulators in the 
heart, effectively a terminally differentiated organ (save for cardiac stem cells, cardiac 
fibroblasts and resident monocytes). Indeed, it has been shown that in fibroblasts, 
induction of SA-β-Gal, for example, is independent of cell cycle regulation and cell 
cycle arrest281, 301, 302. In addition, generation of the SASP response is thought to occur 
independently of cell cycle control via p53 and Rb119, suggesting that senescence can be 
regulated by multiple mechanisms which are independent of cell cycle inhibition.  
 Due to the nature of the system of transgenesis, it was deemed important to 
establish whether other responses to stress were activated. It was suggested that the 
abundant accumulation of uncleavable prelamin A might alone activate stress pathways 
such as the unfolded protein response or autophagy and that these may interfere with, or 
even provide alternative mechanisms of, pathogenesis. However, it was found that these 
systems were not activated. This, coupled with the observation that the nuclear rim 
localisation of prelamin A in this model was very specific, suggests that the mechanism 
of disease is likely to be more complex than hyperactivation of cell degradation 
pathways. However, as highlighted by previous studies, it may also be the case that 
autophagic mechanisms are in fact defective in the setting of prelamin A 
accumulation/lamina disruption240, 241, an interesting concept which provides a basis for 
future work on this model.   
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4.3.4 NF-κB signalling  
 
The observation that accumulation of prelamin A in CMs led to inflammation of the 
myocardium was intriguing. As mentioned above and in chapter 1, inflammation of the 
myocardium is often observed in failing hearts, perhaps most commonly post MI in 
response to ischaemia-induced damage and as a result of CM necrosis. However, sterile 
inflammation, whereby the presence of an external inflammatory stimulus is absent also 
occurs, and was observed in the current model. Interestingly, Osorio et al have shown in 
a global model of premature ageing disease that Zmpste24-/- mice suffer from systemic 
inflammation arising from ATM dependent NF-κB signalling125. Expression analysis 
showed that the p65 subunit of NF-κB was upregulated in the myocardium of PLA Tg 
hearts. This was coupled with an increase in phosphorylated-ATM and phosphorylation 
of IκBα, which together provide evidence for activation of ATM dependent NF-κB 
signalling in hearts that had accumulated prelamin A. Moreover, p65 subunit expression 
was increased when assessed by immunofluorescence microscopy, although it was 
unclear whether translocation to the nucleus was occurring. To confirm this in vitro, 
immunofluorescence microscopy was used to show that, in prelamin A transduced cells, 
p65 localised to the nucleoplasm, whereas EGFP vector transduced cells appeared to 
display diffuse cytoplasmic localisation of p65. Not only do these findings support the 
idea that prelamin A is capable of eliciting an inflammatory response, per se, but that 
this can occur in sterile myocardium. Additionally, Osorio et al linked NF-κB activation 
to increases in transcripts of senescence associated secreted factors, Il-6, MCP-1 and 
TNF-α.  Assessment of SASP associated factors in the current model would have been 
ideal for this line of investigation had time allowed. Indeed, the fibrosis phenotype 
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observed in chapter 3 could potentially be driven by SASP factors, of which MMPs and 
collagen are a part116. 
In summary, the mechanisms by which DCM and ultimately fatal heart failure 
occur in PLA Tg mice appear to be multitudinous but can be categorised into two 
distinct groups: 1) Loss of myocardial contractility involving disruption of the LINC 
complex and mechanical stability and loss of connexins; 2) Inflammation associated 
with DNA damage accumulation, NF-κB signalling and possibly the SASP, a process 
that appears to occur independently of cell cycle regulation. Whether these events are 
independent or occur in a stepwise process due to prelamin A accumulation is explored 
in the next chapter where animals at an earlier timepoint were investigated.  
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Chapter 5: Physiological and molecular characterisation of 2 week old 




In the current study, physiological characterisation of PLA Tg mice at 4 weeks old 
confirmed a DCM-like phenotype, which results in heart failure and death before 6 
weeks of age. Moreover, molecular insights revealed a multifaceted response to 
prelamin A accumulation in CMs, including disruption of the NE and IF protein 
network, loss of connexins, DNA damage accumulation, and potentially, senescence. 
Moreover, the senescence phenotype appeared to be independent of control by p53, p21 
and p16, whilst there is also evidence to suggest UPR and autophagic stress 
response/degradation pathways were not activated. 
 In order to further delineate the mechanistic pathways involved, the model was 
assessed at an earlier timepoint. It was hypothesised that this would give a clear 
indication as to which markers of disease arose first and enable the proposition of a 
temporally defined mechanism of pathogenesis. 
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5.2 Results  
5.2.1 Part 1: Physiological characterisation 
 
5.2.1.1 2 week old mice are unaffected by cardiac specific accumulation of 
prelamin A on morphometric analysis 
 
2 week old mice were photographed and body weights were obtained. At 2 weeks, Wt 
and PLA Tg mice were morphologically similar (Fig 5.1): PLA Tg mice (7.13 g ± 0.27) 
weighed similarly to Wt mice (7.02 ± 0.24), P = 0.75 (Fig 5.2A); heart weights were 
comparable between PLA Tg (45.0 ± 1.44) and Wt (42.5 ± 1.23) cohorts, P = 0.22 (Fig 
5.2B); heart weight to body weight ratios were also comparable (PLA Tg, 6.17 ± 0.16 
and Wt, 6.10 ± 0.24, P = 0.83) (Fig 5.2C). Tibia length was unchanged between PLA 
Tg (7.05 ± 0.26) mice and Wt (6.86 ± 0.28), P = 0.63 (Fig 5.2D). Heart weight to tibia 
length ratio was also unchanged between PLA Tg (6.31 ± 0.11) mice and Wt (6.11 ± 
0.26), P = 0.51 (Fig 5.2E). 
 
5.2.1.2 Echocardiographic analysis shows that at 2 weeks, cardiac function is 
unaffected by prelamin A accumulation 
 
Echocardiographic analysis was performed on images obtained from anaesthetised 2 
week old mice. For all parameters measured—IVS;s, IVS;d, LVID;s,LVID;d, LVPW;s, 
LVPW;d, area;s, area;d, EF, FS, SV, LVESD, LVEDD—there were no major or 
statistically significant changes observed in PLA Tg hearts compared to Wt, indicating 
no difference in heart function between cohorts (Table 5.1 & Fig 5.3).  









Figure 5.1. At 2 weeks of age, Wt and PLA Tg mice were comparable in size. 
Representative photograph of Wt and PLA Tg mice taken at two weeks of age. 
  








Figure 5.2. Morphometric analysis showed that at 2 weeks of age, Wt and PLA Tg 
mice were comparable. (A) Body weight, (B) heart weight, (C) heart weight/body 
weight ratio, (D) tibia length and (E) heart weight/tibia legth ratio were unchanged in 
PLA Tg mice compared to Wt. Values expressed as mean±SEM, N=6 females/group 
  









Table 5.1. B-mode Echocardiographic analysis of PLA Tg hearts in long 
axis orientation showed no difference between cardiac dysfunction in PLA 
Tg hearts compared to Wt at 2 weeks old  
 
Values expressed as mean±SEM, N=8 females/group 
NP=No significance 
IVS = Interventricular septum 
LVID = Left ventricular internal diameter 
LVPW = Left ventricular posterior wall   









Figure 5.3. Heart chamber size was unchanged in PLA Tg hearts. Representative 
B mode images of the LV long axis from echocardiography movies were used to 
analyse cardiac function and showed that chamber size was comparable in PLA Tg 
hearts compared to Wt, supporting the analysed data from Table 5.1.  
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5.2.1.3 Histological analysis of 2 week old mice shows no evidence of myocardial 
disarray or fibrosis in the setting of prelamin A accumulation  
 
H&E staining was performed. There appeared to be no major differences in the 
myocardial tissue arrangement of PLA Tg mice compared to Wt. One minor 
observation was the increased clustering of nuclei in the myocardial interstitium of PLA 
Tg mice (Fig 5.4). Additionally, picrosirius red staining showed no signs of pathologic 
fibrosis in PLA Tg hearts compared to Wt (Fig 5.5). Moreover, TEM of hearts showed 
that there were no observable differences in myofibril or sarcomeric structure in PLA 
Tg hearts compared to Wt and no sign of nuclear morphology defects or chromatin 
disorganisation (Fig 5.6). 
 
5.2.1.4 At 2 weeks old, mRNA levels of β-MHC are significantly increased in hearts 
of mice that are accumulating prelamin A 
 
qPCR was performed on 2 week old hearts to assess mRNA expression of markers 
commonly associated with heart failure. α-MHC, ANP and BNP were not significantly 
changed in PLA Tg hearts compared to Wt. However, β-MHC levels increased 3.55 
fold in PLA Tg hearts compared to Wt, reaching significance (P<0.05) (Fig 5.7). 
  




Figure 5.4. Histological examination of heart sections indicated leukocyte 
invasion of the myocardium had begun to occur in 2 week old PLA Tg mice. H & 
E staining of paraffin embedded heart sections were viewed under light microscopy to 
reveal that regions of PLA Tg hearts were characterised by clustering of nuclei within 
the myocardial interstitium (ellipses), thus indicating leukocyte invasion. Scale bar = 30 
μm  




Figure 5.5. No fibrotic remodelling was detected in 2 week old hearts 
accumulating prelamin A. Picrosirius red staining was performed on paraffin 
embedded heart cross sections of Wt (left panelling) and PLA Tg (right panelling) mice. 
There were no observable differences between Wt and PLA Tg heart sections. Scale 
bar = 60 μm 
  




Figure 5.6. Nuclear morphology and cardiac ultrastructure was comparable 
between 2 week old Wt and PLA Tg myocardium. Perfusion fixed hearts were 
processed and stained for TEM. No differences were observed in nuclear morphology, 
heterochromatin organisation (yellow arrows), the nuclear membrane sarcomere 
junction complex (red arrows), or sarcomere organisation between Wt and PLA Tg 
hearts. Scale bar = 1 μm 
  











Figure 5.7. Analysis of mRNA markers suggested β-MHC was an early biomarker 
for DCM and heart failure in prelamin A accumulating hearts. qPCR was 
performed to assess mRNA markers of heart failure and showed that α-MHC mRNA 
was not significantly changed; β-MHC was significantly increased; ANP was 
unchanged; and BNP was not significantly changed in PLA Tg hearts compared to Wt. 
Values expressed as mean±SEM, *P<0.05, N=3/group 
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5.2.1.5 Leukocyte invasion occurs in 2 week old hearts that accumulate prelamin A 
 
Leukocyte invasion was assessed by western blotting of whole tissue lysates and 
immunofluorescence staining on cryopreserved heart sections using a CD45 antibody. 
Microscopic analysis of cells and cell counting suggested there was a significant 
increase in the number of CD45 positive cells per field of view in PLA Tg hearts (100.5 
cells per field of view ± 22.12) compared to Wt (35.44 ± 6.82)  (P<0.05) (Fig 5.8B). 
Furthermore, Western blotting showed changes in CD45 expression between Wt and 
PLA Tg hearts (Fig 5.9A & B).  
 This was confirmed by TEM, which showed the presence of what, 
morphologically, appeared to be leukocytes present in the myocardial interstitium of 
PLA Tg hearts but not Wt (Fig 5.10). 
 
5.2.2 Part 2: Molecular characterisation 
 
5.2.2.1 At 2 weeks old, expression and distribution patterns of LINC complex and 
intermediate filament proteins in hearts accumulating prelamin A are unchanged  
 
Western blotting of ventricular tissue lysates was performed on 2 week old hearts and 
probed with antibodies for prelamin A and the LINC complex proteins, Emerin, lamin 
A/C, lamin B1, SUN2, nesprin2 and the IF protein desmin. As expected, prelamin A 
was expressed in PLA Tg but not Wt hearts. However, expression levels were 
unchanged for lamin A/C, emerin, SUN2, nesprin2 and desmin (Fig 5.11).  




Figure 5.8. Prelamin A accumulation led to leukocytic invasion of the 
myocardium at 2 weeks of age. (A) Cryopreserved heart cross sections were co-
stained with antibody to CD45 (green) and myomesin (red) and viewed with 
fluorescence microscopy to show that PLA Tg hearts appeared to have more CD45 
positive cells within the myocardial interstitium than Wt hearts. Serum IgG was used as 
a negative control. Scale bar = 20 μm (B) CD45 positive cells per field of view on 63x 
magnification were counted by eye and revealed that there were significantly more 
CD45 positive cells in PLA Tg myocardium than Wt. Values expressed as mean±SEM, 
**P<0.01, N=3/group; 20 randomly selected fields of view from each section were 
counted.   














Figure 5.9. Prelamin A accumulation led to increased CD45 expression in the 
myocardium. (A) CD45 antibody was used to probe western blots of ventricular tissue 
lysates from hearts. (B) Densitometric analysis showed a trend towards increases in 
CD45 expression (140 kDa) in PLA Tg hearts compared to Wt. There was also an 
unknown band expressing in PLA Tg hearts that did not express in Wt. N=3/group  
  












Figure 5.10. Presence of leukocytes in hearts that accumulate prelamin A was 
evident at the ultrastructural level at 2 weeks of age. Perfusion fixed hearts were 
processed and stained for viewing with TEM. Presence of morphologically distinct 
dendritic leukocytes was observable in spaces between CMs of PLA Tg myocardium 
but not in Wt myocardium. Scale bar = 500 nm 
  












Figure 5.11. Expression of LINC complex proteins and IF protein desmin was 
unchanged in 2 week old hearts of mice accumulating prelamin A compared to 
Wt. (A) Ventricular tissue lysates were western blotted and membranes probed with 
antibodies for emerin, prelamin A (C20), lamin A/C (N18) and SUN2, nesprin 2 and 
desmin. GAPDH was used as loading control. (B) Densitometry confirmed that, as 
expected, prelamin A was present in PLA Tg hearts but not Wt. However, no changes 
were apparent in expression of emerin, lamin A/C, SUN2, nesprin2 and desmin in PLA 
Tg hearts compared to Wt. Values expressed as mean±SEM, **P<0.01, N=3/group 
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Cryopreserved 2 week old heart sections were subject to immunofluorescence staining, 
using antibodies for prelamin A, lamin A/C, lamin B1, desmin, α-actinin and 
myomesin. As expected, prelamin A was found to localise to the nuclear rim of CMs of 
PLA Tg mice (Fig 5.12). The distribution of lamin A/C (Fig 5.13), lamin B1 (Fig 5.14), 
desmin (Fig 5.15), α-actinin (Fig 5.12) and myomesin (Fig 5.13) appeared unchanged in 
PLA Tg hearts compared to Wt.  
 Moreover, TEM showed no observable differences between the heterochromatin 
organisation or NE structure of PLA Tg mice compared to Wt (Fig 5.7). 
 
5.2.2.2 Expression of Cx43 appears to be altered in 2 week old hearts that have 
accumulated prelamin A compared to Wt 
 
Western blotting of ventricular tissue lysates was performed using Cx43 antibody. 
Expression of Cx43 appeared marginally, but not significantly, increased in PLA Tg 
hearts compared to Wt (Fig 5.16B & C). In cryopreserved 2 week old hearts, Wt mice 
appeared to show a consistent staining pattern around the sarcolemma, and, whilst PLA 
Tg heart sections appeared to be similar, the pattern was intermittently interrupted 
suggesting loss of Cx43 at some sites. Additionally, in PLA Tg myocardium, Cx43 
appeared to localise at intercalated discs, a feature missing from Wt myocardium (Fig 
5.16A).  
  










Figure 5.12. α-actinin appeared normal in PLA Tg hearts compared to Wt, but 
prelamin A did not appear to co-localise with α-actinin in Wt hearts. 
Cryopreserved heart cross sections were subject to immunofluorescence staining with 
prelamin A (green) and α-actinin (red) antibodies. In PLA Tg hearts, prelamin A 
localised to the nuclear rim as previously shown. In chapter 4, it was evident that 
prelamin A co-localised with α-actinin in Wt hearts. This was not apparent in 2 week old 
Wt hearts. Sections stained with serum IgG were used as negative controls. Scale bar 
= 20 μm  
  










Figure 5.13. Lamin A/C was localised to the nuclear rim and nucleoplasm in all 
cells in the heart and myomesin was localised to the sarcomere in Wt and PLA 
Tg mice. Cryopreserved heart sections were subject to immunofluorescence staining 
with lamin A/C (green) and myomesin (red) antibodies and showed that lamin A/C was 
localised to the nuclear rim and nucleoplasm in CMs of Wt and PLA Tg mice. 
Myomesin was localised to the sarcomere in both Wt and PLA Tg mice with no 
observable differences. Sections stained with serum IgG were used as negative 
controls. Scale bar = 20 μm 
  










Figure 5.14. Lamin B1 localised to the nuclear rim in all cells of the myocardium 
with no observable differences between Wt and PLA Tg at 2 weeks of age. 
Cryopreserved heart sections were subject to immunofluorescence staining with lamin 
B1 antibody (green) and myomesin (red). Lamin B1 was localised to the nuclear rim in 
all cells, with no observable differences between Wt and PLA Tg mice. Myomesin was 
used as a CM marker. Sections stained with serum IgG were used as negative 
controls. Scale bar = 20 μm 
  










Figure 5.15. Prelamin A was localised to the nuclear rim and desmin appeared to 
localise normally in 2 week old PLA Tg mice. Cryopreserved heart cross sections 
were subject to immunofluorescence staining with prelamin A (green) and desmin (red) 
antibodies and viewed with fluorescence microscopy. Prelamin A accumulated in the 
nuclear rim of PLA Tg but not in Wt. Desmin expression appeared normal compared to 
Wt, with a predominantly sarcomeric localisation and some perinuclear staining. 
Sections stained with serum IgG were used as negative controls. Scale bar = 20 μm 
  




Figure 5.16. Prelamin A accumulation led to mislocalisation of Cx43 in 2 week old 
PLA Tg hearts. (A) Cryopreserved heart cross sections were subject to 
immunofluorescence staining with Cx43 (green) and myomesin (red) antibodies. In Wt 
myocardium, Cx43 was localised to the sarcolemma with even patterning and 
distribution. Comparatively, Cx43 localisation was a little uneven and punctuated with 
unstained areas. Scale bar = 20 μm (B) Ventricular tissue lysates were western blotted 
and the membrane was probed with Cx43 antibody. There appeared to be a trend 
towards increase in Cx43 expression in PLA Tg hearts compared to Wt, shown by (C) 
densitometric analysis of the western blot. Values expressed as mean±SEM, 
N=3/group. 
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5.2.2.3 Accumulation of prelamin A in 2 week old heart tissue leads to an increase 
in DNA damage 
 
Increases in the number of γ-H2AX foci in nuclei are a reliable indicator of DNA 
damage accumulation. Cryopreserved 2 week old heart sections were stained with 
antibody raised to γ-H2AX and viewed under fluorescent light. It was observed that γ-
H2AX foci appeared increased in PLA Tg heart sections compared to Wt (Fig 5.17A). 
Western blotting of ventricular tissue lysates was performed using γ-H2AX antibody 





5.3.1 At 2 weeks of age, mice that accumulate prelamin A in a cardiac specific 
manner are morphologically and physiologically normal, but histological changes 
have started to occur 
 
Chapter 4 outlined a number of molecular events associated with the pathological onset 
of DCM. Many of these mechanisms have already been identified in other models of 
LMNA associated DCM or progeroid models of disease, but in many cases, they appear 
to have been studied only when a prominent phenotype was evident, meaning the initial 
trigger for disease remained unidentified. This chapter aimed to determine which of the 
molecular changes observed in the current study occurred earliest in order to establish a   




Figure 5.17. Prelamin A accumulation led to an increase in γ-H2AX foci in 2 week 
old PLA Tg hearts. (A) Cryopreserved heart cross sections were subject to 
immunofluorescence staining with p-H2AX (green) and myomesin (red) antibodies. 
There appeared to more H2AX positive nuclei in PLA Tg myocardium compared to Wt, 
and the number of H2AX foci in the nuclei also appeared increased. Scale bar = 20 μm  
(B) Ventricular tissue lysates were western blotted and the membrane was probed with 
p-H2AX antibody and (C) showed, using densitometric analyses, that p-H2AX 
expression in PLA Tg hearts was comparable to Wt. Values expressed as mean±SEM, 
N=3/group  
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temporally defined model of disease progression. To achieve this, mice were studied at 
2 weeks of age, when they appeared to have no negative health effects caused by 
cardiac specific prelamin A accumulation.  
At 2 weeks of age, PLA Tg mice appeared normal as evidenced by the 
photograph in Figure 5.1. Additionally, the mice displayed no unusual physical or 
behavioural traits compared to Wt littermates. Morphometry and analysis of cardiac 
function by echocardiography also suggested that, from a physiological perspective, the 
PLA Tg mice were free of pathology. The first indication otherwise came when 
analysing the histology of the myocardium, and although there appeared to be no overt 
disarray or fibrosis in PLA Tg mice, it was evident that there were more clusters of 
nuclei in the myocardial interstitium in PLA Tg hearts than there were in Wt hearts, 
indicating that leukocyte infiltration, as observed in 4 week old mice, had started to 
occur at 2 weeks of age. This was confirmed by analysis of CD45 expression and 
distribution within the myocardium and could also be observed in the cardiac 
ultrastructure. Additionally, mRNA expression of β-MHC had significantly increased in 
PLA Tg hearts at 2 weeks of age. Increases in β-MHC mRNA are commonly associated 
with heart failure, including in the case of lamin disruption, suggesting that detrimental 
changes were beginning to occur as early as 2 weeks of age236, 262, 303. 
 
5.3.2 The LINC complex appears to be normal at two weeks but subtle changes to 
Cx43 and γ-H2AX are detectable in 2 week old PLA Tg hearts  
 
At 2 weeks of age, LINC complex protein expression was normal compared to Wt. 
Moreover, no differences were observable in the localisation of the lamins, desmin and 
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the sarcomeric proteins α-actinin and myomesin. However, Cx43 expression and 
localisation appeared to be dysregulated in PLA Tg hearts. In Wt hearts, Cx43 appears 
to stain around the sarcolemma in all myocytes in a consistent manner. In PLA Tg 
myocardium, there appeared to be a staining pattern more consistent with 4 week old 
Wt mice with staining at the intercalated discs being more prominent (although there 
were some observable gaps in the staining pattern suggesting incomplete formation and 
localisation of connexins). This observation led to the following speculations. Firstly, 
that during heart development, Cx43 localises evenly throughout the sarcolemma and 
then polarises to intercalated discs upon maturation; indeed, this is an established model 
of gap junction development and formation304. Secondly, that this process is disrupted 
in prelamin A accumulating hearts, pointing towards a model whereby gap junctions 
polarise to intercalated discs prematurely in comparison to Wt hearts. This means that 
prelamin A potentially hastens the development of gap junctions and may form part of 
the pathologic mechanism.  
 It was also observed that the occurrence of γ-H2AX foci appeared increased in 
PLA Tg hearts. Although not necessarily supported by expression levels on western 
blots, by immunofluorescence, increases in the number of foci in each nuclei, if not 
necessarily the number of nuclei affected, were observed. This indicates that DNA 
damage accumulation was occurring in 2 week old hearts and implicates responses to 
DNA damage either directly or indirectly in the progression of disease in this model. 
Taken with the observation that leukocytic invasion has already started to occur, these 
results potentially suggest an important role for ATM dependent NF-κB signalling in 
pathogenesis of PLA Tg mice. Very little is known about the timing of mechanistic 
activation in models of prelamin A mediated disease and, due to time constraints of the 
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current project, further insights were not achieved. Therefore, more work is required to 
establish whether this is the case, especially with regard to activation of NF-κB 
signalling. 
 To summarise, whilst PLA Tg mice were physiologically normal, there were 
cellular and molecular indicators that some of the pathological mechanisms observed in 
4 week old mice were beginning to occur at 2 weeks of age. β-MHC may be an early 
biomarker for disease, whilst regulation of Cx43 and gap junction formation appears to 
be an important aspect of pathogenesis. Moreover, DNA damage accumulation and 
sterile inflammation of the myocardium are evident at 2 weeks and potentially linked by 
NF-κB signalling. The LINC complex appears to be unaffected at this time point, which 
suggests that changes to the structural protein network may occur as an adaptive 
response to mechanical stress. However, it cannot yet be ruled out that these events 
occur downstream as a direct action of prelamin A accumulation. For example, ATM 
dependent NF-kB activation of inflammation could lead to leukocyte invasion; 
leukocytes migrating through the interstitium could phagocytose components of the 
ECM and cause physical perturbations to the ECM and create tension changes305. The 
subsequent changes in ECM tension may be detected by the CMs via 
mechanosignalling, which may confer expression changes to structural proteins. 
Moreover, the ECM changes potentially caused by this mechanism may also initiate the 
fibrotic remodelling of the ECM as perturbations may also lead to secretion of 
profibrotic factors from surrounding cardiac fibroblasts. Additionally, cell death may 
contribute to this pathway, as matter from necrosed CMs may be capable of activating 
TLR signalling which could lead to leukocyte infiltration. Further investigation is 
required. 
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Further investigation is also required into the mechanical stability of CMs, both 
isolated and as intact tissue, to determine whether cells that accumulate prelamin A are 
susceptible to mechanical stress and whether this induces expression changes of 
important structural scaffold proteins. Therefore, although more work is required, a 
temporally defined model of pathogenesis is beginning to emerge and is highlighted by 
Figure 5.18. 
  










Figure 5.18. Working schematic of the pathogenesis of PLA Tg mice. 
Accumulation of prelamin A in CMs led to a range of pathological outcomes in the 
CMs, including accumulation of DNA damage, activation of NF-κB signalling, 
inflammation, increase in the senescence associated biomarker, SA-β-Gal, disruption 
of Cx43, and disruption of the LINC complex and IF network. 
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As mentioned in chapter 1, the research into the regulation of lamins in CMs is limited. 
This is despite the fact that lamin associated diseases tend to affect muscle cell types. 
However, some studies in myoblast cell lines have highlighted the dynamic nature of 
prelamin A processing in the development of myotubes and suggest an active role for 
lamins and indeed prelamin A in myocyte differentiation260, 306. Moreover, during the 
course of investigation for this thesis, some interesting observations were made 
regarding the expression and localisation of prelamin A in the heart. In chapter 4, it was 
observed that endogenous prelamin A was localised to the sarcomere in 4 week old 
heart tissue of Wt mice; however, in chapter 5 it was noted that this was not evident in 2 
week old Wt heart tissue. These were intriguing observations, which, along with other 
observations made during the characterization of the PLA Tg model, led to a distinct 
line of investigation asking if prelamin A is endogenously expressed in the heart? If so, 
where, and how does it get there? 
  




6.2.1 Unprocessed prelamin A is endogenously expressed in CMs  
 
Current evidence suggests that prelamin A intermediates are rapidly converted into 
mature lamin A for insertion into the nuclear lamina. As such, prelamin A is 
undetectable in normal or healthy cells. However, upon over exposing a western blot 
probed for lamin A/C (N-18) containing Wt and PLA Tg heart tissue samples, the 
74kDa prelamin A band was clearly detectable in Wt tissue (Fig 6.1). This was deemed 
to be compelling evidence for the existence of endogenous prelamin A in the heart and 
stimulated further investigation into prelamin A regulation in the heart. Recognising 
that heart tissue is a dynamic organ consisting of multiple cell types, it was important to 
establish whether CMs were a source of this prelamin A. To achieve this, CMs were 
isolated from neonatal rat hearts. Initially, immunocytochemical staining for lamin A/C 
and prelamin A with α-actinin co-staining revealed that lamin A/C strongly stained the 
nuclear rim of CMs (Fig 6.2), whilst prelamin A stained sarcomeric structures and 
appeared to colocalise with α-actinin, indicating that prelamin A localises to the z-disc 
of the sarcomere (Fig 6.3). To further show this localisation, cells were then co-stained 
with myomesin. Myomesin is a sarcomeric protein that localises to the M-line within 
the H-band of the sarcomere. Prelamin A did not localise with myomesin, but formed 
alternating parallel line patterning with myomesin, supporting the observation of z-disc 
localisation (Fig 6.4). 
  

















Figure 6.1. Prelamin A was detectable in Wt heart tissue. Ventricular tissue lysates 
were subject to western blotting and probed with lamin A/C antibody (N18). After 
overexposure of the membrane to film, prelamin A was indistinguishable from lamin A 
in PLA Tg heart tissue. Prelamin A was also detected in Wt tissue. 
  











Figure 6.2. Lamin A/C localised to the nuclear rim and nucleoplasm of CMs. 
Isolated NRCs were subject to immunofluorescence staining using lamin A/C (green) 
and α-actinin (red) antibodies. Lamin A/C localised to the nuclear rim/nucleoplasm of 
all cells, whilst α-actinin localised to the sarcomere of CMs. It was also possible to 
identify faint staining to the sarcomere in the lamin A/C channel on high power 
magnification and zoom. Scale bar = 20μm  
  













Figure 6.3. Prelamin A localised to the z-disc of the sarcomere in CMs. Isolated 
NRCs were subject to immunofluorescence staining with prelamin A (green) and α-
actinin (red) antibodies. Prelamin A appeared to co-localise with α-actinin at the 
sarcomere. Scale bar = 20 μm 
  









Figure 6.4. Prelamin A localised in parallel to myomesin in CMs. Isolated NRCs 
were subject to immunofluorescence staining with prelamin A (green) and myomesin 
(red) antibodies. Prelamin A appeared to localise in parallel with myomesin at the 
sarcomere. Scale bar = 20 μm 
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6.2.2 Nuclear prelamin A accumulates in CMs of DCM patients 
 
In order to understand the behaviour of prelamin A in the heart further, human heart 
cryosections diagnosed phenotypically as DCM, ischaemic heart disease (IHD), and 
healthy controls, were stained. The DCM sections were from patients with clinical 
presentation of DCM but for which the sequencing is currently being undertaken; 
therefore, potential causative mutations are currently unknown. Patient samples S99 
1036 (DCM), S99 1309 (IHD) and S99 577 (healthy control) were compared directly by 
costaining with prelamin A and α-actinin (Fig 6.5). S99 1036 showed prelamin A 
staining of the sarcomere and appeared to localize with α-actinin. Moreover, there was a 
remarkably consistent prelamin A staining in the nuclear rim of most CMs. Associated 
nuclei were dysmorphic as was CM shape. Cell separation was apparent, and increases 
in the amount of interstitial space were observed, which was associated with clustering 
of nuclei within the interstitial spaces. S99 1309 was negative for prelamin A in the 
sarcomere and in the nucleus, morphologically, nuclei of CMs were normal and the 
CMs appeared rod shaped and had a low level of cell separation. S99 577 heart tissue 
was positive for prelamin A staining in the sarcomere and appeared to localise with α-
actinin in the z-disc region. S99 577 nuclei were negative for prelamin A. CMs were rod 
shaped and there was no cell separation. 
  Patient samples 2.059, 4.066, d4.047, 4.032 (DCM) and ch1 5.089 and ch1 
5.138 (healthy control) were directly compared by co staining with prelamin A and 
myomesin. 2.059 appeared to show prelamin A staining in some nuclei and also showed 
moderate sarcomeric staining, which was localised in parallel to myomesin staining,   




Figure 6.5. A subset of DCM patients accumulated prelamin A in the nuclear rim 
of CMs. Cryosections of human heart biopsies were subject to immunofluorescence 
staining with antibodies to prelamin A (green) and α-actinin (red). DCM patient 
myocardium S99 1036 accumulated prelamin A at the nuclear rim of CMs and had 
nuclear morphology defects (arrows). Nuclei were clustered (blue ellipse) in areas of 
myocardial disarray (red dashed line). Additional striated sarcomeric staining was 
observed colocalised with α-actinin. Prelamin A was barely detected in IHD 
myocardium S99 1309. Healthy myocardium S99 577 showed a compelling sarcomeric 
staining colocalised with α-actinin (yellow border). Scale = 20μm   
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again confirming prelamin A localisation to the z-disc region (Fig 6.6). There was 
moderate cell separation, a moderate increase in interstitial space and cells were highly 
dysmorphic. Nuclei were often enlarged and sometimes exhibited blebbing. 4.066 did 
not have nuclear prelamin A staining and showed relatively low levels of sarcomeric 
staining. The nuclei appeared enlarged; the cells appeared rod shaped; and cell 
separation was evident (Fig 6.6). D4.047 also showed no nuclear prelamin A and very 
little sarcomeric prelamin A. Cells appeared dysmorphic with some cell separation and 
associated clustering of nuclei (Fig 6.7). 4.032 showed frequent nuclear staining of 
prelamin A, which was more diffuse compared to the distinct nuclear rim staining seen 
in S99 1036 DCM tissue. Prelamin A accumulation often occurred in the enlarged 
nuclei. Sarcomeric prelamin A staining was also evident in this tissue (Fig 6.6). As with 
S99 577 (healthy control), ch1 5.089 and ch1 5.138 heart tissue was positive for 
prelamin A staining in the sarcomere and appeared to localise in parallel with 
myomesin, indicating z-disc localisation. The nuclei were negative for prelamin A; CMs 
were rod shaped; and there was no cell separation (Fig 6.6 & 6.7). These observations 
are summarised in Table 6.1. 
 
6.2.3 Ectopic expression of uncleavable prelamin A construct (L647R LMNA) in 
CMs results in nuclear localisation 
 
Prelamin A accumulation observed in many laminopathic disease phenotypes occurs at 
the nuclear rim or within the nucleoplasm. The current findings that suggest CMs retain 
endogenous prelamin A within the sarcomere raise questions as to the distribution of 
prelamin A in the setting of pathogenic accumulation or overexpression in the heart.   




Figure 6.6. A subset of DCM patients accumulated prelamin A in the nuclei of 
CMs. Cryosections of human heart biopsies were subject to immunofluorescence 
staining with antibodies to prelamin A (green) and α-actinin (red). DCM patient 
myocardium 2.059 accumulated prelamin A in the nuclei of a number of CMs and had 
nuclear morphology defects (green and blue arrows) and myocardial disarray (red 
dashed line). Additional striated sarcomeric staining was observed colocalised with α-
actinin. 4.066 showed little prelamin A staining whereas healthy myocardium ch1 5.089 
showed sarcomeric staining in parallel with myomesin. Scale = 20μm  




Figure 6.7. A subset of DCM patients accumulated prelamin A in the nuclear rim 
of CMs. Cryosections of human heart biopsies were subject to immunofluorescence 
staining with antibodies to prelamin A (green) and α-actinin (red). DCM myocardium 
d4.047 did not accumulate nuclear prelamin A, whereas 4.032 did. Nuclei were 
clustered (blue ellipse) in areas of myocardial disarray (red dashed line). Additional 
striated sarcomeric staining was observed. Healthy myocardium ch1 5.138 showed a 
substantial sarcomeric staining (yellow border) in parallel with myomesin. Scale = 
20μm   
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Results from chapter 3 and 4 performed on tissue sections of PLA Tg heart tissue 
suggest that in pathogenic settings, prelamin A accumulates in the nuclear rim. To 
further assess this finding, an adenoviral construct with flag-tagged uncleavable 
prelamin A mutant, L647R-LMNA was transduced into NRCs. Interestingly, 
overexpression of this construct led to prelamin A localisation in the nuclear rim with 
some visible cytoplasmic staining when stained with Flag antibody. Wt LMNA was also 
virally expressed in NRCs and showed only strong nuclear staining. These data support 
the findings made in heart tissue sections and potentially suggest a divergent role for 
prelamin A in physiology and in pathogenesis (Fig 6.8).  
 
6.2.4 Prelamin A is directed to the sarcomere during C2C12 myofibrillogenesis 
and coincides with Zmpste24 expression changes 
 
Having discovered that prelamin A localised to the sarcomere, it was important to next 
assess whether prelamin A was regulated in myofibrillogenesis. There is currently 
evidence for modulation of prelamin A in C2C12 myotube formation as one study has 
shown changes in prelamin A expression with detection of a band at approximately 150 
kDa as opposed to the regular 74 kDa immediately at the onset of differentiation. 
However, this response was reported to return to normal over the course of 36 hours and 
localisation to sarcomeric structures was not reported, as myofibers were not assesed306. 
However, longer incubation periods in differentiation medium of C2C12 myoblasts can 
lead to myofiber formation. Therefore, it was hypothesised that prelamin A would be 
directed to the sarcomere in differentiated C2C12 myofibers. To have the greatest 
chance of obtaining myofibers, a chronic differentiation protocol was devised and time   




Figure 6.8. Ectopic expression of Wt LMNA and L647R LMNA mutant led to 
prelamin A accumulation in the nucleus of CMs. Isolated NRCs were transduced 
with adenoviral constructs containing flag-tagged L647R LMNA, Wt LMNA DNA and an 
empty EGFP vector for negative control purposes and stained with prelamin A (green) 
and myomesin (red) antibodies. Expression of both constructs results in prelamin A 
accumulation in the nucleus, whereas endogenous prelamin A is detectable in the 
cytoplasm of EGFP (negative) control. Cells transduced with flag-tagged L647R LMNA 
were also stained with flag antibody (green), again showing nuclear localisation 
predominantly, but also some cytoplasmic localisation. Scale bar = 20 μm  
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intervals were set at 48, 72 and 168 hours. Cycling myoblasts were used for control 
purposes. Consistent with existing evidence, expression of 74 kDa prelamin A in 
undifferentiated myoblasts and cells that were 48 hours into differentiation was 
observed from whole cell lysates (Fig 6.9). However, contrary to previous reports, at 72 
and 168 hours post differentiation, prelamin A was detectable at 150 kDa. The 
distribution of prelamin A appeared to be within peri-nuclear regions or the 
endoplasmic reticulum in cycling myoblasts and in cells differentiated for 48 hours. The 
distribution became more diffuse in cells differentiated for 72 hours and, after 168 
hours, it was possible to see prelamin A in striations lining up alongside, rather than 
completely colocalised with, α-actinin (Fig 6.10). Additionally, Zmpste24 expression 
underwent a steady and significant decrease over the course of differentiation (Fig 6.9). 
Distribution of Zmpste24 appeared to be more diffuse in cells at 72 and 144 hours post 
differentiation compared to cycling myoblasts and cells 48 hours post differentiation, 
which showed a peri-nuclear localisation and more intense staining (Fig 6.11). Desmin 
expression levels showed a trend towards an increase during differentiation (Fig 6.9), 
and distribution was cytoplasmic diffuse throughout the differentiation protocol (Fig 
6.12). Myomesin was undetectable at all time points according to western blotting but 
was visible at both 72 and 144 hours by immunofluorescence microscopy, showing 
striated sarcomeric localisation (Fig 6.11). Lamin A/C appeared to localise and remain 
at the nuclear rim throughout differentiation (Fig 6.12); lamin A expression was 
consistent throughout, whereas lamin C appeared to increase during differentiation (Fig 
6.9). Lamin B1 also localised at the nuclear rim throughout differentiation (Fig 6.13) 
and appeared to undergo increased expression levels (Fig 6.9). 
  




Figure 6.9. Expression changes to prelamin A, Zmpste24 and desmin occurred in 
the differentiation of C2C12 myoblasts. (A) C2C12 whole cell lysates were subject to 
western blotting and membranes probed with antibodies for prelamin A, Zmpste24, 
lamin A/C, lamin B1 and desmin. (B) Densitometry showed that prelamin A was 
observed in cycling myoblasts and cells 48 hours into the differentiation protocol. 
Detection of a 150kDa band occurred at 72 and 168 hours. Zmpste 24 expression was 
comparable in cycling cells and 48 h differentiated cells whereas expression levels 
were attenuated in 72 and 168 h cells. Lamin A/C and lamin B1 expression appeared 
to increase throughout the differentiation protocol, whilst desmin expression showed a 
trend for increased expression during the course of differentiation up to 168 hours. 
Values expressed as mean±SEM,*P<0.05, **P<0.01, ***P<0.001 N=3   




Figure 6.10. Differentiation of C2C12 myoblasts led to myofibril formation after 
168 hours and sarcomeric localisation of prelamin A. C2C12 myoblasts underwent 
differention protocols, fixed at separate timepoints and then subjected to 
immunofluorescence staining with prelamin A (green) and α-actinin (red) antibodies. At 
168 hours, myofibrils were able to form as indicated by the striated pattern caused by 
α-actinin localisation. Prelamin A localised to perinuclear regions in undifferentiated 
cells and then lined up with α-actinin at the sarcomere upon myofibril formation. Scale 
bar = 20 μm  




Figure 6.11. Zmpste24 localisation became diffuse upon myofibril formation in 
C2C12 cells. C2C12 myoblasts underwent differention protocols, fixed at separate 
timepoints and then subjected to immunofluorescence staining with Zmpste24 (green) 
and myomesin (red) antibodies. Myomesin was detected only in cells differentiated for 
72 hours or more, and was striated in cells differentiated for 168 hours. Zmpste24 was 
localised to nuclear rim and perinuclear regions in cycling myoblasts and cells 
differentiated for 48 and 72 hours; localisation became cytoplasmic diffuse at 168 
hours. Scale bar = 20 μm  




Figure 6.12. Desmin underwent altered localisation whilst lamin A/C distribution 
was consistent throughout C2C12 differentiation. C2C12 myoblasts underwent 
differentiation protocols, fixed at separate timepoints and subjected to 
immunofluorescence staining with lamin A/C (green) and desmin (red) antibodies. 
Desmin localised to perinuclear regions in cycling myoblasts and cells differentiated for 
48 hours but was cytoplasmic diffuse at 72 and 168 hours. Lamin A/C localised to the 
nuclear rim at all timepoints during differentiation. Scale bar = 20 μm  




Figure 6.13. Lamin B1 localised to the nuclear rim throughout C2C12 
differentiation. C2C12 myoblasts underwent differention protocols, fixed at separate 
timepoints and subjected to immunofluorescence staining with lamin B1(green) and α-
actinin (red) antibodies. Lamin B1 was localised to the nuclear rim throughout the 
differentiation protocol. Scale bar = 20 μm 
 





6.3.1 Prelamin A appears to be a component of the sarcomere 
 
Having observed that endogenous prelamin A localised to the sarcomere in Wt mouse 
heart tissue in chapter 3, it was decided that additional investigation was required to 
confirm this observation. Prelamin A immunostaining of isolated NRCs supported this 
observation and western blotting confirmed the presence of endogenous prelamin A. 
These data were further supported by immunostaining of human biopsies of healthy 
myocardium showing staining in the z-disc region of the sarcomere. These data suggest 
that prelamin A may be a component of the sarcomere. However, ectopic expression of 
prelamin A in isolated CMs led primarily to a nuclear localisation, although some 
cytoplasmic staining could be detected. To further address this finding, additional 
investigation is required. Moreover, it may be the case that separate stages of prelamin 
A processing influence the localisation of prelamin A in CMs; therefore, perhaps the 
newly introduced range of prelamin A antibodies, which detect prelamin A at various 
stages of processing, could be useful tools in future investigation.  
 
6.3.2 Prelamin A accumulates in a subset of myocardial biopsies from DCM 
patients  
 
Interestingly, biopsies of myocardium from patients with DCM of unknown cause 
showed a number of characteristics with regard to prelamin A localisation. Some 
biopsies were negative for nuclear prelamin A but had sarcomeric prelamin A as 
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observed in control biopsies. One patient, S99 1036, showed strong and frequent 
prelamin A staining in the nuclear rim with nuclear morphology defects and severe 
myocardial disarray and possible leukocytic invasion, indicated by the clustering of 
nuclei. This strongly mimics the structural appearance of PLA Tg mouse heart tissue 
when cross sections are viewed under fluorescent light. As such, one might speculate 
that this patient has a LMNA mutation. This is based on the fact that LMNA mutations 
are a common cause of DCM. Furthermore, evidence suggests that a number of 
mutations, other than those located at the c-terminal domain, can also cause 
accumulation of prelamin A260. Additionally, two biopsies, 2.059 and 4.032, displayed 
less frequent nuclear prelamin A staining that appeared more diffuse compared to the 
striking nuclear rim localisation of S99 1036. Myocardial disarray was also less 
pronounced in these sections. This would suggest the possibility of a paradigm in which 
prelamin A accumulation can occur adaptively in response to stress or in response to 
non-LMNA mutations. This, however, is speculative and would require sequencing 
information and additional investigation in order to verify. Taken together, these data 
imply that prelamin A sarcomere localisation and prelamin A nuclear rim accumulation 
may have divergent physiological and pathological roles, respectively. 
 
6.3.3 Prelamin A and Zmpste24 are dynamically regulated during 
myofibrillogenesis 
 
It has been previously shown that prelamin A is dynamically regulated during C2C12 
myotube differentiation306. However, this previous study focused primarily on nuclear 
events and did not describe the formation of myofibrils and did not study timepoints 
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later than 120 hours. To see whether prelamin A could localise to the sarcomere upon 
myofibrillogenesis, C2C12 differentiation was studied up to 168 hours. Expression 
analysis of prelamin A showed the expression of 74 kDa prelamin A in cycling 
myoblasts and 48 hours into differentiation whilst the detection of a 150 kDa band, a 
possible prelamin A dimer, was observed at 72 hours and 168 hours in differentiation 
media. Previously published data suggested that a 150 kDa band occurs at 24 hours in 
differentiation media and then returns to 74 kDa at 48 hours and finally steadily 
decreases until 120 hours, at which point expression of prelamin A is almost 
undetectable. Whilst these data do not concur entirely with the previous study, there is 
clear evidence for dynamic regulation of prelamin A in myotube differentiation. 
Moreover, immunostaining showed that at 168 hours in differentiation media, when 
sarcomeres formed, prelamin A localised to the z-disc along with α-actinin, coinciding 
with the observation of the 150 kDa protein band. Hypothetically, dimerisation of 
prelamin A to form a homo- or hetero-dimer could facilitate the localisation of prelamin 
A from the nuclear rim/peri-nuclear region to more polarised regions of the cell to form 
part of the z-disc. Further investigation is required.  
 Zmpste24, as previously stated, is crucial in the processing of prelamin A 
intermediates to form lamin A/C. Expression and localisation analysis of Zmpste24 
during myotube differentiation suggests that there is also a dynamic role for Zmpste24. 
Zmpste24 was abundantly expressed in cycling myoblasts and after 48 hours in 
differentiation medium, and was localised to the nuclear rim/perinuclear region of cells. 
At 72 hours, expression was attenuated and then further diminished at 168 hours, at 
which point distribution of Zmpste24 was diffuse in the cytoplasm of differentiated 
cells. The changes seen coincided with changes to prelamin A, which suggests that it is 
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possible that the dynamic regulation during differentiation of prelamin A and Zmpste24 
are linked. In human ageing, it is thought that prelamin A accumulation occurs when 
ZMPSTE24 expression is negatively regulated by age associated events such as DNA 
damage and oxidative stress256, 257, 307, 308. Whilst it is unlikely that ‘ageing’ regulates 
myoblast differentiation, the reduced serum conditions used to induce differentiation are 
likely to change the metabolic state of the cell and potentially increase ROS production, 
consequently regulating Zmpste24 expression. This, too, requires further investigation.  
 Desmin is well characterized in C2C12 cells309. It is present at low levels in 
cycling myoblasts and increases during myogenic differentiation. Moreover, it is 
present in mice embryos from 8.5 days post-coitus and is known to be crucial for 
maintaining and strengthening muscle tissue, although it is not critical for development 
in vivo310. Therefore, desmin expression increase was seen as a good indicator of 
successful differentiation. As expected, the expression of desmin showed a trend to 
increase during differentiation.  
Expression of the lamins A/C and B1 showed an interesting trend. Lamin A 
remained relatively constant throughout differentiation, whereas lamin C and lamin B1 
both underwent significant increases during differentiation. The meaning of these 
observations is as yet unclear and they are possibly complicated by the fact that these 
experiments were performed on plastic tissue culture substrates. This is because during 
development, the concentration of A-type lamin protein expression is strongly 
influenced by the tension and stiffness of the physical environment311, 312. For a clearer 
understanding of these developmental events, these experiments need to be repeated on 
a softer substrate, which mimics that of muscle ECM. Additionally, for a more thorough 
understanding of the importance of prelamin A and Zmpste24 in C2C12 
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myofibrillogenesis, siRNAs directed towards lamin A/C and Zmpste24, as well as 
pharmacological inhibition of lamin A maturation might be informative.  
 To summarise, prelamin A and Zmpste24 are dynamically regulated in 
myofibrillogenesis and prelamin A localises to the sarcomere upon myofibril formation. 
Moreover, prelamin A is localised to the z-disc region of the sarcomere in fully 
differentiated CMs/myocardium to form part of the cardiac cytoskeleton. Aberrant 
expression or accumulation of prelamin A due to mutations, and/or potentially faulty 
processing, results in nuclear localisation and is associated with pathological 
progression towards DCM and heart failure. 
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Chapter 7: Final Discussion 
 
7.1 Thesis summary 
 
Currently, the literature states that mutations to ZMPSTE24 or LMNA that cause the 
accumulation of prelamin A and progerin lead to premature ageing disorders in 
humans202, 205, 313. Attempts to validate this in vivo have led to the discovery of multiple 
mechanisms involved in accelerated ageing and the development of therapeutic regimes 
which have entered clinical trials, but so far these have failed to significantly improve 
prognosis211. Two crucial flaws exist in the research to date of these mechanisms. 
Firstly, studies have tended to focus primarily on isolated skin fibroblasts of patients in 
vitro. Whilst skin ageing is part of the premature ageing process, it is changes to the 
cardiovascular system that appear to be ultimately fatal and therefore should be of 
higher consideration228, 229. Additionally, DCM is one of the most common 
manifestations arising from LMNA mutations and may also be associated with the 
accumulation of prelamin A in a pathogenic manner. Secondly, in vivo studies utilise 
models of disease that mimic mutations seen in humans. But whereas the disease in 
humans is a dominant negative phenotype caused by a heterozygous mutation, most 
disease models only seem to show disease phenotypes when the mutation is 
homozygous, with the exception of the LmnaΔK32/+ and LmnaMHC-M371K models250, 253. 
Therefore, LmnaΔK32/+ and LmnaMHC-M371K models aside, modelling of LMNA associated 
DCM tends to occur in a setting in which wildtype lamins are not made, and this may be 
an important factor in the search for a mechanism of pathogenesis, as human 
phenotypes tend to be autosomal dominant.  
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In order to address these issues, a model of targeted transgenesis, whereby 
LMNA L647R mutated DNA was inserted into the Rosa26 locus, was utilised. In 
isolated cell studies, viral transduction of this plasmid leads to prelamin A 
accumulation124, 256; therefore, it was assumed this should also occur in vivo. A 
‘transgenic’ model was used instead of a knock-in model to avoid the second issue, 
described above, that previous Lmna knock-in mouse models have only displayed 
significant phenotypes when homozygous and as such are not accurate recreations of 
the clinical disease setting. Therefore, it was decided that the redundant Rosa26 locus, 
which is commonly utilised in targeted transgenesis studies, would be used for this 
study. Theoretically, as well as expressing prelamin A, a full compliment of lamins A/C 
would also be expressed. In order to address the issue of tissue heterogeneity/specificity 
and target the cardiovascular system, we decided to utilise the MLC2v promoter in 
order to selectively express L647R-LMNA in the heart.  
Chapter 3 served to confirm a working system of transgenesis and highlighted 
the toxic nature of prelamin A accumulation in the heart. Prelamin A accumulated in the 
nuclear rim of CMs in mice expressing the transgene (PLA Tg mice). PLA Tg mice 
suffered from retarded growth and developed a DCM-like phenotype which very 
quickly progressed to HF and death. Detailed analysis confirmed physiological, 
morphological, histological and molecular abnormalities consistent with DCM and heart 
failure and allowed the comparison of existing models of heart dysfunction with lamin 
involvement including Lmna-/-, Lmna+/-, LmnaH222P/H222P, LmnaN195K/N195K, LmnaMHC-
M371K, LmnaG609G/G609G and Zmpste24-/- mice.  
The most phenotypically similar of these models to PLA Tg mice proved to be 
the Lmna-/- mice, which also failed to thrive and survived only to 6-8 weeks of age 
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because of DCM and heart failure and suggested that more detailed mechanistic 
analysis should begin by analysing pathways similar to those seen in Lmna-/- mice225, 244. 
As with a number of DCM models, the current study found myocardial disarray and 
significant levels of fibrosis, which pointed towards myocardial remodelling. But 
perhaps the most striking feature of the characterisation was the observation that 
leukocyte invasion of the myocardial interstitium occurred. Inflammation is known to 
be part of the progression to heart failure especially in cases involving infarct events305; 
however, there also seems to be a body of evidence emerging suggesting that sterile 
inflammation of the myocardium can occur independently of ischaemic injury due to 
the breakdown of endogenous cellular safeguards such as autophagy268. Interestingly, 
global Zmpste24-/- mice appear to experience leukocyte invasion of the myocardium in 
the presence of no haemodynamic or environmental stress214. In the same conditions, 
Zmpste24-/- mice also suffered from systemic inflammation, suggesting that there is an 
internal mechanism activating inflammatory responses125. Consequently, these 
investigative leads were at the forefront of the planning process for the mechanistic 
analysis of PLA Tg mice. 
These mechanisms were the subject of scrutiny in Chapter 4. Firstly, uncoupling 
of the IF protein system was explored in conjunction with pathways reported by 
Nikolova et al with regard to Lmna-/- mice225, 244. The findings in the current study 
suggested that similar mechanisms are at play with regard to the expression changes 
observed in nesprins and desmin, as well as the localisation changes seen with desmin. 
These results suggest that mechanical instability and susceptibility to mechanical 
stress/load are potentially a causative reason for DCM in CMs accumulating prelamin 
A. Dysregulation of connexins has been reported in clinical cases of DCM and sudden 
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cardiac death314-316 and many Lmna associated DCM models have identified the 
misexpression and mislocalisation of Cx43 as potential mechanisms for arrhythmogenic 
activity and depressed cardiac function248. Cx43 expression and, in particular, 
localisation was disrupted in PLA Tg hearts compared to Wt, confirming a role for 
Cx43 in prelamin A mediated DCM. 
 Curiously, despite DNA damage being a hallmark trait of prelamin A 
accumulating premature ageing disorders, Lmna associated DCM models have rarely 
focussed on the potential role of DDR. DNA damage was assessed here by the presence 
of a classic DNA damage marker γ-H2AX. Increases in γ-H2AX were observed in PLA 
Tg hearts and reiterated the dogma that prelamin A accumulation leads to increases in 
DNA damage. Having established this, it was important to assess the downstream 
effects and ascertain whether the increases in DNA damage played a role in the 
pathogenesis of cardiac dysfunction. Classically, DNA damage induces cell cycle arrest 
via DDR regulators of cell cycle such as p53, p21 and p16 and, in the setting of terminal 
cell cycle arrest, can lead to SIPS, which, alongside replicative senescence, can be 
detected by the SA-β-Gal assay. As discussed in this thesis, the notion of cardiac 
senescence per se is a tentative one as CMs are non-renewable from an early age. 
Moreover, use of the SA-β-Gal assay on tissue samples is in its infancy; however, it is 
now understood that replication is not the only barometer of senescence and protocols 
for detection of senescence in situ have been established285. Perhaps somewhat 
surprisingly, use of this assay produced a strong result suggesting that PLA Tg heart 
tissue was senescent. To follow this up, expression analysis of the aforementioned p53, 
p21 and p16 was performed, which provided a negative result. Expression of all three of 
these proteins was undetectable in Wt and PLA Tg tissue samples, suggesting that if 
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senescence does occur in PLA Tg hearts, then it occurs independently of p53, p21 and 
p16. However, the role of DDR is not limited to the regulation of cell cycle as 
highlighted by recent publications125, suggesting ATM dependent NF-κB signalling can 
lead to systemic inflammation. Considering the observation of myocardial inflammation 
in our system, analysis of ATM dependent signalling was performed which supported a 
potential role for ATM dependent signalling within the pathogenic response to prelamin 
A accumulation in CMs. 
Largely absent from current literature is the elucidation of temporally defined 
mechanisms. Although some publications have tackled this question to a degree with 
regard to manifestation of DCM250, timelines of pathogenic mechanisms have not been 
included in reports from Zmpste24-/- mice, which are generally studied at 3 months of 
age. Chapter 5 aimed to provide insight into how the phenotype and mechanisms 
observed in chapters 3 and 4 were regulated at an earlier 2 week timepoint. It was hoped 
that this would provide clues as to how disease manifested and progressed in hearts in 
which CMs accumulated prelamin A. The results indicated that, whilst there was no 
overt phenotype in 2 week old mice, certain changes were taking place at the cellular 
level. Cardiac function was normal and there was no fibrosis to report; however, there 
was moderate leukocytic invasion of the myocardium. Molecular assessment of 
expression and localisation ruled out early changes to the IF and LINC protein network, 
suggesting CMs were mechanically sound at 2 weeks of age; however, CD45 positive 
cells were increased, and reinforced the observation of leukocytic infiltration of the 
myocardium in PLA Tg mice. Interestingly, Cx43 expression/localisation appeared 
dysregulated at 2 weeks of age. The localisation of Cx43 in Wt tissue was sarcolemmal, 
whilst in PLA Tg myocardium Cx43 expression was nominally increased and appeared 
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to be polarised/localised to intercalated discs. These data suggest that gap junction 
formation is premature in prelamin A expressing hearts. Therefore, not only may Cx43 
dysregulation contribute phenotypically by inefficient propagation of electrical signals 
between CMs in 4 week old hearts but may also indicate mistimed gap junction 
formation which may contribute to disruption of the cardiac milieu during maturation. 
Finally, DNA damage also seemed to be increased in PLA Tg hearts at 2 weeks of age 
compared to Wt. Taken with the finding that leukocytic invasion is occurring at 2 weeks 
of age, it can be postulated that NF-κB signalling may be active at 2 weeks.  Further 
investigation is required. 
The final chapter, chapter 6, explored the regulation of prelamin A in CMs. It 
was observed in mouse heart sections that prelamin A antibody was localising to the 
cytoplasm in a striated fashion, suggesting that prelamin A localised to the sarcomere. 
Furthermore, overexposure of a western blot suggested that prelamin A was expressed 
in low concentrations endogenously in Wt ventricular tissue homogenates. To explore 
this novel finding further, NRCs were isolated and stained with prelamin A and co-
stained with myomesin or α-actinin. Prelamin A appeared to colocalise with α-actinin, 
albeit not completely, and localised in parallel with myomesin, confirming that prelamin 
A localised to the Z-disc region of the sarcomere.  
During the course of the investigation, I was privileged to obtain some sections 
of DCM patient and healthy control heart biopsies, courtesy of Dr Elisabeth Ehler. 
Staining with prelamin A antibody revealed z-disc staining, particularly in healthy 
controls. Additionally, a selection of DCM sections showed positive prelamin A 
staining in the nucleus. However, this response was inconsistent as some hearts showed 
compelling nuclear rim staining, whereas others showed less frequent and more nuclear 
 On the role of prelamin A in the heart  
 
 221 
diffuse staining. This could have been due to various reasons. Firstly, in the heart 
sections with frequent and strong nuclear rim staining, there is likely to be a LMNA 
mutation and in less intensely stained sections there may not be. In the case of the latter, 
prelamin A accumulation may be an adaptive or downstream response of the original 
manifestation, which could be a non-LMNA gene mutation or extrinsic stressors such as 
chemotherapy or alcohol. Alternatively, sections in which nuclei stained intensely for 
prelamin A might have a mutation closer to the ZMPSTE24/FACE1 processing site of 
the LMNA gene, with less intensely stained sections having a LMNA mutation in a 
region further from the ZMPSTE24/FACE1 processing site. The sequencing results will 
be crucial in further informing this line of study. 
Finally, C2C12 myofibrollogenesis assays revealed that prelamin A is 
dynamically regulated during myoblast differentiation to myotubes as expression of a 
150 kDa prelamin A is detected late into myofibrillogenesis, suggesting formation of a 
prelamin A dimer, either homo- or hetero-  (with lamin C or lamin B1 for example), and 
that prelamin A is capable of localising to sarcomeric structures upon myofibril 
formation. Moreover, Zmpste24 undergoes a distinct reduction in expression late into 
myofibrillogenesis, which could speculatively serve to regulate the observed expression 
and localisation changes to prelamin A. 
 
7.2 Study limitations and future work 
 
As with many studies, the most pressing limitation was time. There were many 
elements of the study which merit further investigation. It would have been ideal to 
have a full characterisation of the 2 week old mice as well as the 4 week old mice in 
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order to directly compare all mechanistic pathways, especially with regard to SA-β-Gal 
staining and assessment of the NF-κB signalling pathway.  I would have liked to have 
rigorously explored the idea of a ‘cardiac senescence like phenotype’ by analysing the 
mRNA expression levels of the β-galactosidase gene, GLB1, in order to quantify and 
ratify the SA-β-Gal staining observed. The increase in lysosomal β-galactosidase is 
thought to be an adaptive response to the accumulation of undegradeable 
macromolecules in the cytoplasm of cells. This poses the question as to whether cell 
housekeeping systems, such as the ubiquitin proteasome system and autophagy, are 
deregulated in senescence and if so, how? Utilising the current model to assess this 
would be fascinating because interestingly, LmnaH222P/H222P mice hearts display 
defective autophagy, whereas Zmpste24-/- mice experience an increase in autophagic 
activity. It would require fasting the mice for over 24 hours to activate autophagy. 
Subsequent assessment of LC3 lipidation status using immunoblotting would be able to 
indicate whether autophagy was defective in PLA Tg hearts.  
 Moreover, assaying the cytokine profile of PLA Tg heart tissue by qPCR of 
mRNA expression may provide insights as to whether the heart displays a SASP-like 
phenotype in the setting of prelamin A accumulation and help establish the notion of a 
cardiac senescence paradigm.  
The absence of a mouse line overexpressessing Wt LMNA is limiting. Studies of 
mutated overexpression are often controlled by Wt overexpression animals; however, 
our lab currently lacks a mouse which overexpresses lamin A/C and the costs of 
obtaining one with the same system of targeted transgenesis is likely to be unaffordable. 
A model does exist where an α-MHC driven Lmna overexpressor, expresses, Wt Lmna 
exclusively in the heart. It is long lived and suffers no adverse pathology of the heart 
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tissue253. Through the work of Wang et al, we can be reasonably sure that 
overexpressing Wt Lmna in the heart alone is non pathogenic and does not lead to the 
same series of underlying mechanistic deficiencies observed in the current model. In 
this study, we have established that prelamin A expression is pathogenic in its own right 
and does not rely on a degree of the absence of wildtype lamins to mediate its 
deleterious effects.  
 The current study has identified a number of potential mechanisms that may 
regulate the pathogenic response to prelamin A accumulation and, despite the study of 
data from a 2 week timepoint, it is still not clear whether any single event (prelamin A 
accumulation aside) is responsible for initiating the onset of disease. With the nuclear 
rim localisation of prelamin A, it is clear that the initial source of the disease must 
originate from within the CM. To pinpoint the manifestation of disease, it might be 
helpful to isolate neonatal PLA Tg CMs and study them independently of the cardiac 
milieu in order to determine which mechanistic events identified by this study might 
occur, despite the lack of a tissue environment. Any specific disturbances to CM 
signalling could be deemed important and provide a platform for further investigation in 
vivo. 
 In our model, the disease manifests at a very young age and at a rapid rate, and 
is useful in looking at the impact of prelamin A accumulation during development as 
may occur with disease causing LMNA mutations. However, it is desirable, that 
assuming prelamin A was to accumulate in the face of advancing age, to perform such 
experiments on adult myocardium. To achieve this, a separate approach, in which the 
expression of prelamin A is temporally regulated, would be required. Fortunately, as 
well as spatial control of expression, targeted transgenesis facilitates temporally 
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controlled expression with the use of MerCreMer mouse lines. In these mice, cre-
recombinase is retained in the cytoplasm, which upon exposure by injection to 
tamoxifen is then translocated to the nucleus where the floxxed STOP cassette of the 
transgene is deleted and inhibition of transcription is relieved. This system would allow 
the assessment of the impact of prelamin A accumulation in the developed heart and 
reveal the importance of prelamin A in general adult ageing of the myocardium. 
 
7.3 Final Conclusions 
 
In summary, I have established in vivo that pathogenic prelamin A accumulation in 
CMs elicits a response which involves DDR, inflammmation of the myocardium, Cx43 
disruption, and LINC complex disruption, and that these pathways are potentially 
unified by the emerging notion of ‘myocardial senescence’. In addition, I have showed 
some evidence that prelamin A may play a role in the sarcomeric structure of healthy 
CMs and that prelamin A accumulated in the nuclei of CMs in a number of human 
DCM biopsies. Therefore, nuclear prelamin A accumulation may occur as a result of 
mutations to LMNA, downstream of non-LMNA DCM mutations, or possibly even 
downstream of environmental stress factors, and may elicit a pathogenic response via 
one or all of the mechanisms described here in our in vivo model. 
  
 On the role of prelamin A in the heart  
 
 225 
Chapter 8: References 
1. Crisp M, Liu Q, Roux K, Rattner JB, Shanahan C, Burke B, et al. Coupling of 
the nucleus and cytoplasm: role of the LINC complex. The Journal of cell 
biology. 2006;172(1):41-53. 
2. Rienks M, Papageorgiou AP, Frangogiannis NG, Heymans S. Myocardial 
extracellular matrix: an ever-changing and diverse entity. Circulation research. 
2014;114(5):872-88. 
3. Zipes DP, Braunwald E. Braunwald's heart disease : a textbook of 
cardiovascular medicine. 7th ed. Philadelphia, Pa.: W.B. Saunders; 2005. 
4. Solaro RJ, Rarick HM. Troponin and tropomyosin: proteins that switch on and 
tune in the activity of cardiac myofilaments. Circulation research. 
1998;83(5):471-80. 
5. Eisner DA, Kashimura T, O'Neill SC, Venetucci LA, Trafford AW. What role 
does modulation of the ryanodine receptor play in cardiac inotropy and 
arrhythmogenesis? Journal of molecular and cellular cardiology. 
2009;46(4):474-81. 
6. Diaz ME, Graham HK, O'Neill S C, Trafford AW, Eisner DA. The control of 
sarcoplasmic reticulum Ca content in cardiac muscle. Cell calcium. 2005;38(3-
4):391-6. 
7. Bers DM. Cardiac excitation-contraction coupling. Nature. 
2002;415(6868):198-205. 
8. Ehler E, Perriard JC. Cardiomyocyte cytoskeleton and myofibrillogenesis in 
healthy and diseased heart. Heart failure reviews. 2000;5:259-69. 
9. Chang AN, Potter JD. Sarcomeric protein mutations in dilated cardiomyopathy. 
Heart failure reviews. 2005;10(3):225-35. 
10. Gerull B, Gramlich M, Atherton J, McNabb M, Trombitas K, Sasse-Klaassen S, 
et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial 
dilated cardiomyopathy. Nature genetics. 2002;30(2):201-4. 
11. Herman DS, Lam L, Taylor MRG, Wang L, Teekakirikul P, Christodoulou D, et 
al. Truncations of titin causing dilated cardiomyopathy. The New England 
journal of medicine. 2012;366:619-28. 
12. Itoh-Satoh M, Hayashi T, Nishi H, Koga Y, Arimura T, Koyanagi T, et al. Titin 
mutations as the molecular basis for dilated cardiomyopathy. Biochemical and 
biophysical research communications. 2002;291(2):385-93. 
13. Mohapatra B, Jimenez S, Lin JH, Bowles KR, Coveler KJ, Marx JG, et al. 
Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated 
cardiomyopathy and endocardial fibroelastosis. Molecular genetics and 
metabolism. 2003;80(1-2):207-15. 
14. Malhotra R, Mason PK. Lamin A/C deficiency as a cause of familial dilated 
cardiomyopathy. Current opinion in cardiology. 2009;24:203-8. 
15. Sylvius N, Tesson F. Lamin A/C and cardiac diseases. Current opinion in 
cardiology. 2006;21(3):159-65. 
16. Bione S, Small K, Aksmanovic VM, D'Urso M, Ciccodicola A, Merlini L, et al. 
Identification of new mutations in the Emery-Dreifuss muscular dystrophy gene 
and evidence for genetic heterogeneity of the disease. Human molecular 
genetics. 1995;4(10):1859-63. 
 On the role of prelamin A in the heart  
 
 226 
17. Wulff K, Parrish JE, Herrmann FH, Wehnert M. Six novel mutations in the 
emerin gene causing X-linked Emery-Dreifuss muscular dystrophy. Human 
mutation. 1997;9:526-30. 
18. Puckelwartz MJ, Kessler EJ, Kim G, Dewitt MM, Zhang Y, Earley JU, et al. 
Nesprin-1 mutations in human and murine cardiomyopathy. Journal of 
molecular and cellular cardiology. 2010;48:600-8. 
19. Lakatta EG. Age-associated cardiovascular changes in health: impact on 
cardiovascular disease in older persons. Heart failure reviews. 2002;7:29-49. 
20. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular 
disease enterprises: Part III: cellular and molecular clues to heart and arterial 
aging. Circulation. 2003;107:490-7. 
21. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in 
cardiovascular disease enterprises: Part II: the aging heart in health: links to 
heart disease. Circulation. 2003;107:139-46. 
22. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, 
et al. Lifetime risk for developing congestive heart failure: the Framingham 
Heart Study. Circulation. 2002;106(24):3068-72. 
23. Goldberg LR. Heart failure. Annals of internal medicine. 2010;152(11):ITC61-
15; quiz ITC616. 
24. Burchfield JS, Xie M, Hill Ja. Pathological ventricular remodeling: mechanisms: 
part 1 of 2. Circulation. 2013;128:388-400. 
25. Packer M. Can brain natriuretic peptide be used to guide the management of 
patients with heart failure and a preserved ejection fraction? The wrong way to 
identify new treatments for a nonexistent disease. Circulation Heart failure. 
2011;4(5):538-40. 
26. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, et 
al. Prevalence and significance of alterations in cardiac structure and function in 
patients with heart failure and a preserved ejection fraction. Circulation. 
2011;124(23):2491-501. 
27. Swynghedauw B. Molecular mechanisms of myocardial remodeling. 
Physiological reviews. 1999;79:215-62. 
28. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, et al. Disruption of 
coordinated cardiac hypertrophy and angiogenesis contributes to the transition to 
heart failure. The Journal of clinical investigation. 2005;115:2108-18. 
29. Cupesi M, Yoshioka J, Gannon J, Kudinova A, Stewart CL, Lammerding J. 
Attenuated hypertrophic response to pressure overload in a lamin A/C 
haploinsufficiency mouse. Journal of molecular and cellular cardiology. 
2010;48(6):1290-7. 
30. Gossios TD, Lopes LR, Elliott PM. Left ventricular hypertrophy caused by a 
novel nonsense mutation in FHL1. European journal of medical genetics. 
2013;56(5):251-5. 
31. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular 
signalling pathways. Nature reviews Molecular cell biology. 2006;7:589-600. 
32. Lappé JM, Pelfrey CM, Tang WHW. Recent insights into the role of 
autoimmunity in idiopathic dilated cardiomyopathy. Journal of cardiac failure. 
2008;14:521-30. 
 On the role of prelamin A in the heart  
 
 227 
33. Martino TA, Liu P, Sole MJ. Review Viral Infection and the Pathogenesis of 
Dilated Cardiomyopathy. Circulation research. 2012:182-8. 
34. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. The New 
England journal of medicine. 2011;364(17):1643-56. 
35. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et 
al. Report of the 1995 World Health Organization/International Society and 
Federation of Cardiology Task Force on the Definition and Classification of 
cardiomyopathies. Circulation. 1996;93(5):841-2. 
36. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, 
et al. Mutations in sarcomere protein genes as a cause of dilated 
cardiomyopathy. The New England journal of medicine. 2000;343(23):1688-96. 
37. Maron BJ, Thompson PD, Puffer JC, McGrew CA, Strong WB, Douglas PS, et 
al. Cardiovascular preparticipation screening of competitive athletes. A 
statement for health professionals from the Sudden Death Committee (clinical 
cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease 
in the young), American Heart Association. Circulation. 1996;94(4):850-6. 
38. Bonne G, Carrier L, Richard P, Hainque B, Schwartz K. Familial hypertrophic 
cardiomyopathy: from mutations to functional defects. Circulation research. 
1998;83(6):580-93. 
39. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in 
hypertrophic cardiomyopathy. Lancet. 2000;355(9197):58-60. 
40. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, et al. 
Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of 
mutations, and implications for a molecular diagnosis strategy. Circulation. 
2003;107(17):2227-32. 
41. Marston S, Copeland O, Jacques A, Livesey K, Tsang V, McKenna WJ, et al. 
Evidence from human myectomy samples that MYBPC3 mutations cause 
hypertrophic cardiomyopathy through haploinsufficiency. Circulation research. 
2009;105(3):219-22. 
42. van Dijk SJ, Dooijes D, dos Remedios C, Michels M, Lamers JM, Winegrad S, 
et al. Cardiac myosin-binding protein C mutations and hypertrophic 
cardiomyopathy: haploinsufficiency, deranged phosphorylation, and 
cardiomyocyte dysfunction. Circulation. 2009;119(11):1473-83. 
43. Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile 
proteins that cause hypertrophic cardiomyopathy. Cardiovascular research. 
1999;44(1):20-36. 
44. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation 
identification to mechanistic paradigms. Cell. 2001;104(4):557-67. 
45. Kirschner SE, Becker E, Antognozzi M, Kubis HP, Francino A, Navarro-Lopez 
F, et al. Hypertrophic cardiomyopathy-related beta-myosin mutations cause 
highly variable calcium sensitivity with functional imbalances among individual 
muscle cells. American journal of physiology Heart and circulatory physiology. 
2005;288(3):H1242-51. 
46. Knollmann BC, Kirchhof P, Sirenko SG, Degen H, Greene AE, Schober T, et al. 
Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-
induced ventricular tachycardia and Ca2+-dependent action potential 
remodeling. Circulation research. 2003;92(4):428-36. 
 On the role of prelamin A in the heart  
 
 228 
47. Huke S, Knollmann BC. Increased myofilament Ca2+-sensitivity and 
arrhythmia susceptibility. Journal of molecular and cellular cardiology. 
2010;48(5):824-33. 
48. Bers DM, Guo T. Calcium signaling in cardiac ventricular myocytes. Annals of 
the New York Academy of Sciences. 2005;1047:86-98. 
49. Robinson P, Griffiths PJ, Watkins H, Redwood CS. Dilated and hypertrophic 
cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing 
effects on the calcium affinity of cardiac thin filaments. Circulation research. 
2007;101(12):1266-73. 
50. Kataoka A, Hemmer C, Chase PB. Computational simulation of hypertrophic 
cardiomyopathy mutations in troponin I: influence of increased myofilament 
calcium sensitivity on isometric force, ATPase and [Ca2+]i. Journal of 
biomechanics. 2007;40(9):2044-52. 
51. Smith GA, Dixon HB, Kirschenlohr HL, Grace AA, Metcalfe JC, Vandenberg 
JI. Ca2+ buffering in the heart: Ca2+ binding to and activation of cardiac 
myofibrils. The Biochemical journal. 2000;346 Pt 2:393-402. 
52. Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy:a 
paradigm for myocardial energy depletion. Trends in genetics : TIG. 
2003;19(5):263-8. 
53. Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, et al. 
Mutations in the gamma(2) subunit of AMP-activated protein kinase cause 
familial hypertrophic cardiomyopathy: evidence for the central role of energy 
compromise in disease pathogenesis. Human molecular genetics. 
2001;10(11):1215-20. 
54. Araújo-Vilar D, Lado-Abeal J, Palos-Paz F, Lattanzi G, Bandín Ma, Bellido D, 
et al. A novel phenotypic expression associated with a new mutation in LMNA 
gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis 
and hypertrophic cardiomyopathy. Clinical endocrinology. 2008;69:61-8. 
55. Hegele RA. Familial partial lipodystrophy: a monogenic form of the insulin 
resistance syndrome. Molecular genetics and metabolism. 2000;71(4):539-44. 
56. Hegele RA. Monogenic forms of insulin resistance: apertures that expose the 
common metabolic syndrome. Trends in endocrinology and metabolism: TEM. 
2003;14(8):371-7. 
57. Mercuri E, Brown SC, Nihoyannopoulos P, Poulton J, Kinali M, Richard P, et 
al. Extreme variability of skeletal and cardiac muscle involvement in patients 
with mutations in exon 11 of the lamin A/C gene. Muscle & nerve. 
2005;31(5):602-9. 
58. Sen-Chowdhry S, Morgan RD, Chambers JC, McKenna WJ. Arrhythmogenic 
cardiomyopathy: etiology, diagnosis, and treatment. Annual review of medicine. 
2010;61:233-53. 
59. Sen-Chowdhry S, McKenna WJ. The utility of magnetic resonance imaging in 
the evaluation of arrhythmogenic right ventricular cardiomyopathy. Current 
opinion in cardiology. 2008;23(1):38-45. 
60. McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, 
Fontaine G, et al. Diagnosis of arrhythmogenic right ventricular 
dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and 
Pericardial Disease of the European Society of Cardiology and of the Scientific 
 On the role of prelamin A in the heart  
 
 229 
Council on Cardiomyopathies of the International Society and Federation of 
Cardiology. British heart journal. 1994;71(3):215-8. 
61. Tabib A, Loire R, Chalabreysse L, Meyronnet D, Miras A, Malicier D, et al. 
Circumstances of death and gross and microscopic observations in a series of 
200 cases of sudden death associated with arrhythmogenic right ventricular 
cardiomyopathy and/or dysplasia. Circulation. 2003;108(24):3000-5. 
62. Kirchhof P, Fabritz L, Zwiener M, Witt H, Schafers M, Zellerhoff S, et al. Age- 
and training-dependent development of arrhythmogenic right ventricular 
cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation. 
2006;114(17):1799-806. 
63. Asimaki A, Syrris P, Wichter T, Matthias P, Saffitz JE, McKenna WJ. A novel 
dominant mutation in plakoglobin causes arrhythmogenic right ventricular 
cardiomyopathy. American journal of human genetics. 2007;81(5):964-73. 
64. Protonotarios N, Tsatsopoulou A. Naxos disease and Carvajal syndrome: 
cardiocutaneous disorders that highlight the pathogenesis and broaden the 
spectrum of arrhythmogenic right ventricular cardiomyopathy. Cardiovascular 
pathology : the official journal of the Society for Cardiovascular Pathology. 
2004;13(4):185-94. 
65. Sen-Chowdhry S, Syrris P, McKenna WJ. Genetics of right ventricular 
cardiomyopathy. Journal of cardiovascular electrophysiology. 2005;16(8):927-
35. 
66. Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the 
management of patients with arrhythmogenic right ventricular 
dysplasia/cardiomyopathy. Journal of the American College of Cardiology. 
2007;50(19):1813-21. 
67. Beffagna G, Occhi G, Nava A, Vitiello L, Ditadi A, Basso C, et al. Regulatory 
mutations in transforming growth factor-beta3 gene cause arrhythmogenic right 
ventricular cardiomyopathy type 1. Cardiovascular research. 2005;65(2):366-
73. 
68. Merner ND, Hodgkinson KA, Haywood AF, Connors S, French VM, 
Drenckhahn JD, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 
is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in 
the TMEM43 gene. American journal of human genetics. 2008;82(4):809-21. 
69. Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, 
Khoury DS, et al. Suppression of canonical Wnt/beta-catenin signaling by 
nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular 
cardiomyopathy. The Journal of clinical investigation. 2006;116(7):2012-21. 
70. MacRae CA, Birchmeier W, Thierfelder L. Arrhythmogenic right ventricular 
cardiomyopathy: moving toward mechanism. The Journal of clinical 
investigation. 2006;116(7):1825-8. 
71. Larsen MK, Nissen PH, Berge KE, Leren TP, Kristensen IB, Jensen HK, et al. 
Molecular autopsy in young sudden cardiac death victims with suspected 
cardiomyopathy. Forensic science international. 2012;219(1-3):33-8. 
72. Quarta G, Syrris P, Ashworth M, Jenkins S, Zuborne Alapi K, Morgan J, et al. 
Mutations in the Lamin A/C gene mimic arrhythmogenic right ventricular 
cardiomyopathy. European heart journal. 2011. 
 On the role of prelamin A in the heart  
 
 230 
73. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. 
Contemporary definitions and classification of the cardiomyopathies: an 
American Heart Association Scientific Statement from the Council on Clinical 
Cardiology, Heart Failure and Transplantation Committee; Quality of Care and 
Outcomes Research and Functional Genomics and Translational Biology 
Interdisciplinary Working Groups; and Council on Epidemiology and 
Prevention. Circulation. 2006;113(14):1807-16. 
74. Yajima T. Viral myocarditis: potential defense mechanisms within the 
cardiomyocyte against virus infection. Future microbiology. 2011;6(5):551-66. 
75. Yajima T, Knowlton KU. Viral myocarditis: from the perspective of the virus. 
Circulation. 2009;119(19):2615-24. 
76. Walker RK, Cousins VM, Umoh NA, Jeffress MA, Taghipour D, Al-Rubaiee 
M, et al. The good, the bad, and the ugly with alcohol use and abuse on the 
heart. Alcoholism, clinical and experimental research. 2013;37(8):1253-60. 
77. Raj S, Franco VI, Lipshultz SE. Anthracycline-induced cardiotoxicity: a review 
of pathophysiology, diagnosis, and treatment. Current treatment options in 
cardiovascular medicine. 2014;16(6):315. 
78. Yoshikawa T, Baba A, Nagatomo Y. Autoimmune mechanisms underlying 
dilated cardiomyopathy. Circulation journal : official journal of the Japanese 
Circulation Society. 2009;73(4):602-7. 
79. Mestroni L, Rocco C, Gregori D, Sinagra G, Di Lenarda A, Miocic S, et al. 
Familial dilated cardiomyopathy: evidence for genetic and phenotypic 
heterogeneity. Heart Muscle Disease Study Group. Journal of the American 
College of Cardiology. 1999;34(1):181-90. 
80. Vatta M, Mohapatra B, Jimenez S, Sanchez X, Faulkner G, Perles Z, et al. 
Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left 
ventricular non-compaction. Journal of the American College of Cardiology. 
2003;42(11):2014-27. 
81. Tsubata S, Bowles KR, Vatta M, Zintz C, Titus J, Muhonen L, et al. Mutations 
in the human delta-sarcoglycan gene in familial and sporadic dilated 
cardiomyopathy. The Journal of clinical investigation. 2000;106(5):655-62. 
82. Franz WM, Cremer M, Herrmann R, Grunig E, Fogel W, Scheffold T, et al. X-
linked dilated cardiomyopathy. Novel mutation of the dystrophin gene. Annals 
of the New York Academy of Sciences. 1995;752:470-91. 
83. Taylor MR, Slavov D, Ku L, Di Lenarda A, Sinagra G, Carniel E, et al. 
Prevalence of desmin mutations in dilated cardiomyopathy. Circulation. 
2007;115(10):1244-51. 
84. Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, et 
al. A mutation in the human phospholamban gene, deleting arginine 14, results 
in lethal, hereditary cardiomyopathy. Proceedings of the National Academy of 
Sciences of the United States of America. 2006;103(5):1388-93. 
85. Cowan J, Li D, Gonzalez-Quintana J, Morales A, Hershberger RE. 
Morphological Analysis of 13 LMNA Variants Identified in a Cohort of 324 
Unrelated Patients With Idiopathic or Familial Dilated Cardiomyopathy. Circ 
Cardiovasc Genet.3:6-14. 
86. Hayflick L. The Limited in Vitro Lifetime of Human Diploid Cell Strains. 
Experimental cell research. 1965;37:614-36. 
 On the role of prelamin A in the heart  
 
 231 
87. Siddiqi S, Sussman MA. Cardiac Hegemony of Senescence. Current 
translational geriatrics and experimental gerontology reports. 2013;2(4). 
88. Williams GM, Jeffrey aM. Oxidative DNA damage: endogenous and chemically 
induced. Regul Toxicol Pharmacol. 2000;32:283-92. 
89. Mahmoudi M, Mercer J, Bennett M. DNA damage and repair in atherosclerosis. 
Cardiovascular research. 2006;71:259-68. 
90. Mirzoeva OK, Petrini JH. DNA replication-dependent nuclear dynamics of the 
Mre11 complex. Mol Cancer Res. 2003;1:207-18. 
91. Bermudez VP, Lindsey-Boltz LA, Cesare AJ, Maniwa Y, Griffith JD, Hurwitz J, 
et al. Loading of the human 9-1-1 checkpoint complex onto DNA by the 
checkpoint clamp loader hRad17-replication factor C complex in vitro. 
Proceedings of the National Academy of Sciences of the United States of 
America. 2003;100:1633-8. 
92. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA. Toward maintaining the 
genome: DNA damage and replication checkpoints. Annu Rev Genet. 
2002;36:617-56. 
93. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR 
kinases. Genes & development. 2001;15:2177-96. 
94. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, et al. Enhanced 
phosphorylation of p53 by ATM in response to DNA damage. Science. 
1998;281:1674-7. 
95. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat 
Rev Cancer. 2003;3:155-68. 
96. Lou Z, Chen J. Cellular senescence and DNA repair. Experimental cell research. 
2006;312:2641-6. 
97. Andreassi MG. DNA damage, vascular senescence and atherosclerosis. J Mol 
Med. 2008;86:1033-43. 
98. Barouch LA, Gao D, Chen L, Miller KL, Xu W, Phan AC, et al. Cardiac 
myocyte apoptosis is associated with increased DNA damage and decreased 
survival in murine models of obesity. Circulation research. 2006;98:119-24. 
99. Chan KK, Zhang QM, Dianov GL. Base excision repair fidelity in normal and 
cancer cells. Mutagenesis. 2006;21:173-8. 
100. Vogel H, Lim DS, Karsenty G, Finegold M, Hasty P. Deletion of Ku86 causes 
early onset of senescence in mice. Proceedings of the National Academy of 
Sciences of the United States of America. 1999;96:10770-5. 
101. Weeda G, Donker I, de Wit J, Morreau H, Janssens R, Vissers CJ, et al. 
Disruption of mouse ERCC1 results in a novel repair syndrome with growth 
failure, nuclear abnormalities and senescence. Current biology : CB. 
1997;7:427-39. 
102. Yndestad A, Neurauter CG, Oie E, Forstrom RJ, Vinge LE, Eide L, et al. Up-
regulation of myocardial DNA base excision repair activities in experimental 
heart failure. Mutation research. 2009;666:32-8. 
103. Puente BN, Kimura W, Muralidhar SA, Moon J, Amatruda JF, Phelps KL, et al. 
The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest 
through DNA damage response. Cell. 2014;157(3):565-79. 
104. Finkel T, Holbrook NJ. biology of ageing. Nature. 2000;408:239-47. 
 On the role of prelamin A in the heart  
 
 232 
105. Bedard K, Krause K-hH. The NOX family of ROS-generating NADPH 
oxidases: physiology and pathophysiology. Physiological reviews. 2007;87:245-
313. 
106. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a 
gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac 
hypertrophy in mice. Circulation. 2002;105:293-6. 
107. Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, et al. 
Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after 
myocardial infarction. Hypertension. 2008;51:319-25. 
108. Zhang M, Brewer AC, Schröder K, Santos CXC, Grieve DJ, Wang M, et al. 
NADPH oxidase-4 mediates protection against chronic load-induced stress in 
mouse hearts by enhancing angiogenesis. Proceedings of the National Academy 
of Sciences of the United States of America. 2010;107:18121-6. 
109. Beckman KB, Ames BN. The free radical theory of aging matures. 
Physiological reviews. 1998;78:547-81. 
110. Fenton HJH. LXXIII.-Oxidation of tartaric acid in presence of iron. Journal of 
the Chemical Society, Transactions. 1894;65:899-910. 
111. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the 
degenerative diseases of aging. Proceedings of the National Academy of 
Sciences of the United States of America. 1993;90:7915-22. 
112. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis. 2000;21:361-70. 
113. Allen A. The cardiotoxicity of chemotherapeutic drugs. Seminars in oncology. 
1992;19(5):529-42. 
114. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. The New 
England journal of medicine. 1998;339(13):900-5. 
115. Yoshida M, Shiojima I, Ikeda H, Komuro I. Chronic doxorubicin cardiotoxicity 
is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and 
attenuated by pitavastatin through the inhibition of Rac1 activity. Journal of 
molecular and cellular cardiology. 2009;47:698-705. 
116. Coppé J-P, Desprez P-Y, Krtolica A, Campisi J. The senescence-associated 
secretory phenotype: the dark side of tumor suppression. Annual review of 
pathology. 2010;5:99-118. 
117. Parrinello S, Coppe JP, Krtolica A, Campisi J. Stromal-epithelial interactions in 
aging and cancer: senescent fibroblasts alter epithelial cell differentiation. 
Journal of cell science. 2005;118(Pt 3):485-96. 
118. Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of 
xenograft tumors via matrix metalloproteinase secretion. Cancer research. 
2007;67(7):3117-26. 
119. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, et al. 
Persistent DNA damage signalling triggers senescence-associated inflammatory 
cytokine secretion. Nature cell biology. 2009;11:973-9. 
120. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, et al. 
Reversal of human cellular senescence: roles of the p53 and p16 pathways. The 
EMBO journal. 2003;22(16):4212-22. 
121. Shelton DN, Chang E, Whittier PS, Choi D, Funk WD. Microarray analysis of 
replicative senescence. Current biology : CB. 1999;9(17):939-45. 
 On the role of prelamin A in the heart  
 
 233 
122. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen 
to good cells. Nature reviews Molecular cell biology. 2007;8(9):729-40. 
123. Ghigo A, Franco I, Morello F, Hirsch E. Myocyte signalling in leucocyte 
recruitment to the heart. Cardiovascular research. 2014. 
124. Liu Y, Drozdov I, Shroff R, Beltran LE, Shanahan CM. Prelamin A accelerates 
vascular calcification via activation of the DNA damage response and 
senescence-associated secretory phenotype in vascular smooth muscle cells. 
Circulation research. 2013;112(10):e99-109. 
125. Osorio FG, Bárcena C, Soria-Valles C, Ramsay AJ, de Carlos F, Cobo J, et al. 
Nuclear lamina defects cause ATM-dependent NF-κB activation and link 
accelerated aging to a systemic inflammatory response. Genes & development. 
2012. 
126. Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, Kamm RD, et 
al. Lamin A/C deficiency causes defective nuclear mechanics and 
mechanotransduction. The Journal of clinical investigation. 2004;113:370-8. 
127. Lin J, Epel E, Blackburn E. Telomeres and lifestyle factors: roles in cellular 
aging. Mutation research. 2012;730(1-2):85-9. 
128. Leri A, Malhotra A, Liew CC, Kajstura J, Anversa P. Telomerase activity in rat 
cardiac myocytes is age and gender dependent. Journal of molecular and 
cellular cardiology. 2000;32(3):385-90. 
129. Epel ES, Lin J, Wilhelm FH, Wolkowitz OM, Cawthon R, Adler NE, et al. Cell 
aging in relation to stress arousal and cardiovascular disease risk factors. 
Psychoneuroendocrinology. 2006;31(3):277-87. 
130. Epel ES, Merkin SS, Cawthon R, Blackburn EH, Adler NE, Pletcher MJ, et al. 
The rate of leukocyte telomere shortening predicts mortality from cardiovascular 
disease in elderly men. Aging. 2009;1(1):81-8. 
131. Anversa P, Kajstura J, Leri A, Bolli R. Life and death of cardiac stem cells: a 
paradigm shift in cardiac biology. Circulation. 2006;113(11):1451-63. 
132. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, 
et al. Evidence for cardiomyocyte renewal in humans. Science. 
2009;324(5923):98-102. 
133. Chimenti C, Kajstura J, Torella D, Urbanek K, Heleniak H, Colussi C, et al. 
Senescence and death of primitive cells and myocytes lead to premature cardiac 
aging and heart failure. Circulation research. 2003;93(7):604-13. 
134. Leri A, Franco S, Zacheo A, Barlucchi L, Chimenti S, Limana F, et al. Ablation 
of telomerase and telomere loss leads to cardiac dilatation and heart failure 
associated with p53 upregulation. The EMBO journal. 2003;22(1):131-9. 
135. De Vos WH, Houben F, Hoebe RA, Hennekam R, van Engelen B, Manders EM, 
et al. Increased plasticity of the nuclear envelope and hypermobility of telomeres 
due to the loss of A-type lamins. Biochimica et biophysica acta. 
2010;1800(4):448-58. 
136. Uhlirova R, Horakova AH, Galiova G, Legartova S, Matula P, Fojtova M, et al. 
SUV39h- and A-type lamin-dependent telomere nuclear rearrangement. Journal 
of cellular biochemistry. 2010;109(5):915-26. 
137. Benson EK, Lee SW, Aaronson SA. Role of progerin-induced telomere 
dysfunction in HGPS premature cellular senescence. Journal of cell science. 
2010;123(Pt 15):2605-12. 
 On the role of prelamin A in the heart  
 
 234 
138. North BJ, Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. 
Genome biology. 2004;5(5):224. 
139. Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP. SIRT3 is a 
stress-responsive deacetylase in cardiomyocytes that protects cells from stress-
mediated cell death by deacetylation of Ku70. Molecular and cellular biology. 
2008;28(20):6384-401. 
140. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 
blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent 
antioxidant defense mechanisms in mice. The Journal of clinical investigation. 
2009;119(9):2758-71. 
141. Pillai VB, Sundaresan NR, Kim G, Gupta M, Rajamohan SB, Pillai JB, et al. 
Exogenous NAD blocks cardiac hypertrophic response via activation of the 
SIRT3-LKB1-AMP-activated kinase pathway. The Journal of biological 
chemistry. 2010;285(5):3133-44. 
142. Chen CJ, Fu YC, Yu W, Wang W. SIRT3 protects cardiomyocytes from 
oxidative stress-mediated cell death by activating NF-kappaB. Biochemical and 
biophysical research communications. 2013;430(2):798-803. 
143. McBurney MW, Yang X, Jardine K, Hixon M, Boekelheide K, Webb JR, et al. 
The mammalian SIR2alpha protein has a role in embryogenesis and 
gametogenesis. Molecular and cellular biology. 2003;23(1):38-54. 
144. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, et al. Sirt1 regulates 
aging and resistance to oxidative stress in the heart. Circulation research. 
2007;100(10):1512-21. 
145. Tong C, Morrison A, Mattison S, Qian S, Bryniarski M, Rankin B, et al. 
Impaired SIRT1 nucleocytoplasmic shuttling in the senescent heart during 
ischemic stress. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology. 2013;27(11):4332-42. 
146. Anderson RM, Shanmuganayagam D, Weindruch R. Caloric restriction and 
aging: studies in mice and monkeys. Toxicologic pathology. 2009;37(1):47-51. 
147. Nair S, Ren J. Autophagy and cardiovascular aging: lesson learned from 
rapamycin. Cell cycle. 2012;11(11):2092-9. 
148. Burtner CR, Kennedy BK. Progeria syndromes and ageing: what is the 
connection? Nature reviews Molecular cell biology.11:567-78. 
149. Mariño G, Ugalde AP, Fernández AF, Osorio FG, Fueyo A, Freije JMP, et al. 
Insulin-like growth factor 1 treatment extends longevity in a mouse model of 
human premature aging by restoring somatotroph axis function. Proceedings of 
the National Academy of Sciences of the United States of America. 
2010;107:16268-73. 
150. Mariño G, Ugalde AP, Salvador-Montoliu N, Varela I, Quirós PM, Cadiñanos J, 
et al. Premature aging in mice activates a systemic metabolic response involving 
autophagy induction. Human molecular genetics. 2008;17:2196-211. 
151. Agarwal aK. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral 
dysplasia. Human molecular genetics. 2003;12:1995-2001. 
152. Bonne G, Di Barletta MR, Varnous S, Bécane HM, Hammouda EH, Merlini L, 
et al. Mutations in the gene encoding lamin A/C cause autosomal dominant 
Emery-Dreifuss muscular dystrophy. Nature genetics. 1999;21:285-8. 
 On the role of prelamin A in the heart  
 
 235 
153. Cao H, Hegele Ra. Nuclear lamin A/C R482Q mutation in canadian kindreds 
with Dunnigan-type familial partial lipodystrophy. Human molecular genetics. 
2000;9:109-12. 
154. Chen L, Lee L, Kudlow BA, Santos HGD, Sletvold O, Shafeghati Y, et al. 
Mechanisms of disease LMNA mutations in atypical Werner ’ s syndrome 
GLOSSARY. The Lancet. 1959. 
155. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, et al. 
Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford 
progeria syndrome. Nature. 2003;423:293-8. 
156. Warren DT, Zhang Q, Weissberg PL, Shanahan CM. Nesprins: intracellular 
scaffolds that maintain cell architecture and coordinate cell function? Expert 
reviews in molecular medicine. 2005;7:1-15. 
157. Zhang Q, Ragnauth C, Greener MJ, Shanahan CM, Roberts RG. The nesprins 
are giant actin-binding proteins, orthologous to Drosophila melanogaster muscle 
protein MSP-300. Genomics. 2002;80(5):473-81. 
158. Zhang Q, Ragnauth CD, Skepper JN, Worth NF, Warren DT, Roberts RG, et al. 
Nesprin-2 is a multi-isomeric protein that binds lamin and emerin at the nuclear 
envelope and forms a subcellular network in skeletal muscle. Journal of cell 
science. 2005;118:673-87. 
159. Zhang Q, Skepper JN, Yang F, Davies JD, Hegyi L, Roberts RG, et al. Nesprins: 
a novel family of spectrin-repeat-containing proteins that localize to the nuclear 
membrane in multiple tissues. Journal of cell science. 2001;114(Pt 24):4485-98. 
160. Lin F, Blake DL, Callebaut I, Skerjanc IS, Holmer L, McBurney MW, et al. 
MAN1, an inner nuclear membrane protein that shares the LEM domain with 
lamina-associated polypeptide 2 and emerin. The Journal of biological 
chemistry. 2000;275:4840-7. 
161. Haque F, Lloyd DJ, Smallwood DT, Dent CL, Shanahan CM, Fry AM, et al. 
SUN1 interacts with nuclear lamin A and cytoplasmic nesprins to provide a 
physical connection between the nuclear lamina and the cytoskeleton. Molecular 
and cellular biology. 2006;26(10):3738-51. 
162. Ben-Harush K, Wiesel N, Frenkiel-Krispin D, Moeller D, Soreq E, Aebi U, et al. 
The supramolecular organization of the C. elegans nuclear lamin filament. 
Journal of molecular biology. 2009;386:1392-402. 
163. Lin F, Worman HJ. Structural organization of the human gene encoding nuclear 
lamin A and nuclear lamin C. The Journal of biological chemistry. 
1993;268:16321-6. 
164. Davies BS, Fong LG, Yang SH, Coffinier C, Young SG. The posttranslational 
processing of prelamin A and disease. Annu Rev Genomics Hum Genet. 
2009;10:153-74. 
165. Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of 
essential genes in cultured mammalian cells using small interfering RNAs. 
Journal of cell science. 2001;114:4557-65. 
166. Broers JL, Machiels BM, Kuijpers HJ, Smedts F, van den Kieboom R, Raymond 
Y, et al. A- and B-type lamins are differentially expressed in normal human 
tissues. Histochemistry and cell biology. 1997;107:505-17. 
167. Zwerger M, Jaalouk DE, Lombardi ML, Isermann P, Mauermann M, Dialynas 
G, et al. Myopathic lamin mutations impair nuclear stability in cells and tissue 
 On the role of prelamin A in the heart  
 
 236 
and disrupt nucleo-cytoskeletal coupling. Human molecular genetics. 
2013;22(12):2335-49. 
168. Lammerding J, Fong LG, Ji JY, Reue K, Stewart CL, Young SG, et al. Lamins 
A and C but not lamin B1 regulate nuclear mechanics. The Journal of biological 
chemistry. 2006;281:25768-80. 
169. Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, Kamm RD, et 
al. Lamin A / C deficiency causes defective nuclear mechanics and 
mechanotransduction. 2004;113. 
170. Lammerding J, Hsiao J, Schulze PC, Kozlov S, Stewart CL, Lee RT. Abnormal 
nuclear shape and impaired mechanotransduction in emerin-deficient cells. The 
Journal of cell biology. 2005;170:781-91. 
171. Lammerding J, Lee RT. The nuclear membrane and mechanotransduction: 
impaired nuclear mechanics and mechanotransduction in lamin A/C deficient 
cells. Novartis Foundation symposium. 2005;264:264-73; discussion 73-8. 
172. Liu Y, Rusinol A, Sinensky M, Wang Y, Zou Y. DNA damage responses in 
progeroid syndromes arise from defective maturation of prelamin A. Journal of 
cell science. 2006;119:4644-9. 
173. Liu Y, Wang Y, Rusinol AE, Sinensky MS, Liu J, Shell SM, et al. Involvement 
of xeroderma pigmentosum group A (XPA) in progeria arising from defective 
maturation of prelamin A. FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology. 2008;22:603-11. 
174. Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon 
LB, et al. Accumulation of mutant lamin A causes progressive changes in 
nuclear architecture in Hutchinson-Gilford progeria syndrome. Proceedings of 
the National Academy of Sciences of the United States of America. 
2004;101:8963-8. 
175. Boyd MW, Grant AP. Werner's syndrome (progeria of the adult); further 
pathological and biochemical observations. Br Med J. 1959;2:920-5. 
176. Emery AE. Emery-Dreifuss syndrome. J Med Genet. 1989;26:637-41. 
177. Gilford H. Ateleiosis and progeria. British Medical Journal. 1904;1904:914-8. 
178. Chen L, Lee L, Kudlow BA, Dos Santos HG, Sletvold O, Shafeghati Y, et al. 
LMNA mutations in atypical Werner's syndrome. Lancet. 2003;362(9382):440-
5. 
179. De Sandre-Giovannoli A, Chaouch M, Kozlov S, Vallat JM, Tazir M, Kassouri 
N, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope 
proteins, cause autosomal recessive axonal neuropathy in human (Charcot-
Marie-Tooth disorder type 2) and mouse. American journal of human genetics. 
2002;70(3):726-36. 
180. Charniot JC, Pascal C, Bouchier C, Sebillon P, Salama J, Duboscq-Bidot L, et 
al. Functional consequences of an LMNA mutation associated with a new 
cardiac and non-cardiac phenotype. Human mutation. 2003;21(5):473-81. 
181. Muchir A, Bonne G, van der Kooi AJ, van Meegen M, Baas F, Bolhuis PA, et 
al. Identification of mutations in the gene encoding lamins A/C in autosomal 
dominant limb girdle muscular dystrophy with atrioventricular conduction 
disturbances (LGMD1B). Human molecular genetics. 2000;9(9):1453-9. 
182. Caux F, Dubosclard E, Lascols O, Buendia B, Chazouilleres O, Cohen A, et al. 
A new clinical condition linked to a novel mutation in lamins A and C with 
 On the role of prelamin A in the heart  
 
 237 
generalized lipoatrophy, insulin-resistant diabetes, disseminated 
leukomelanodermic papules, liver steatosis, and cardiomyopathy. The Journal of 
clinical endocrinology and metabolism. 2003;88(3):1006-13. 
183. Novelli G, Muchir A, Sangiuolo F, Helbling-Leclerc A, D'Apice MR, Massart 
C, et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding 
lamin A/C. American journal of human genetics. 2002;71(2):426-31. 
184. Navarro CL, De Sandre-Giovannoli A, Bernard R, Boccaccio I, Boyer A, 
Genevieve D, et al. Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear 
disorganization and identify restrictive dermopathy as a lethal neonatal 
laminopathy. Human molecular genetics. 2004;13(20):2493-503. 
185. Barrowman J, Wiley Pa, Hudon-Miller SE, Hrycyna Ca, Michaelis S. Human 
ZMPSTE24 disease mutations: residual proteolytic activity correlates with 
disease severity. Human molecular genetics. 2012:1-10. 
186. Scharner J, Gnocchi VF, Ellis Ja, Zammit PS. Genotype-phenotype correlations 
in laminopathies: how does fate translate? Biochemical Society transactions. 
2010;38:257-62. 
187. Rankin J, Auer-Grumbach M, Bagg W, Colclough K, Nguyen TD, Fenton-May 
J, et al. Extreme phenotypic diversity and nonpenetrance in families with the 
LMNA gene mutation R644C. American journal of medical genetics Part A. 
2008;146A(12):1530-42. 
188. DeBusk FL. The Hutchinson-Gilford progeria syndrome. Report of 4 cases and 
review of the literature. The Journal of pediatrics. 1972;80(4):697-724. 
189. Gordon CM, Gordon LB, Snyder BD, Nazarian A, Quinn N, Huh S, et al. 
Hutchinson-Gilford progeria is a skeletal dysplasia. Journal of bone and mineral 
research : the official journal of the American Society for Bone and Mineral 
Research. 2011;26(7):1670-9. 
190. Gordon LB, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, 
Berns SD, et al. Disease progression in Hutchinson-Gilford progeria syndrome: 
impact on growth and development. Pediatrics. 2007;120(4):824-33. 
191. Hennekam RC. Hutchinson-Gilford progeria syndrome: review of the 
phenotype. American journal of medical genetics Part A. 2006;140(23):2603-
24. 
192. Kieran MW, Gordon L, Kleinman M. New approaches to progeria. Pediatrics. 
2007;120(4):834-41. 
193. Hutchinson J. Congenital Absence of Hair and Mammary Glands with Atrophic 
Condition of the Skin and its Appendages, in a Boy whose Mother had been 
almost wholly Bald from Alopecia Areata from the age of Six. Medico-
chirurgical transactions. 1886;69:473-7. 
194. Gruenbaum Y, Margalit A, Goldman RD, Shumaker DK, Wilson KL. The 
nuclear lamina comes of age. Nature reviews Molecular cell biology. 2005;6:21-
31. 
195. Beck LA, Hosick TJ, Sinensky M. Isoprenylation is required for the processing 
of the lamin A precursor. The Journal of cell biology. 1990;110(5):1489-99. 
196. Sinensky M. Recent advances in the study of prenylated proteins. Biochimica et 
biophysica acta. 2000;1484(2-3):93-106. 
197. Sinensky M, Fantle K, Trujillo M, McLain T, Kupfer A, Dalton M. The 
processing pathway of prelamin A. Journal of cell science. 1994;107 ( Pt 1:61-7. 
 On the role of prelamin A in the heart  
 
 238 
198. Weber K, Plessmann U, Traub P. Maturation of nuclear lamin A involves a 
specific carboxy-terminal trimming, which removes the polyisoprenylation site 
from the precursor; implications for the structure of the nuclear lamina. FEBS 
letters. 1989;257(2):411-4. 
199. Lutz RJ, Trujillo MA, Denham KS, Wenger L, Sinensky M. Nucleoplasmic 
localization of prelamin A: implications for prenylation-dependent lamin A 
assembly into the nuclear lamina. Proceedings of the National Academy of 
Sciences of the United States of America. 1992;89:3000-4. 
200. Sinensky M, Fantle K, Dalton M. An antibody which specifically recognizes 
prelamin A but not mature lamin A: application to detection of blocks in 
farnesylation-dependent protein processing. Cancer research. 1994;54:3229-32. 
201. Corrigan DP, Kuszczak D, Rusinol AE, Thewke DP, Hrycyna Ca, Michaelis S, 
et al. Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24. 
The Biochemical journal. 2005;387:129-38. 
202. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, et 
al. Lamin a truncation in Hutchinson-Gilford progeria. Science. 2003;300:2055. 
203. De Sandre-Giovannoli A, Levy N. Altered splicing in prelamin A-associated 
premature aging phenotypes. Prog Mol Subcell Biol. 2006;44:199-232. 
204. De Sandre-giovannoli AD, Cau P, Navarro C, Amiel J, Lyonnet S, Stewart CL, 
et al. Lamin A Truncation in Hutichnson-Gilford Progeria. Science. 
2003;300:21702. 
205. Shackleton S, Smallwood DT, Clayton P, Wilson LC, Agarwal aK, Garg a, et al. 
Compound heterozygous ZMPSTE24 mutations reduce prelamin A processing 
and result in a severe progeroid phenotype. Journal of medical genetics. 
2005;42:e36. 
206. Liu B, Wang J, Chan KM, Tjia WM, Deng W, Guan X, et al. Genomic 
instability in laminopathy-based premature aging. Nature medicine. 
2005;11:780-5. 
207. Misteli T, Scaffidi P. Genome instability in progeria: when repair gets old. Nat 
Med. 2005;11:718-9. 
208. Verstraeten VL, Ji JY, Cummings KS, Lee RT, Lammerding J. Increased 
mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: 
effects of farnesyltransferase inhibitors. Aging cell. 2008;7(3):383-93. 
209. Glynn MW, Glover TW. Incomplete processing of mutant lamin A in 
Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed 
by farnesyltransferase inhibition. Human molecular genetics. 2005;14:2959-69. 
210. Toth JI, Yang SH, Qiao X, Beigneux AP, Gelb MH, Moulson CL, et al. 
Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from 
humans with progeroid syndromes. Proceedings of the National Academy of 
Sciences of the United States of America. 2005;102:12873-8. 
211. Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, 
Gerhard-Herman M, et al. Clinical trial of a farnesyltransferase inhibitor in 
children with Hutchinson-Gilford progeria syndrome. Proceedings of the 
National Academy of Sciences of the United States of America. 
2012;109(41):16666-71. 
 On the role of prelamin A in the heart  
 
 239 
212. Varela I, Pereira S, Ugalde AP, Navarro CL, Suárez MF, Cau P, et al. Combined 
treatment with statins and aminobisphosphonates extends longevity in a mouse 
model of human premature aging. Nature medicine. 2008;14:767-72. 
213. Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, Kendall LV, et al. 
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle 
weakness, and a prelamin A processing defect. Proceedings of the National 
Academy of Sciences of the United States of America. 2002;99:13049-54. 
214. Pendás AM, Zhou Z, Cadiñanos J, Freije JMP, Wang J, Hultenby K, et al. 
Defective prelamin A processing and muscular and adipocyte alterations in 
Zmpste24 metalloproteinase-deficient mice. Nature genetics. 2002;31:94-9. 
215. Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C, et al. A protein 
farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. 
Science (New York, NY). 2006;311:1621-3. 
216. Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, Sandoval S, et al. Blocking 
protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with 
a targeted Hutchinson-Gilford progeria syndrome mutation. Proceedings of the 
National Academy of Sciences of the United States of America. 2005;102:10291-
6. 
217. Yang SH, Meta M, Qiao X, Frost D, Bauch J, Coffinier C, et al. A 
farnesyltransferase inhibitor improves disease phenotypes in mice with a 
Hutchinson-Gilford progeria syndrome mutation. 2006;116:2115-21. 
218. Yang SH, Andres DA, Spielmann HP, Young SG, Fong LG. Progerin elicits 
disease phenotypes of progeria in mice whether or not it is farnesylated. The 
Journal of clinical investigation. 2008;118:3291-300. 
219. Davies BSJ, Barnes RH, Tu Y, Ren S, Andres DA, Spielmann HP, et al. An 
accumulation of non-farnesylated prelamin A causes cardiomyopathy but not 
progeria. Human molecular genetics. 2010;19:2682-94. 
220. Yang SH, Chang SY, Ren S, Wang Y, Andres DA, Spielmann HP, et al. 
Absence of progeria-like disease phenotypes in knock-in mice expressing a non-
farnesylated version of progerin. Human molecular genetics. 2010;20:ddq490-. 
221. Coffinier C, Jung H-J, Li Z, Nobumori C, Yun UJ, Farber Ea, et al. Direct 
synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei 
in fibroblasts but no detectable pathology in mice. The Journal of biological 
chemistry. 2010;285:20818-26. 
222. Fong LG, Ng JK, Lammerding J, Vickers TA, Meta M, Cote N, et al. Prelamin 
A and lamin A appear to be dispensable in the nuclear lamina. The Journal of 
clinical investigation. 2006;116:743-52. 
223. Davies BS, Coffinier C, Yang SH, Barnes RH, Jung H-J, Young SG, et al. 
Investigating the purpose of prelamin A processing. Nucleus (Austin, Tex). 
2011;2:4-9. 
224. Fong LG, Ng JK, Meta M, Coté N, Yang SH, Stewart CL, et al. Heterozygosity 
for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-
deficient mice. Proceedings of the National Academy of Sciences of the United 
States of America. 2004;101:18111-6. 
225. Nikolova V, Leimena C, McMahon AC, Tan JC, Chandar S, Jogia D, et al. 
Defects in nuclear structure and function promote dilated cardiomyopathy in 
 On the role of prelamin A in the heart  
 
 240 
lamin A/C-deficient mice. The Journal of clinical investigation. 
2004;113(3):357-69. 
226. Sullivan T, Escalante-Alcalde D, Bhatt H, Anver M, Bhat N, Nagashima K, et 
al. Loss of A-type lamin expression compromises nuclear envelope integrity 
leading to muscular dystrophy. The Journal of cell biology. 1999;147:913-20. 
227. Wolf CM, Wang L, Alcalai R, Pizard A, Burgon PG, Ahmad F, et al. Lamin 
A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered 
cardiac conduction system disease. Journal of molecular and cellular 
cardiology. 2008;44:293-303. 
228. Olive M, Harten I, Mitchell R, Beers JK, Djabali K, Cao K, et al. Cardiovascular 
Pathology in Hutchinson-Gilford Progeria: Correlation With the Vascular 
Pathology of Aging. Arterioscler Thromb Vasc Biol. 2010;30:2301-9. 
229. Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, Miller 
DT, et al. Mechanisms of premature vascular aging in children with Hutchinson-
Gilford progeria syndrome. Hypertension. 2012;59:92-7. 
230. Chang S-H, Tsai C-T, Lai L-P, Lei M-H. Identification of a lamin A/C gene 
mutation in a Taiwanese family with limb girdle muscular dystrophy and 
cardiomyopathy. International journal of cardiology. 2010;145:598-9. 
231. van Berlo JH, de Voogt WG, van der Kooi AJ, van Tintelen JP, Bonne G, Yaou 
RB, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene 
mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol 
Med. 2005;83:79-83. 
232. Arimura T, Helbling-Leclerc A, Massart C, Varnous S, Niel F, Lacene E, et al. 
Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and 
dilated cardiomyopathy similar to human striated muscle laminopathies. Human 
molecular genetics. 2005;14(1):155-69. 
233. Muchir A, Pavlidis P, Decostre V, Herron AJ, Arimura T, Bonne G, et al. 
Activation of MAPK pathways links LMNA mutations to cardiomyopathy in 
Emery-Dreifuss muscular dystrophy. The Journal of clinical investigation. 
2007;117(5):1282-93. 
234. Muchir A, Shan J, Bonne G, Lehnart SE, Worman HJ. Inhibition of extracellular 
signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation 
in the gene encoding A-type lamins. Human molecular genetics. 
2009;18(2):241-7. 
235. Wu W, Shan J, Bonne G, Worman HJ, Muchir A. Pharmacological inhibition of 
c-Jun N-terminal kinase signaling prevents cardiomyopathy caused by mutation 
in LMNA gene. Biochimica et biophysica acta. 2010;1802(7-8):632-8. 
236. Wu W, Muchir A, Shan J, Bonne G, Worman HJ. Mitogen-Activated Protein 
Kinase Inhibitors Improve Heart Function and Prevent Fibrosis in 
Cardiomyopathy Caused by Mutation in Lamin A/C Gene. Circulation. 
2010;123:53-61. 
237. Muchir A, Reilly Sa, Wu W, Iwata S, Homma S, Bonne G, et al. Treatment with 
selumetinib preserves cardiac function and improves survival in cardiomyopathy 
caused by mutation in the lamin A/C gene. Cardiovascular research. 
2012;93:311-9. 
238. Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. 
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung 
 On the role of prelamin A in the heart  
 
 241 
cancer: a randomised, multicentre, placebo-controlled, phase 2 study. The lancet 
oncology. 2013;14(1):38-47. 
239. Choi JC, Wu W, Muchir A, Iwata S, Homma S, Worman HJ. Dual specificity 
phosphatase 4 mediates cardiomyopathy caused by lamin A/C (LMNA) gene 
mutation. The Journal of biological chemistry. 2012:1-24. 
240. Choi JC, Muchir A, Wu W, Iwata S, Homma S, Morrow JP, et al. Temsirolimus 
activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene 
mutation. Science translational medicine. 2012;4(144):144ra02. 
241. Ramos FJ, Chen SC, Garelick MG, Dai DF, Liao CY, Schreiber KH, et al. 
Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, 
rescues cardiac and skeletal muscle function, and extends survival. Science 
translational medicine. 2012;4(144):144ra03. 
242. Cattin ME, Muchir A, Bonne G. 'State-of-the-heart' of cardiac laminopathies. 
Current opinion in cardiology. 2013;28(3):297-304. 
243. Lu JT, Muchir A, Nagy PL, Worman HJ. LMNA cardiomyopathy: cell biology 
and genetics meet clinical medicine. Disease models & mechanisms. 
2011;4(5):562-8. 
244. Nikolova-Krstevski V, Leimena C, Xiao X-H, Kesteven S, Tan JC, Yeo LS, et 
al. Nesprin-1 and actin contribute to nuclear and cytoskeletal defects in lamin 
A/C-deficient cardiomyopathy. Journal of molecular and cellular cardiology. 
2011;50:479-86. 
245. Chen SC, Kennedy BK, Lampe PD. Phosphorylation of connexin43 on 
S279/282 may contribute to laminopathy-associated conduction defects. 
Experimental cell research. 2013;319:888-96. 
246. Frock RL, Chen SC, Da D-F, Frett E, Lau C, Brown C, et al. Cardiomyocyte-
specific expression of lamin a improves cardiac function in lmna(-/-) mice. PloS 
one. 2012;7:e42918. 
247. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, et al. 
Missense mutations in the rod domain of the lamin A/C gene as causes of dilated 
cardiomyopathy and conduction-system disease. The New England journal of 
medicine. 1999;341(23):1715-24. 
248. Mounkes LC, Kozlov SV, Rottman JN, Stewart CL. Expression of an LMNA-
N195K variant of A-type lamins results in cardiac conduction defects and death 
in mice. Human molecular genetics. 2005;14(15):2167-80. 
249. Nguyen-Tran VT, Kubalak SW, Minamisawa S, Fiset C, Wollert KC, Brown 
AB, et al. A novel genetic pathway for sudden cardiac death via defects in the 
transition between ventricular and conduction system cell lineages. Cell. 
2000;102(5):671-82. 
250. Cattin M-E, Bertrand AT, Schlossarek S, Le Bihan M-C, Skov Jensen S, Neuber 
C, et al. Heterozygous LmnadelK32 mice develop dilated cardiomyopathy 
through a combined pathomechanism of haploinsufficiency and peptide toxicity. 
Human molecular genetics. 2013:1-13. 
251. Quijano-Roy S, Mbieleu B, Bonnemann CG, Jeannet PY, Colomer J, Clarke NF, 
et al. De novo LMNA mutations cause a new form of congenital muscular 
dystrophy. Annals of neurology. 2008;64(2):177-86. 
252. Bonne G, Mercuri E, Muchir A, Urtizberea A, Becane HM, Recan D, et al. 
Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss 
 On the role of prelamin A in the heart  
 
 242 
muscular dystrophy due to mutations of the lamin A/C gene. Annals of 
neurology. 2000;48(2):170-80. 
253. Wang Y, Herron AJ, Worman HJ. Pathology and nuclear abnormalities in hearts 
of transgenic mice expressing M371K lamin A encoded by an LMNA mutation 
causing Emery-Dreifuss muscular dystrophy. Human molecular genetics. 
2006;15:2479-89. 
254. Chandar S, Yeo LS, Leimena C, Tan J-C, Xiao X-H, Nikolova-Krstevski V, et 
al. Effects of mechanical stress and carvedilol in lamin A/C-deficient dilated 
cardiomyopathy. Circulation research. 2010;106:573-82. 
255. Mounkes LC, Kozlov S, Hernandez L, Sullivan T, Stewart CL. A progeroid 
syndrome in mice is caused by defects in A-type lamins. Nature. 
2003;423(6937):298-301. 
256. Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, Figg N, et al. Prelamin A 
acts to accelerate smooth muscle cell senescence and is a novel biomarker of 
human vascular aging. Circulation. 2010;121:2200-10. 
257. Lattanzi G, Ortolani M, Columbaro M, Prencipe S, Mattioli E, Lanzarini C, et 
al. Lamins are rapamycin targets that impact human longevity: a study in 
centenarians. Journal of cell science. 2014;127(Pt 1):147-57. 
258. de la Rosa J, Freije JMP, Cabanillas R, Osorio FG, Fraga MF, Fernández-García 
MS, et al. Prelamin A causes progeria through cell-extrinsic mechanisms and 
prevents cancer invasion. Nature communications. 2013;4. 
259. Osorio FG, Navarro CL, Cadinanos J, Lopez-Mejia IC, Quiros PM, Bartoli C, et 
al. Splicing-Directed Therapy in a New Mouse Model of Human Accelerated 
Aging. Science translational medicine. 2011;3:106ra7-ra7. 
260. Brodsky GL, Bowersox JA, Fitzgerald-miller L, Miller LA, Maclean KN. The 
prelamin A pre-peptide induces cardiac and skeletal myoblast differentiation. 
Biochemical and biophysical research communications. 2007;356:872-9. 
261. Yaffe D, Saxel O. A myogenic cell line with altered serum requirements for 
differentiation. Differentiation; research in biological diversity. 1977;7(3):159-
66. 
262. Arimura T, Onoue K, Takahashi-Tanaka Y, Ishikawa T, Kuwahara M, Setou M, 
et al. Nuclear accumulation of androgen receptor in gender difference of dilated 
cardiomyopathy due to lamin A/C mutations. Cardiovascular research. 
2013;99(3):382-94. 
263. Moran CM, Thomson AJ, Rog-Zielinska E, Gray GA. High-resolution 
echocardiography in the assessment of cardiac physiology and disease in 
preclinical models. Experimental physiology. 2013;98(3):629-44. 
264. Miyata S, Minobe W, Bristow MR, Leinwand LA. Myosin heavy chain isoform 
expression in the failing and nonfailing human heart. Circulation research. 
2000;86(4):386-90. 
265. Natanzon A, Kronzon I. Pericardial and pleural effusions in congestive heart 
failure-anatomical, pathophysiologic, and clinical considerations. The American 
journal of the medical sciences. 2009;338(3):211-6. 
266. Holmström M, Kivistö S, Heliö T, Jurkko R, Kaartinen M, Antila M, et al. Late 
gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene 
mutation related dilated cardiomyopathy. Journal of cardiovascular magnetic 
 On the role of prelamin A in the heart  
 
 243 
resonance : official journal of the Society for Cardiovascular Magnetic 
Resonance. 2011;13:30. 
267. Mann DL. Inflammatory mediators and the failing heart: past, present, and the 
foreseeable future. Circulation research. 2002;91(11):988-98. 
268. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, et al. 
Mitochondrial DNA that escapes from autophagy causes inflammation and heart 
failure. Nature. 2012;485:251-5. 
269. Takemura G, Kanoh M, Minatoguchi S, Fujiwara H. Cardiomyocyte apoptosis 
in the failing heart--a critical review from definition and classification of cell 
death. International journal of cardiology. 2013;167(6):2373-86. 
270. Kanoh M, Takemura G, Misao J, Hayakawa Y, Aoyama T, Nishigaki K, et al. 
Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) 
in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. 
Circulation. 1999;99(21):2757-64. 
271. Krishnan V, Chow MZY, Wang Z, Zhang L, Liu B, Liu X, et al. Histone H4 
lysine 16 hypoacetylation is associated with defective DNA repair and 
premature senescence in Zmpste24-deficient mice. Proceedings of the National 
Academy of Sciences of the United States of America. 2011;108:12325-30. 
272. Varela I, Cadiñanos J, Pendás AM, Gutiérrez-Fernández A, Folgueras AR, 
Sánchez LM, et al. Accelerated ageing in mice deficient in Zmpste24 protease is 
linked to p53 signalling activation. Nature. 2005;437:564-8. 
273. Osorio FG, Varela I, Lara E, Puente XS, Espada J, Santoro R, et al. Nuclear 
envelope alterations generate an aging-like epigenetic pattern in mice deficient 
in Zmpste24 metalloprotease. Aging cell. 2010. 
274. Yu K-R, Lee S, Jung J-W, Hong I-S, Kim H-S, Seo Y, et al. MicroRNA-141-3p 
plays a role in human mesenchymal stem cell aging by directly targeting 
ZMPSTE24. Journal of cell science. 2013. 
275. Peinado JR, Quirós PM, Pulido MR, Mariño G, Martínez-Chantar ML, 
Vázquez-Martínez R, et al. Proteomic profiling of adipose tissue from 
Zmpste24-/- mice, a model of lipodystrophy and premature aging, reveals major 
changes in mitochondrial function and vimentin processing. Molecular & 
cellular proteomics : MCP. 2011;10:M111.008094. 
276. Ugalde AP, Mariño G, López-Otín C. Rejuvenating somatotropic signaling: a 
therapeutical opportunity for premature aging? Aging. 2010;2:1017-22. 
277. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, et al. 
Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. 
Science. 1998;281:1677-9. 
278. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, et al. ATM 
associates with and phosphorylates p53: mapping the region of interaction. 
Nature genetics. 1998;20:398-400. 
279. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, et al. p53-
induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. 
Nature. 2007;446:444-8. 
280. Chang BD, Watanabe K, Broude EV, Fang J, Poole JC, Kalinichenko TV, et al. 
Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for 
carcinogenesis, senescence, and age-related diseases. Proceedings of the 
 On the role of prelamin A in the heart  
 
 244 
National Academy of Sciences of the United States of America. 
2000;97(8):4291-6. 
281. Chen QM, Liu J, Merrett JB. Apoptosis or senescence-like growth arrest: 
influence of cell-cycle position, p53, p21 and bax in H2O2 response of normal 
human fibroblasts. The Biochemical journal. 2000;347(Pt 2):543-51. 
282. Romanov VS, Pospelov VA, Pospelova TV. Cyclin-dependent kinase inhibitor 
p21(Waf1): contemporary view on its role in senescence and oncogenesis. 
Biochemistry Biokhimiia. 2012;77(6):575-84. 
283. Sorrentino JA, Krishnamurthy J, Tilley S, Alb JG, Jr., Burd CE, Sharpless NE. 
p16INK4a reporter mice reveal age-promoting effects of environmental 
toxicants. The Journal of clinical investigation. 2014;124(1):169-73. 
284. Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC, et al. Senescence-
associated beta-galactosidase is lysosomal beta-galactosidase. Aging cell. 
2006;5(2):187-95. 
285. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to 
detect senescence-associated beta-galactosidase (SA-betagal) activity, a 
biomarker of senescent cells in culture and in vivo. Nature protocols. 
2009;4:1798-806. 
286. Hetz C, Martinon F, Rodriguez D, Glimcher LH. The unfolded protein response: 
integrating stress signals through the stress sensor IRE1alpha. Physiological 
reviews. 2011;91(4):1219-43. 
287. Boya P, Reggiori F, Codogno P. Emerging regulation and functions of 
autophagy. Nature cell biology. 2013;15(7):713-20. 
288. McCool KW, Miyamoto S. DNA damage-dependent NF-κB activation: NEMO 
turns nuclear signaling inside out. Immunological reviews. 2012;246:311-26. 
289. Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable 
progress and outstanding questions. Genes & development. 2012;26(3):203-34. 
290. Miyamoto S. Nuclear initiated NF-kappaB signaling: NEMO and ATM take 
center stage. Cell research. 2011;21(1):116-30. 
291. Jaalouk DE, Lammerding J. Mechanotransduction gone awry. Nature reviews 
Molecular cell biology. 2009;10(1):63-73. 
292. Isermann P, Lammerding J. Nuclear mechanics and mechanotransduction in 
health and disease. Current biology : CB. 2013;23(24):R1113-21. 
293. Wang N, Tytell JD, Ingber DE. Mechanotransduction at a distance: 
mechanically coupling the extracellular matrix with the nucleus. Nature reviews 
Molecular cell biology. 2009;10(1):75-82. 
294. Rao L, Perez D, White E. Lamin proteolysis facilitates nuclear events during 
apoptosis. The Journal of cell biology. 1996;135(6 Pt 1):1441-55. 
295. Haque F, Mazzeo D, Patel JT, Smallwood DT, Ellis Ja, Shanahan CM, et al. 
Mammalian SUN protein interaction networks at the inner nuclear membrane 
and their role in laminopathy disease processes. The Journal of biological 
chemistry. 2010;285:3487-98. 
296. Camozzi D, D'Apice MR, Schena E, Cenni V, Columbaro M, Capanni C, et al. 
Altered chromatin organization and SUN2 localization in mandibuloacral 
dysplasia are rescued by drug treatment. Histochemistry and cell biology. 
2012;138(4):643-51. 
 On the role of prelamin A in the heart  
 
 245 
297. Kandert S, Luke Y, Kleinhenz T, Neumann S, Lu W, Jaeger VM, et al. Nesprin-
2 giant safeguards nuclear envelope architecture in LMNA S143F progeria cells. 
Human molecular genetics. 2007;16(23):2944-59. 
298. Collins JF, Pawloski-Dahm C, Davis MG, Ball N, Dorn GW, 2nd, Walsh RA. 
The role of the cytoskeleton in left ventricular pressure overload hypertrophy 
and failure. Journal of molecular and cellular cardiology. 1996;28(7):1435-43. 
299. Hein S, Kostin S, Heling A, Maeno Y, Schaper J. The role of the cytoskeleton in 
heart failure. Cardiovascular research. 2000;45(2):273-8. 
300. Pawlak A, Gil RJ, Walczak E, Seweryniak P. Desmin expression in human 
cardiomyocytes and selected clinical and echocardiographic parameters in 
patients with chronic heart failure. Kardiologia polska. 2009;67(9):955-61. 
301. Chen QM. Replicative senescence and oxidant-induced premature senescence. 
Beyond the control of cell cycle checkpoints. Annals of the New York Academy 
of Sciences. 2000;908:111-25. 
302. Chen QM, Tu VC, Liu J. Measurements of hydrogen peroxide induced 
premature senescence: senescence-associated beta-galactosidase and DNA 
synthesis index in human diploid fibroblasts with down-regulated p53 or Rb. 
Biogerontology. 2000;1(4):335-9. 
303. Muchir A, Wu W, Choi JC, Iwata S, Morrow J, Homma S, et al. Abnormal p38α 
mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by 
lamin A/C gene mutation. Human molecular genetics. 2012:1-9. 
304. Palatinus JA, Rhett JM, Gourdie RG. The connexin43 carboxyl terminus and 
cardiac gap junction organization. Biochimica et biophysica acta. 
2012;1818(8):1831-43. 
305. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and 
remodelling. Nature reviews Cardiology. 2014;11(5):255-65. 
306. Capanni C, Del Coco R, Squarzoni S, Columbaro M, Mattioli E, Camozzi D, et 
al. Prelamin A is involved in early steps of muscle differentiation. Experimental 
cell research. 2008;314:3628-37. 
307. Lattanzi G, Marmiroli S, Facchini a, Maraldi NM. Nuclear damages and 
oxidative stress: new perspectives for laminopathies. European Journal of 
Histochemistry. 2012;56. 
308. Lattanzi G, Ortolani M, Columbaro M, Prencipe S, Mattioli E, Lanzarini C, et 
al. Centenarian lamins: rapamycin targets in longevity. Journal of cell science. 
2013. 
309. Li H, Choudhary SK, Milner DJ, Munir MI, Kuisk IR, Capetanaki Y. Inhibition 
of desmin expression blocks myoblast fusion and interferes with the myogenic 
regulators MyoD and myogenin. The Journal of cell biology. 1994;124(5):827-
41. 
310. Li Z, Colucci-Guyon E, Pincon-Raymond M, Mericskay M, Pournin S, Paulin 
D, et al. Cardiovascular lesions and skeletal myopathy in mice lacking desmin. 
Developmental biology. 1996;175(2):362-6. 
311. Bainer R, Weaver V. Strength Under Tension. Science. 2013;341:965-6. 
312. Swift J, Ivanovska IL, Buxboim a, Harada T, Dingal PCDP, Pinter J, et al. 
Nuclear Lamin-A Scales with Tissue Stiffness and Enhances Matrix-Directed 
Differentiation. Science. 2013;341:1240104-. 
 On the role of prelamin A in the heart  
 
 246 
313. Navarro CL, Cadiñanos J, De Sandre-Giovannoli A, Bernard R, Courrier S, 
Boccaccio I, et al. Loss of ZMPSTE24 (FACE-1) causes autosomal recessive 
restrictive dermopathy and accumulation of Lamin A precursors. Human 
molecular genetics. 2005;14:1503-13. 
314. Chen X, Zhang Y. Myocardial Cx43 expression in the cases of sudden death due 
to dilated cardiomyopathy. Forensic science international. 2006;162(1-3):170-3. 
315. Kitamura H, Ohnishi Y, Yoshida A, Okajima K, Azumi H, Ishida A, et al. 
Heterogeneous loss of connexin43 protein in nonischemic dilated 
cardiomyopathy with ventricular tachycardia. Journal of cardiovascular 
electrophysiology. 2002;13(9):865-70. 
316. Kitamura H, Yoshida A, Ohnishi Y, Okajima K, Ishida A, Galeano EJ, et al. 
Correlation of connexin43 expression and late ventricular potentials in 
nonischemic dilated cardiomyopathy. Circulation journal : official journal of 
the Japanese Circulation Society. 2003;67(12):1017-21. 
 
 
 
